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Abstract 
Introduction: Schizophrenia is a devastating mental illness that impairs mental and 
social functioning and often leads to the development of co-morbid diseases. They are 
at greater risk for metabolic dysfunctions than other individuals due to a number of 
reasons, including inactive lifestyle, poor dietary choices, and side effects of 
antipsychotic medications. Atypical antipsychotics were reported to be associated with 
increased risk of hyperglycaemia and hyperlipidemia, and subsequently increase the 
risk of metabolic syndrome. However, ziprasidone and aripiprazole have a favourable 
metabolic profile.   
Objectives: i) To determine the prevalence of metabolic syndrome and its components 
among schizophrenia patients. ii) To determine the improvement and reversibility of 
metabolic syndrome, its components and lipid profiles after switching to aripiprazole 
or ziprasidone. iii) To determine the safety and efficacy of aripiprazole and 
ziprasidone in the treatment of schizophrenia patients with metabolic syndrome. 
Methodology:Screening -The study was conducted at four mental institutions and 
four general hospitals. Study population were schizophrenia patients aged between 18 
and 65 years old, who met the DSM-IV TR criteria for schizophrenia. Patients should 
receive antipsychotic treatment for at least 1 year and were not on mood stabilizer. 
Metabolic syndrome was defined by using the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) criteria-modified for Asian waist 
circumference. 
Randomized double-blind controlled trial was conducted for 6-month after 
screening.The dose of aripiprazole and ziprasidone, can be either increased or reduced 
based on clinical assessment. The total daily dosage of ziprasidone ranges from 80mg 
- 160mg.The total daily dosage of aripiprazole ranges from 10mg - 30 mg. The 
outcome measures included body mass index (BMI), waist circumference, blood 
 v 
pressure(BP), fasting blood sugar (FBS) and lipid profile, adverse effects monitoring 
and clinical rating scale such as Positive and Negative Symptoms Scale (PANSS), 
Clinical Global Impression Scale (CGI), Abnormal Involuntary Movement Scale 
(AIMS), Barnes Akathasia Scale (BAS) and Simpson Angus Scale (SAS).Intention-to-
treat analysis and mixed-effects model with repeated measures (MMRM) for statistical 
analysis were done. 
Results: A total of 527 patients were screened but only 270 schizophrenia patients 
fulfil all inclusion and did not have any exclusion criteria. The prevalence of metabolic 
syndrome was 46.7%. There was improvement in the prevalence of all metabolic 
syndrome component from baseline to 6-month after switching to aripiprazole or 
ziprasidone; waist circumference (aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% 
vs. 35.3%), HDL cholesterol (aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 
23.5%), triglycerides (aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), 
BP (aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%), FBS (aripiprazole 
42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). Switching to either 
aripiprazole or ziprasidone cause statistically significant reduction in prevalence of 
metabolic syndrome after 6 month of treatment (aripiprazole 58.9% vs. 30.0%, 
ziprasizone 51.8% vs. 15.3%, p<0.05). There was statistically significant improvement 
in PANSS, CGI, BARS and SAS after switching to aripiprazole or ziprasidone. 
Conclusion: The prevalence of metabolic syndrome in schizophrenia patients 
receiving antipsychotic in Malaysia was very high. Switching to aripiprazole or 
ziprazidone was effective in reversing the metabolic syndrome and its components 
among schizophrenia patients who had metabolic syndrome. 
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Abstrak  
 
 
Pendahuluan: Skizophrenia adalah penyakit mental yang boleh menyebabkan 
kesengsaraan, melemahkan fungsi sosial dan mental, dan kerap menjurus kepada 
pencetusan penyakit-penyakit lain. Pengidapnya mempunyai risiko yang lebih tinggi 
untuk metabolik tidak berfungsi berbanding dengan orang ramai disebabkan beberapa 
faktor termasuk kehidupan yang tidak aktif, pemilihan pemakanan yang salah dan 
kesan sampingan ubat-ubatan antipsikotik. Antipsikotik atipikal telah dilaporkan 
mempunyai kaitan dengan pertambahan risiko hiperglisemia, hiperlipidemia dan 
seterusnya meningkatkan risiko sindrom metabolik. Walaubagaimanapun, ziprasidone 
dan aripiprazole mempunyai profil metabolik yang lebih selamat.    
Objektif: i) Untuk mengetahui prevalen sindrom metabolik dan komponennya di 
kalangan pesakit skizophrenia. ii) Untuk mengetahui tahap pembaikan dan kebolehan 
untuk pulih dari sindrom metabolik dan komponennya serta profil lemak setelah 
ditukarkan ke ubat aripiprazole atau ziprasidone. iii) Untuk mengetahui keselamatan 
dan keberkesanan aripiprazole dan ziprasidone di dalam rawatan pesakit skizophrenia 
yang menghadapi masalah sindrom metabolik. 
Kaedah: Kajian ini telah diadakan di empat institusi mental dan empat hospital umum 
kerajaan. Populasi kajian ini terdiri daripada pesakit skizophrenia yang berumur di 
antara 18 ke 65 tahun dan mereka memenuhi kriteria DSM-IV TR untuk skizophrenia. 
Pesakit mestilah menerima rawatan antipsikotik sekurang-kurangnya selama setahun 
dan tidak boleh mengambil ubat penstabil emosi. Sindrom metabolik telah 
didefinasikan mengunakan kriteria Program Kebangsaan Pendidikan Kolesterol Panel 
Rawatan Dewasa III (NCEP ATP III) diubahsuai mengikut ukuran pinggang orang 
Asia. Kajian rawak dwi rabun telah dijalankan selama 6 bulan selepas saringan. Dos 
ubat ziprasidone adalah di antara julat 80mg-160mg. Jumlah dos harian untuk 
aripiprazole adalah di dalam julat 10mg-30mg. Penanda aras kajian termasuk Index 
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Jisim Badan (BMI), ukuran lilit pinggang,tekanan darah, paras gula dan lemak ketika 
berpuasa, pengawasan kesan sampingan ubat, Skala Simptom Positif dan Negatif 
(PANSS), Skala Impresi Global Klinikal (CGI), Skala Pergerakan Luar Kawal Tidak 
Normal (AIMS), Skala Akathasia Barnes (BAS) dan Skala Simpson Angus (SAS). 
Analisa tindakan untuk saringan dan model kesan bercampur dengan pengukuran 
berulang (MMRM) telah digunakan di dalam analisa statistik.  
Keputusan: Sejumlah 527 pesakit telah disaring tetapi hanya 270 pesakit skizophrenia 
memenuhi semua kriteria kemasukan dan tidak mempunyai kriteria pengasingan. 
Prevalen sindrom metabolik adalah sebanyak 46.7%. Terdapat penambahbaikan di 
dalam semua prevalen komponen sindrom metabolik dari permulaan sehingga 6 bulan 
selepas pertukaran rawatan kepada aripiprazole atau ziprasidone; ukuran lilit pinggang 
(aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), HDL kolesterol 
(aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), triglycerides 
(aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), tekanan darah 
(aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%) , paras gula berpuasa 
(aripiprazole 42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). Penukaran 
kepada aripiprazole atau ziprasidione menyebabkan pengurangan prevalan sindrom 
metabolik selepas rawatan selama 6 bulan (aripiprazole 58.9% vs. 30.0%, ziprasizone 
51.8% vs. 15.3%, p<0.05). Terdapat perbezaan dari segi statistik untuk PANSS, CGI, 
BARS dan SAS selepas penukaran kepada aripiprazole atau ziprasidione. 
Kesimpulan: Prevalan sindrom metabolik di kalangan pesakit skizophrenia yang 
mengambil ubat antipsikotik di Malaysia adalah sangat tinggi. Penukaran ubat kepada 
aripiprazole atau ziprasidone adalah berkesan untuk memulihkan sindrom metabolik di 
kalangan pesakit skizophrenia yang mengalami masalah tersebut. 
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Chapter ONE:  Introduction  
 
Schizophrenia is a severe and persistent disabling brain disorders characterized by a 
disintegration of the process of thinking, of contact with reality and of emotional 
responsiveness. The breakdown in these processes manifests as symptoms of 
hallucinations, delusions, disorganized communication, poor planning, reduced 
motivation and blunted effect. All of these have a profound impact on social or 
occupational function of the afflicted individual (Awad et al.,1997a; Awad et 
al.,1997b). 
1.1   History of Schizophrenia 
Symptoms resembling schizophrenia had been described in as early as 2000 BC by 
ancient Egyptians. However only in 1887 when Emil Kraepelin (1856-1926)  
classified it as a discrete mental disorder with the term ‘dementia praecox’ for 
individuals who present with symptoms associated with schizophrenia by today’s 
definition (Kraepelin,1907).  
The psychiatrist Kurt Schneider (1887-1967) then listed the forms of psychotic 
symptoms that he thought distinguished schizophrenia from other psychotic 
symptoms. These were called first-rank symptoms or Schneider’s first-rank symptoms 
(Schneider,1959). While these symptoms have contributed to the current diagnostic 
criteria, their reliability has been questioned (Bertelsen,2002). The first-rank 
symptoms include: 
 
• Delusions of being controlled by an external force 
• The belief that thoughts are being inserted into or withdrawn from one’s conscious 
mind 
• The belief that one’s thoughts are being broadcast to other people 
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• Hearing hallucinatory voices that comment on one’s thoughts or actions or that 
have a conversation with other hallucinated voices.  
In 1911, Eugen Bleuler proposed the term ‘schizophrenia’ (translated from Greek as 
‘splitting of the mind’) to describe the separation of function between personality, 
thinking, memory and perception as seen in this mental disease. Blueler was also the 
first to describe the symptoms as ‘positive’ and ‘negative’ (Bleuler,1984).   
Schizophrenia is not synonymous with dissociative identity disorder (or known as 
‘split personality’). It is a common misunderstanding partly due to the meaning of the 
term used (‘splitting of the mind’). Although some people diagnosed with 
schizophrenia may hear voices and may experience the voices as distinct personalities, 
schizophrenia does not involve a person changing among distinct multiple 
personalities.   
There were at least 15 different diagnostic systems for schizophrenia identified in the 
literature over the last 3 decades (Berner et al.,1983). While the operational approach 
in psychiatry has been considered by many as a progress in the right direction, it was 
also being increasingly criticized for a number of negative pragmatic consequences 
(Andreasen,1998; Maj,1998; Tucker,1998; Parnas and Zahayi,2002). The obvious 
unpredictability of the contemporary diagnosis poses a serious problem for etiological 
research especially genetic linkage research and early intervention studies (Jansson et 
al.,2002).  
The issues of validity and reliability of psychiatric diagnosis are frequently conflated 
in the literature. For instance, in a study that made comparisons of International 
Classification of Diseases 9 (ICD-9) and International Classification of Diseases 10 
(ICD-10) in first-admitted patients, it was found that only formal thought disorder and 
family history might be considered as ‘concurrent/construct validity’ indicators, (i.e. as 
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extra-clinical measures) (Kendler,1990). On both indices, some investigators 
suggested that the ICD-10 appears to be less valid than the ICD-9 (Parnas and 
Bovet,1991; Kendler,1990). Clearly, continuing debate and research on the boundaries 
of schizophrenia was warranted to assess the validity of current diagnostic systems.  
1.2   Epidemiology of Schizophrenia 
 
The worldwide prevalence of schizophrenia is estimated to be around 1%, as reported 
in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) 
(1994), though the rate may vary across the world, within countries, and among local 
neighbourhoods (Jablensky et al.,1992; Kirkbride et al.,2006; Kirkbride et al.,2007).  
The onset of schizophrenia symptoms usually occurs in young adulthood (Castle et 
al.,1991). Diagnosis was largely based on the patient’s self-reported experience and 
observed behaviour. Currently scientist still exploring the laboratory test for 
schizophrenia (Schwarz et al.,2010).
 
While it was a widely held view that schizophrenia was much more common in men  
(McGrath et al.,2004; Isohanni et al.,2006), a systematic review by Saha et al (2005) 
found that schizophrenia was just as common in women.  
In Saha’s review, a total of 1,721 prevalence estimates from 188 studies were 
identified. These estimates were drawn from 46 countries, including Argentina, 
Australia, Botswana, Canada, China, Croatia, the European countries, India, Indonesia, 
Iran, Israel, Japan, New Zealand, Papua New Guinea, Russia, Sri Lanka, Taiwan, 
United Kingdom, United States, Uzbekistan, Yugoslavia and others. The identified 
studies were divided into core studies (n=132), migrant studies (n=15) and studies 
based on other special groups (n=41). Based on combined prevalence estimates, the 
review found no significant differences in schizophrenia incidence between males and 
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females. In addition, there was also no substantial difference between urban, rural and 
mixed sites, although developing countries tended to have lower prevalence rates.  
While 15 migrant studies were identified from eight countries (i.e. Australia, 
Germany, India, Israel, Taiwan, the Netherlands, United Kingdom and United States), 
only 5 studies were suitable to be included for analysis. Based on the limited data, the 
prevalence of schizophrenia in migrants was noted to be higher compared to the native 
population.  
The special group studies came from 14 countries: Australia, Canada, Denmark, 
Finland, Germany, India, Israel, Japan, Romania, Spain, Sweden, Taiwan, United 
Kingdom and United States. Due to the marked heterogeneity of the data from the 
special group studies, it was not possible to perform a combined analysis. However, it 
was noted that prevalence estimates were very high in the homeless populations. On 
the other hand, religious groups (e.g. Amish) tended to have lower prevalence 
estimates. 
1.3   Causes and Pathophysiology 
The exact causes of schizophrenia are not known, but are believed to be a combination 
of biological, psychological and social factors (Nasrallah et al.,2011). Biological 
factors include genetically inherited brain abnormality (Shepherd et al.,2012) with or 
without obstetric complications (Brown and Derkits,2010), which can lead to subtle 
alterations in the brain that make a person susceptible to developing schizophrenia. 
Other factors, such as early environmental and psychosocial stressors (e.g. family 
stress or social stress during childhood or young adulthood) serve as precipitating or 
exacerbating factors (Day et al.,1987).   
1.4   The Disease Burden of Schizophrenia 
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Schizophrenia is known to be a major cause of disability. In a study of 17 health 
conditions in 14 countries, active psychosis was ranked the third-most-disabling 
condition, right after quadriplegia and dementia, and before paraplegia and blindness 
(Ustun et al.,1999). In addition to the direct burden, the patients are confronted with 
prejudice and discrimination. The stigma attached to schizophrenia creates a vicious 
cycle of discrimination leading to social isolation, unemployment, drug abuse, long-
lasting institutionalisation or even homelessness (Rossler et al.,2005). All of these 
further decrease the chances for recovery and reintegration into normal life. 
Schizophrenia is indeed the most burdensome and costly illness worldwide. The life 
expectancy is reduced by approximately 10 years, mostly as a consequence of suicide 
(Caldwell and Gottesman,1990; Erlangsen et al.,2012). According to the Global 
Burden of Disease Study, schizophrenia causes a high degree of disability, which 
accounts for 1.1% of the total disability-adjusted life years (DALYs) (Murray and 
Lopez,1996; Murray and Lopez,1997),  which was a metric to quantify the overall 
disease burden. One DALY can be considered as 1 lost year of “healthy” life.   
In the World Health Report, schizophrenia was listed as the 8
th
 leading cause of 
DALYs worldwide in the age group of 15-44 years. While there are direct costs of 
providing care for individuals with schizophrenia, the indirect costs encompasses loss 
of productivity through impairments, disability and premature death, as well as some 
legal problems including violence (WHO,2001).  
In addition to direct burden, there is considerable burden on the caregivers of 
schizophrenia patients. The caregivers are usually family members. The burden on 
families ranges from emotional reactions to the illness, the stress coping with disturbed 
behaviour, the disruption of household routine, the stigma they are confronted with, 
the restriction of social activities and  economic difficulties. In a study that assessed a 
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cohort of caregivers of schizophrenia patients using the Involvement Evaluation 
Questionnaire (European version), it was found that 51% of caregivers experienced 
significant emotional distress. Higher patient’s psychopathology, higher numbers of 
patient-rated needs, patients’ lower global functioning and patients’ poorer quality of 
life were found to be related to the severity of family burden (Parabiaghi et al.,2007).
  
1.5   Signs and symptoms 
The symptoms of schizophrenia usually follow a waxing and waning course. However, 
the patient’s pattern of symptoms might change over years (Nasrallah et al.,2011). 
Patients with schizophrenia manifest a variety of symptoms, which can fall into three 
broad categories (Peralta and Cuesta,2001; Oyebode,2002).   
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1.5.1 Positive symptoms 
 
Positive symptoms of schizophrenia are easily noticeable behaviours not seen in 
healthy people. They include hallucinations, delusions, disorganized behaviour and 
disorganized speech. 
 
1.5.2 Negative symptoms 
 
The term ‘negative symptoms’ refers to the loss or absence of normal emotional and 
behavioural traits or abilities, such as flat or blunted effect and emotion, poverty of 
speech, anhedonia and lack of motivation. These symptoms are not obvious, therefore 
are harder to recognize as part of the disorder.  
Despite the appearance of blunted affect, recent studies indicate that there is often a 
normal or even heightened level of emotionality in schizophrenia, especially in 
response to stressful or negative events (Cohen and Docherty,2004).
 
 
1.5.3 Cognitive symptoms 
 
Cognitive symptoms or cognitive deficit are problems with  attention (e.g. inability to 
sustain attention) (Kurtz,2005), certain types of memory (e.g. the ability to keep 
recently learned information and use it right away), and executive functioning (e.g. the 
ability to absorb and interpret information and make decision based on that 
information) (Bentall et al.,2007). These symptoms are subtle and are often detected 
only when neuropsychological tests are performed. Cognitive impairments often 
interfere with the patient's ability to lead a normal life and earn a living. This can 
cause great emotional distress. 
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1.6   Diagnostic Criteria and Classification 
The diagnosis of schizophrenia is largely based on self-reported experiences, as well 
as abnormalities in behaviour reported by family members, friends or co-workers, 
followed by secondary signs observed by a psychiatrist, social worker, clinical 
psychologist or other clinician in a clinical assessment.  
There is a list of criteria that must be met for someone to be diagnosed with this 
mental illness. The current most widely used criteria for diagnosing schizophrenia are 
from the American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) (2000), and the World 
Health Organization’s International Statistical Classification of Diseases, Tenth 
Revision (ICD-10) (WHO,1994a) .   
While ICD-10 criteria are commonly used in Europe, DSM-IV-TR criteria are used in 
the USA and the rest of the world, and are more popular in research studies.   
 
1.6.1 DSM-IV-TR Criteria 
Based on DSM IV-TR criteria, a person must display certain characteristics or 
symptoms to be diagnosed with schizophrenia.
  
Characteristic symptoms 
 
Presenting two or more of the following, each for a significant portion of time during a 
one-month period (or less, if successfully treated): 
 Delusions 
 Hallucinations 
 Disorganized speech (e.g. frequent incoherence, speaking in abstracts) 
 Severely disorganized behaviour (e.g. dressing inappropriately, crying frequently) 
or catatonic behaviour 
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 Negative symptoms, such as affective flattening (lack in emotional response), 
alogia (lack in speech), or avolition (lack in motivation) 
However, if delusions are bizarre or hallucinations involve commentary voices, only 
one of the above symptoms is required for diagnosis. 
Duration  
Individual must shows continuous signs of the disturbance for at least 6 months. This 
6-month period must include at least 1 month of active-phase symptoms (or less, if 
successfully treated). 
Social/occupational dysfunction 
One or more major areas of functioning, such as work, interpersonal relations or self-
care, are markedly below the level achieved prior to the onset for a significant portion 
of the time since the onset. 
Note that schizophrenia cannot be diagnosed if symptoms of mood disorder or 
pervasive developmental disorder are present, or if symptoms are the direct result of a 
substance (e.g. abuse of a drug/medication) or a general medical condition. 
Based on the predominance of certain symptoms and absence of others, the DSM-IV-
TR distinguishes five clinical subtypes of schizophrenia: 
 Paranoid type 
Delusions and hallucinations are present but thought disorder, disorganized behaviour, 
and affective flattening are absent (DSM code 295.3, corresponding to ICD code 
F20.0). 
 Disorganized type 
Thought disorder and flat affect are present together in this subtype of schizophrenia 
(DSM code 295.1, corresponding to ICD code F20.1), also known as ‘hebephrenic 
schizophrenia’ in the ICD-10 criteria. 
1 Introduction  
 
10 
 
 Catatonic type 
Prominent psychomotor disturbances are apparent. Symptoms can include catatonic 
stupor and waxy flexibility (DSM code 295.2, corresponding to ICD code F20.2). 
 Undifferentiated type 
Psychotic symptoms are present, but do not meet the criteria for paranoid, 
disorganized or catatonic types (DSM code 295.9, corresponding to ICD code F20.3). 
 Residual type 
Positive symptoms are present at a low intensity only (DSM code 295.6, 
corresponding to ICD code F20.5). 
 
1.6.2 ICD-10 Criteria 
ICD-10 classification and diagnosis of schizophrenia differs only slightly from the 
DSM IV-TR classification. The ICD-10 distinguishes nine symptomatic categories to 
diagnose schizophrenia: 
(a)  Thought insertion or withdrawal.  
(b)   Delusions of control, influence or passivity. 
(c)   Hallucinatory voices.  
(d)   Persistent delusions that is culturally inappropriate or completely impossible.  
(e)   Persistent hallucinations in any modality, accompanied by fleeting or delusions 
without clear affective content.  
(f)  Breaks in train of thought, incoherence or irrelevant speech, neologisms.  
(g)  Catatonic behaviour.  
(h)  Negative symptoms.  
(i)  Significant and consistent change in personal behaviour (such as idleness, self-
absorbed attitude).  
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The normal requirement for a diagnosis of schizophrenia is that a minimum of one 
very clear symptom (and usually two or more if less clear-cut) belonging to any one of 
the groups listed as (a) to (d) above, or symptoms from at least two of the groups 
referred to as (e) to (h), should have been clearly present for most of the time during a 
period of 1 month or more.   
Based on the predominance of certain symptoms and absence of others, the ICD-10 
also distinguishes schizophrenia into different subtypes. Apart from the five subtypes 
recognized in DSM-IV-TR, the ICD-10 recognizes a further two subtypes: 
 Post-schizophrenic depression 
This refers to a depressive episode arising in the aftermath of a schizophrenic illness, 
where some low-level schizophrenic symptoms may still be present (ICD code F20.4). 
 Simple schizophrenia 
Insidious but progressive development of prominent negative symptoms with no 
history of psychotic episodes is observed in this subtype (ICD code F20.6). 
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1.7   Complications and Impact of Schizophrenia 
Schizophrenia is associated with several complications that significantly affect the 
health and life of patients, as well as their family, friends and caregivers. This mental 
illness causes suffering to patients as a result of symptoms, lower quality of life, lost 
independence, poorer social integration, co-existing medical morbidity, and increased 
mortality (Becker et al.,2002). Schizophrenia also puts a considerable burden on the 
society, and leads to reduced economic productivity.   
 
1.7.1 Outcome after First Episode 
 
(a) Recovery 
 
Follow up studies have shown a substantial number of schizophrenia patients 
achieving full recovery (i.e. sustained improvement in both symptoms and 
social/vocational functioning) when examined decades after an index admission 
(Harrison et al.,2001; Torgalsboen,2012).
 
In a study by Robinson et al (2004), for instance, data from a prospective study that 
followed up patients for a period of up to 9 years from their first episode of 
schizophrenia or schizoaffective disorder was examined. Their analysis suggested that 
patients with first-episode schizophrenia or schizoaffective disorder can recover. 
Although some patients with first-episode schizophrenia can achieve sustained 
symptomatic and functional recovery, the overall rate of recovery during the early 
years of the illness was low - only 13.7% of subjects met full recovery criteria for 2 
years or longer. Almost half of the subjects achieved symptom remission though, and 
about a quarter had adequate social functioning for 2 years or more.  
They also reported that better cognitive better cognitive functioning at stabilization 
was more likely to lead to full recovery, both adequate social or vocational functioning 
1 Introduction  
 
13 
 
and symptom remission. More cerebral asymmetry was also associated with full 
recovery and, adequate social and vocational functioning. 
(b) Quality of Life 
 
In a study  that involved 50 first episode schizophrenic patients, who were mostly 
neuroleptic-naïve at study intake, found that negative symptom severity was positively 
and significantly correlated with later occupational impairment, financial dependence 
on others, impaired relationships with friends, impaired ability to enjoy recreational 
activities, and global assessment of functioning, i.e. negative symptoms moderately 
predicted poorer quality of life early in the course of schizophrenia (Ho et al.,1998).   
Knowing that negative symptoms were a portent or poor quality of life may influence 
the clinician to go for atypical neuroleptic treatment (Singam et al.,2011; Buchanan et 
al.,2012) and stress the need for more intensive psychosocial interventions for patients 
with prominent initial negative symptoms (McGlashan et al.,1990). 
Severe negative symptoms at the time of hospitalization might be a portent of poor 
outcome. In general, the psychotic and the disorganized symptom dimensions did not 
appear to predict subsequent quality of life (Schennach et al.,2011) . 
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(c) Relapse 
 
There was a high rate of relapse within 5 years of recovery from a first episode of 
schizophrenia and schizoaffective disorder. This risk was diminished by maintenance 
antipsychotic drug treatment as reported by Robinson et al(1999).  Results showed that 
5 years after initial recovery, the cumulative first relapse rate was 81.9%, and the 
second relapse rate was 78.0%. By 4 years after recovery from a second relapse, the 
cumulative third relapse rate was 86.2%. 
 
Discontinuing antipsychotic drug therapy increased the risk of relapse by almost 5 
times. Subsequent analyses controlling for antipsychotic drug use showed that patients 
with poor pre-morbid adaptation to school and pre-morbid social withdrawal relapsed 
earlier. Other factors, such as baseline symptoms, neuroendocrine measures, time to 
response of the initial episode, adverse effects during treatment, and presence of 
residual symptoms after the initial episode were not significantly related to time to 
relapse (Robinson et al.,1999).   
 
(d) Treatment Response 
 
In general, first-episode patients appeared to be more sensitive to the pharmacologic 
effects of antipsychotic drugs than older chronic patients in that they exhibited higher 
rates of recovery, more frequent extrapyramidal side effects, and required lower drug 
doses (Remington et al.,1998; Petersen et al.,2008). However, following their recovery 
first-episode patients experienced a high rate of psychotic relapse particularly if they 
discontinued antipsychotic medication (Gitlin et al.,2001; Ucok et al.,2006).
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1.7.2 Social Burden 
Impaired information processing was probably the most harmful symptom of 
schizophrenia, as it significantly affects patients’ social functioning, leading to lower 
rates of employment, marriage and independent living compared to other healthy 
individuals (Shrivastava et al.,2011). 
 
Schizophrenia might also cause patients to abuse substance. Alcohol and drug abuse 
were common in schizophrenia patients, particularly in younger men (Weiser et 
al.,2003; van Nimwegen et al.,2005; Jones et al.,2011). Substance abuse was 
associated with increased hostility and violence, and problems such as non-compliance 
with medication, poor nutrition and suicide (Smith and Hucker,1994; Foti et al.,2010).  
Not all violence behaviour among schizophrenia patients was attributed to substance 
abuse though. Some patients who were schizophrenic might be violent due to 
hallucinations or delusions , or as a result of psychosis (Ho et al.,1998). In fact, 
Western studies reported that 5% to 10% of those charged with murder have a 
schizophrenia spectrum disorder (Mullen,2006; Fazel and Grann,2004; A. I. Simpson 
et al.,2004).
 
 
Schizophrenia was also related to other social problems, such as long-term 
unemployment, poverty and homelessness (Selten et al.,2007; Mueser and 
McGurk,2004).
 
 
1.7.3 Economical Burden 
 
Schizophrenia is by far the most costly psychiatric illness because of the range of 
healthcare needs schizophrenia patients have. As with other major chronic diseases, 
schizophrenia places a great economic burden on the society (Martin,1995), in terms 
of :
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 Direct costs (e.g. in and outpatient care, residential care, drug therapy); 
 Indirect cost (e.g. absence from work, lost productivity due to unemployment); and 
 Intangible costs (e.g. suffering experienced by the patient and family). 
The cost of lost productivity was especially large. In England, nearly 80% of 
schizophrenia patients remained unemployed. The estimated total societal cost which 
includes direct cost of treatment and care, and indirect costs to the society in 2004 and 
2005 was 6.7 billion pounds (Mangalore and Knapp,2007).  
 
Similarly, the indirect excess cost due to unemployment was the largest component of 
overall schizophrenia excess annual costs in US in 2002 (Wu et al.,2005).
 
 
1.7.4 Impact on Quality of Life 
 
Schizophrenia was a debilitating long-term disorder that has a profound impact on 
patients’ quality of life. The cognitive and emotional disturbances experienced in this 
psychiatric disorder tend to have a lasting effect on many areas of a patient’s life 
functioning and subsequently on quality of life (Gee et al.,2003). 
 
Several areas that affected in a schizophrenia patient’s life was described by Gee 
(2003) include :
 
 Interpersonal relationships 
Patients felt isolated and were difficult to establish interpersonal relationship 
because of their mental health problems. They worried about what others thought 
of them. Friends and family might try to avoid a schizophrenia patient due to his or 
her psychiatric status. 
 Control of behaviour and actions 
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Schizophrenia patients usually avoid situations that they had previously enjoyed 
and choose to be isolated because of fear of they would lose control of their 
behaviour and actions. 
 Opportunity to fulfil occupational roles 
The illness of schizophrenia made them to work or fulfil occupational roles. This 
reduces their job choices, leaving them feeling useless, experiencing loss of respect 
and value in the job market, and thus loss of contact with others.  
 Activities and plans 
 
Schizophrenia patients experienced constraint in carrying out activities and plans, 
such as not being able to travel, go on holiday, live where they would choose, or 
plan anything too far ahead.  
 Self-value 
Low self-esteem, lowered morale, fear, feeling helpless and useless are some of the 
psychological responses of schizophrenia patients to their illness.   
 Labelling and attitudes from others 
The stigma attached to having schizophrenia or any other mental health problems 
result in the public to reject schizophrenia patients, causing a negative impact on 
their relationships, social life, work and image. 
1.7.5 Mortality in Schizophrenia 
Mortality rate was generally higher and life expectancy decreased among people with 
schizophrenia than the general population (Mortensen and Juel,1993; Harris and 
Barraclough,1997; Tenback et al.,2012). Taking into account of all premature deaths, 
people with schizophrenia usually live 9-12 years shorter than the general population 
(Goldman,1999; Babidge et al.,2001; Brown et al.,2000; Lawrence et al.,2000). For 
example, an Australian study showed that patients with schizophrenia were found to 
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be 2.9 times more likely to die of natural causes than people in the general population 
(Ruschena et al.,1998).   
Mortality was also increased because of coexisting medical illnesses, whether due to a 
combination of unhealthy lifestyles (e.g. lack in exercise, smoking, poor diet), side 
effects of medication, or decreased health care (Brown et al.,2000).
 
Other causes of mortality include cardiovascular disease (CVD), diabetes and its 
complications (e.g. kidney failure), respiratory disease (including pneumonia, 
influenza), and infectious disease (e.g. HIV/AIDS) (Parks et al.,2006). The rates of 
mortality from these diseases in schizophrenia patients were several times higher than 
observed in the general population (Osby et al.,2000) (Table 1.1). 
Table 1.1: Prevalence of natural causes of death in schizophrenia are greater 
compared with general population 
 
Cause of Death Prevalence in Relative to General 
Population 
Endocrine disorders (diabetes) 2.7 times 
CVD 2.3 times 
Respiratory disease 3.2 times 
Infectious disease 3.4 times 
 
Nevertheless, study also showed that, as a whole, a diagnosis of schizophrenia was 
associated with a better life expectancy than substance abuse, personality disorder, 
heart attack and stroke (Hannerz et al.,2001).   
While 60% of premature deaths in schizophrenia patients were due to ‘natural causes’ 
(i.e. non-suicide related) (Brown and Mitchell,2011) , suicide was a well-known 
contributing factors to shorter life span in people with schizophrenia, accounting for 
about 30%-40% of excess mortality (Mortensen and Juel,1993; Erlangsen et al.,2012), 
A recent study showed that 30% of patients diagnosed with this condition had 
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attempted suicide at least once during their lifetime (Radomsky et al.,1999). Another 
study reported that 10% of individuals with schizophrenia die by suicide (Caldwell 
and Gottesman,1990). 
1.7.6 Care and management barriers 
There were many popular misconceptions surrounding schizophrenia, and the stigma 
associated with this mental disorder has been identified as a major obstacle in the 
treatment and recovery of patients with schizophrenia (McGorry,1999). Individuals 
with schizophrenia were thought to be violent by the majority of the public (Link et 
al.,1999). They were also believed not able to make decisions regarding their treatment 
and on money management (Pescosolido et al.,1999).  
1.8   Prognosis 
While full recovery was only attained in about one third of patients, numerous 
international studies have demonstrated favourable long-term outcomes for 
schizophrenia, even though full recovery was not achieved (Robinson et al.,2004; 
Harding et al.,1987). For example, a 5-year community study  found that as many as 
62% of people with schizophrenia showed overall improvement on a composite 
measure of symptomatic, clinical and functional outcomes (Harvey et al.,2007). 
Multiple factors appear to influence the outcome of this disease. Symptoms during the 
acute illness early in the presentation of schizophrenia have some prognostic value.  
Factors that predict good outcome highlighted by some studies (Davidson and 
McGlashan,1997; Lieberman et al.,1996) include: 
 Gender 
Prognosis was usually better in female patients, as they responded better to 
antipsychotic medications than the male patients (Canuso and Pandina,2007).
 
 Type of symptoms 
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If schizophrenia was treated quickly and consistently with good response to treatment, 
the prognosis was usually very good (Cohen et al.,2008). However, this was true 
mainly for positive symptoms that responded fairly well to antipsychotic medication. 
Presence of mood symptoms and good pre-morbid functioning also help to improve 
disease outcome (Amminger et al.,1997). 
 Onset of illness 
Chances for recovery were better for acute onset compared with insidious onset of the 
disease (Freudenreich et al.,2007). Prognosis was also better if the first episode occurs 
at older age (Rajji et al.,2009).   
 Family history of schizophrenia 
Family history of schizophrenia was relevant (Licanin and Redzic,2010). Prognosis 
was better if no one in the immediate biological family of first degree relatives has 
schizophrenia or a related condition. 
 Structural brain abnormalities 
The presence of abnormal brain structure and function as indicated by a brain scan 
usually predicts a poor prognosis (O'Brien et al.,1996). 
 
On the other hand, predictors of poor outcome were (Ho et al.,1998):
 
• Poor pre-morbid adjustment 
• Longer interval from the onset to treatment 
• Absence of any clear precipitating events 
• Presence of negative symptoms. 
1.9   Medical Co-morbidity of Schizophrenia 
Schizophrenia has been described as a ‘life-shortening disease’ (Allebeck,1989; 
Goldman,1999; Babidge et al.,2001), because it was associated with excessive medical 
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morbidity and mortality (Druss et al.,2011). The high mortality and morbidity may 
generally be attributed to an environment, in which unhealthy and high-risk 
behaviours such as smoking, substance abuse, lack of exercise and poor diet are 
prevalent in a schizophrenia patient’s lifestyle (Brown et al.,1999).   
People diagnosed with schizophrenia were also likely to be diagnosed with co-morbid 
medical conditions, including clinical depression and anxiety disorders (Sim et 
al.,2006; Lysaker et al.,2010), metabolic disturbances (Huang et al.,2009) and 
cardiovascular disease (Lahti et al.,2012). 
1.9.1 Prevalence of Medical Co-Morbidity in Schizophrenia 
In a study by Carney et al (2006), where they examined chronic medical co-morbidity 
in people with schizophrenia, it was found that subjects with schizophrenia were 
significantly more likely to have one or more chronic conditions compared with those 
who had not reported of any psychiatric disorder. Adjusted odds ratio (95% CI) 
reported for some of the chronic conditions were: 
 OR: 2.62 ( 95% CI: 2.09 to 3.28) for hypothyroidism 
 OR:1.88 (95% CI: 1.51 to 2.32) for chronic obstructive pulmonary disease 
 OR:2.11 (95% CI: 1.36 to 3.28) for diabetes with complications 
 OR:7.54 (95% CI: 3.55 to 15.99) for hepatitis C 
 OR:4.21 (95% CI: 3.25 to 5.44) for fluid/electrolyte disorders 
 OR: 2.77 (95% CI: 2.23 to 3.44) for nicotine abuse/dependence. 
 
Other health conditions known to be particularly problematic for  schizophrenia 
patients also include high blood pressure, obesity and high cholesterol levels (De Hert 
et al.,2009).
 
 
1.9.2 Risk factors of medical co-morbidity  
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Common chronic medical co-morbidity found in patients with schizophrenia was 
usually related to their psychiatric conditions, psychotropic medications used and 
lifestyle habits.  
People with schizophrenia and other mental illnesses have a higher rate of lifestyle risk 
factors such as smoking, high alcohol consumption, poor diet and lack of exercise 
(Brown et al.,1999; Vancampfort et al.,2011). These unhealthy lifestyle factors 
increased the cardiovascular risk significantly in people with mental illness compared 
with the general population (Davidson,2002).  
The study showed that there were more smokers or ex-smokers (70% vs. 50%) in 
individuals with mental illness, who also used harmful levels of alcohol more 
frequently than the general population (11.5% vs. 3.1%, respectively). There was also 
a notably high percentage of people with schizophrenia who were obese compared 
with the general population (40% vs. 8%)  (Davidson,2002).   
In terms of diet, the cognitive and social deficit symptoms of schizophrenia might 
predispose patients to choose unhealthy diet (e.g. easily obtainable ‘fast’ foods) as 
their major source of nutrition (Gupta and Craig,2009). Schizophrenia patients were 
also less motivated to keep physically active to counter the health effects of their poor 
diet and to maintain general fitness (Lambert et al.,2003; McCreadie,2003).
 
Together, these lifestyle factors increased the risk or severity of medical conditions, 
particularly the development of metabolic syndrome (Kilbourne et al.,2007; Meyer 
and Stahl,2009)  and subsequently CVD (Bobes et al.,2007; Lahti et al.,2012). 
1.9.3 Metabolic disturbances 
 
People with schizophrenia were more prone to developing metabolic disturbances 
(Subashini et al.,2011), as metabolic risk factors tend to be more prevalent among 
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patients with mental illness than in the general population. They were at increased risk 
of developing glucose-regulation abnormalities, insulin resistance and type 2 diabetes 
mellitus (Timonen et al.,2009; Dasgupta et al.,2010).  
While lifestyle factors (e.g. poor diet, sedentary behaviour, smoking) evidently play a 
contributing role here (Vancampfort et al.,2011), treatment with psychotropic 
medications, including some of the second generation antipsychotic agents, were also 
responsible for adverse effects on the body metabolic processes (Narasimhan and 
Bailey,2008; Meyer et al.,2008).  
 
Disturbances in metabolic processes result in a cluster of metabolic dysfunction, such 
as insulin resistance, dyslipidaemia, impaired glucose tolerance, which is known as the 
metabolic syndrome thereby putting patients at risk of CVD (Cho,2011). 
 
This has been demonstrated in the Clinical Trials of Antipsychotic Intervention 
Effectiveness (CATIE) study involving 1,424 patients with schizophrenia. Their 
baseline data revealed that 20% of the patients had hypertension, 14% 
hyperlipidaemia, and 11% diabetes (Chwastiak et al.,2006).  
While increased risk of diabetes has been attributed to lifestyle determinants and 
antipsychotic drugs, the association between schizophrenia and diabetes has been well 
aware even before lifestyle factors and pharmacological interventions were introduced 
(Gough and O'Donovan,2005). In fact, schizophrenia has been considered as a 
predisposing factor to diabetes, which was believed to be an integral part of the mental 
illness (Kohen,2004). A recent study showed that despite cessation of antipsychotic 
treatment, insulin resistance may persist (Arranz et al.,2004).  
The observations suggested a possibility of a shared genetic basis between 
schizophrenia and diabetes, as both were common diseases with a complex mode of 
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inheritance and were influenced by genetic factors and environmental determinants 
(Gough and O'Donovan,2005).
 
 
1.9.4 Cardiovascular risk 
CVD was dominated as the number one cause of death in patients with schizophrenia 
and in fact, in severe mental illness (Osby et al.,2000). Greater mortality rate due to 
ischaemic heart disease, cardiac arrhythmias and myocardial infarction has been 
reported in people with mental illness (Lawrence et al.,2010).  
In the CATIE study, it was found that the 10-year risk for coronary heart disease was 
significantly raised in male (9.4% vs 7.0%) and female (6.3% vs 4.2%) patients with 
schizophrenia compared with the general population (P=.0001) (Goff et al.,2005). 
The elevated CV risk in this psychiatric population was not unexpected. The high 
prevalence of lifestyle risk factors and metabolic syndrome in schizophrenia placed the 
patients at increased risk for CVD. In the CATIE study, there were 40.9% and 42.7% 
respectively of patients diagnosed for metabolic syndrome at baseline using the 
National Cholesterol Education Program (NCEP) and the American Heart Association 
(AHA) criteria (McEvoy et al.,2005).   
Again, the use of antipsychotic medication may also partly heighten the CV risk. In 
the CATIE study (Daumit et al.,2008), it was found that the 10-year risk for coronary 
heart disease was significantly raised with olanzapine (0.5%, SE 0.3) and quetipine 
(0.3%, SE 0.3).  
1.9.5 Other medical co-morbidity 
i) Infectious disease (e.g. HIV/AIDS, hepatitis) 
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Incidence of HIV/AIDS in people with schizophrenia (estimated to be 4%-23%) 
appeared to be higher than in the general population (Davidson et al.,2001b; Cournos 
and McKinnon,1997). Risk factors include unsafe sex and substance abuse. About half 
of schizophrenia patients tend to have co-occurring substance abuse disorder (Regier 
et al.,1990), they were 2-3 times more likely to become infected with HIV and 
hepatitis than schizophrenia patients without substance disorder.  
When compared to the general population, the prevalence of HIV infection in 
individuals with severe mental illness including schizophrenia was reported to be 
about 8 times higher (29.1%) (Singh et al.,2009), while the prevalence rates of 
hepatitis B virus (23.4%) and hepatitis C virus (19.6%) were approximately 5 and 11 
times the overall estimated population rates for these infections, respectively 
(Rosenberg et al.,2001).   
 
ii) Osteoporosis 
 
The accelerated rates of osteoporosis in schizophrenia could be attributed to several 
risk factors, including antipsychotic-driven decrease in oestrogen and testosterone, 
reduced calcium due to smoking and alcoholism, as well as polydipsia (Abraham et 
al.,2003; Howard et al.,2007).
 
 
iii) Hyperprolactinaemia 
High doses of typical antipsychotics and the atypical antipsychotics (e.g. risperidone 
and amisulpride) raised prolactin levels, causing galactorrhoea, amenorrhoea, 
oligomenorrhoea, sexual dysfunction and contributing to CVD (Canuso et al.,2002; 
Rettenbacher et al.,2010).
 
 
1.9.6 Barriers to detection and treatment of schizophrenia co-morbidity 
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While the excessive medical morbidity and mortality of schizophrenia were largely 
due to treatable medical conditions, the detection rate of the physical illness among 
people with schizophrenia and mental illness in general was very poor (Reeves et 
al.,2010).
 
 
The recognition and management of the medical co-morbidity were made more 
difficult by barriers related to patients themselves as well as the medical providers. 
Medical provider-related factors include (Goldman,1999; Jeste et al.,1996; 
Wright,1996; Carney et al.,2006):
 
 Physical complaints regarded by psychiatrists as psychosomatic symptoms. 
 Reticence of non-psychiatrists to treat people with serious mental illness. 
 Perception of specialist psychiatrists that physical health should be under the care 
of referring doctors. 
 Changes of treating doctor, resulting in patients not having a longitudinal history 
available. 
 Specialist’s attention focused principally on patient’s psychiatric problems, with 
physical examination conducted infrequently. 
 Time and resources for medical examinations not available in current mental 
healthcare service settings. 
 
Patient-related factors include (Goldman,1999; Jeste et al.,1996; Anath,1984): 
 Poor general treatment compliance. 
 Avoidance or neglect of contact with general practitioners or general healthcare 
services. 
 Unawareness of physical problems because of cognitive deficits associated with 
mental illness. 
 Patients’ difficulty in communicating their physical needs and problems in general. 
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 Reduction in pain sensitivity associated with use of antipsychotic drugs. 
 Reluctance of patients to discuss problems. 
It was therefore, imperative to improve the detection and treatment of co-occurring 
medical illness, as it will lead to significant benefits in the psychosocial functioning 
and overall quality of life in patients with schizophrenia. 
1.10   Psychiatric Co-morbidity  
Psychiatric co-morbidity was common in schizophrenia, contributing to further 
impairment. Researchers have documented frequent occurrence of depression (Geerts 
and Brune,2009; Felmet et al.,2011), panic disorder (Ulas et al.,2007; Ulas et al.,2010) 
and anxiety disorder (Braga et al.,2004; Achim et al.,2011), among patients who have 
a diagnosis of schizophrenia. 
It has been reported as many as 25% of patients with schizophrenia exhibit significant 
symptoms of depression (Kilzieh et al.,2004), which was associated with greater 
overall symptom severity and a poorer quality of life (Kennedy et al.,2004). Co-
morbid depression might also increase suicide risk (Montross et al.,2008), and has 
been associated with higher rates of relapse and rehospitalisation (Herz and 
Melville,1980; Johnson,1988), hopelessness (Drake and Cotton,1986), and poor 
psychosocial skills (Glazer et al.,1981; Kollias et al.,2008).
 
In a study by Ulas et al (2007), the prevalence of panic attack and panic disorder in 
patients with schizophrenia was rather significant. Those patients presented with panic 
symptoms were found to have higher scores of Positive and Negative Syndrome Scale 
(PANSS), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression 
(CGI), and Extrapyramidal Symptoms Rating Scale (ESRS). These co-morbid panic 
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symptoms in schizophrenia were suggested to be related to positive symptoms, 
extrapyramidal side effects and depression.  
 
Co-morbid psychiatric illness was also common in childhood-onset schizophrenia 
(Remschmidt and Theisen,2005). Study by Ross and colleague (Ross et al.,2006) 
reported that 99% of children and young adolescents with schizophrenia or 
schizoaffective disorder had at least one co-morbid psychiatric illness, with the most 
common co-morbid conditions being attention deficit hyperactivity disorder (84%), 
oppositional defiant disorder (43%), depression (36%), and separation anxiety disorder 
(25%). 
1.11 Therapy for Schizophrenia: Pharmacological and Non-
pharmacological Approaches 
 
Pharmacological treatment: Antipsychotics 
 
Drug therapy has been the main modality for managing schizophrenia, and 
antipsychotics are the mainstay of drug treatment for this psychiatric illness. The 
development of new antipsychotics and evaluation of their safety and efficacy is an 
important ongoing field of research (Tandon,2011).  
1.11.1 History of antipsychotics 
 
The first generation of antipsychotics, known as typical antipsychotics, was discovered 
in the 1950s. Chlorpromazine, originally developed as a surgical anaesthetic, was the 
first modern antipsychotic drug introduced into psychiatry in 1952 (Janicak et 
al.,2011). It was first used on psychiatric patients owing to its potent calming effect. 
 
This was followed by the introduction of other antipsychotics, such as haloperidol and 
thioridazine, which were also referred as neuroleptic drugs. Due to their neurological 
side effects, particularly extrapyramidal side effects (EPS) and tardive dyskinesia 
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(Miyamoto et al.,2005), second generation antipsychotics or atypical antipsychotics 
were developed (Melnik et al.,2010). 
 
The first atypical antipsychotic drug, clozapine was introduced into clinical practice in 
the 1970s. This was followed by the introduction of other atypical drugs, such as 
olanzapine, risperidone and quetiapine during the 1990s (Shen,1999), and ziprasidone 
and aripiprazole in the early 2000s. The newer atypical antipsychotic, asenapine was 
approved by the FDA in late 2009.     
 
1.11.2 Classification: Typical and Atypical 
 
Antipsychotics can be broadly divided into two groups, the typical or first generation 
antipsychotics and the atypical or second generation antipsychotics.  
1.11.2.1   Typical antipsychotics (First generation) 
Typical antipsychotics (Table 1.2) were available in different formulations, such as 
acute intramuscular injections, liquid form, tablets and in depot formulations. Depot 
injections were useful for the treatment of non-compliant or partially compliant 
patients (Furiak et al.,2011).
 
Table 1.2: Commonly used typical antipsychotics (First generation) 
 
 Chemical group Type 
 
Butyrophenones Haloperidol, bromperidol, trifluperidol, etc. 
 
Phenotiazines Chlorpromazine, fluphenazine, perphenazine, 
prochlorperazine, thioridazine, trifluoperazine, 
promazine, promethazine, etc. 
 
Thioxanthenes 
 
Chlorprothixene, flupenthixol, thiothixene, 
zuclopenthizol 
Diphenylbutylpiperidines Fluspirilene, penfluridol, pimozide 
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Typical antipsychotics effectively treat positive symptoms, but their efficacy in 
treating negative symptoms was limited. It has been reported that 30%-50% of patients 
with positive symptoms of schizophrenia were either not responsive or only partially 
responsive to typical antipsychotics (Kane and Correll,2010). Negative symptoms and 
neurocognitive deficits  also tend to respond poorly to typical antipsychotics, and 
might even be exacerbated by them (Tandon,2011). In fact, first generation 
antipsychotics have been reported to cause negative symptoms, such as anhedonia. 
These conventional antipsychotics have little effect on the depression and suicidal 
behaviour in schizophrenia, leaving to a commit suicidal rate as low as 10% 
(Bitter,2006).  
Nevertheless, the typical antipsychotics had a significant impact on the life of 
schizophrenia patients. Studies showed that about 20% of patients treated with typical 
medications had full remission, and only 30%-40% of patients relapsed during 
treatment, as compared with 80% among those without treatment (Bitter,2006).
 
1.11.2.2  Atypical antipsychotics (Second generation) 
 
The atypical antipsychotics (Table 1.3) worked slightly differently from typical 
antipsychotics. This newer generation of drugs differ from each other in terms of 
receptor binding, efficacy and side-effect profile. 
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Table 1.3: Commonly used atypical antipsychotics (Second generation) 
 
 Chemical group Type 
 
Diazepines/oxazepines/thiazepines Clozapine, olanzapine, quetiapine, asenapine 
 
Benzisoxazoles Risperidone, ziprasidone, paliperidone 
 
Indoles Sertindole 
 
Benzamides Sulpride, remoxipride, amisulpride 
 
Quinolinone 
 
Aripiprazole 
 
 
Atypical antipsychotics were in general more efficacious than typical antipsychotics, 
especially with regard to the improvement in negative, depressive and cognitive 
symptoms of schizophrenia (Bitter,2006). In addition, the second generation drugs 
decreased relapse rates and the need for hospitalisation, and were more efficacious in 
reducing violent behaviour than the first generation drugs (Kane and Correll,2010). 
The defining characteristic of atypical antipsychotics was probably the decreased 
tendency of these agents to cause EPS (Farah,2005) and an absence of sustained 
prolactin elevation (Seeman,2002). 
The above mentioned reasons explained why the atypical antipsychotics were now 
considered to be the first-line treatment for schizophrenia, and were gradually 
replacing the typical antipsychotics. Table 1.4 delineated the advantages of the 
atypical antipsychotics compared with the typical medications. 
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Table 1.4: Advantages of atypical antipsychotics (Second generation) compared 
with typical antipsychotics (First generation)   
 
• Improved therapeutic effect in some treatment-resistant patients. 
• Improved therapeutic effect on negative symptoms and neurocognitive deficits. 
• Reduced potential to cause acute EPS (e.g. akathisia, dystonia, parkinsonism). 
• Reduced potential to cause longer-term EPS (e.g. tardive dystonia, tardive 
dyskinesia, tardive akathisia). 
• Reduced potential to elevate prolactin levels (with the exception of risperidone and 
amisulpride). 
(Lambert and Castle,2003) 
 
1.11.3  Mechanism of Action 
 
Antipsychotics primarily block post-synaptic dopamine D2 receptors in the dopamine 
pathways. They might also variably have activity at other receptors (e.g. serotonergic, 
muscarinic, alpha-adrenergic, histaminergic) to play an important role in both their 
beneficial and adverse effects (Tandon,2011). 
Excess release of dopamine in the mesolimbic pathway has been linked to psychotic 
experiences (Davis et al.,1991). Blocking activity at D2 receptors in the mesolimbic 
pathways was thought to underlie the therapeutic effects of antipsychotics on positive 
symptoms (Lambert and Castle,2003). At the same time, antipsychotic drugs acting on 
D2 receptors in the basal ganglia and hypothalamus typically cause EPS and 
neurohormonal changes (Castle et al.,2008).  
Typical antipsychotics were not particularly selective, they also blocked dopamine 
receptors in the mesocortical pathway, tuberoinfundibular pathway and the 
nigrostriatal pathway. Blocking D2 receptors in these other pathways was thought to 
produce some of the unwanted side effects associated with typical antipsychotics. 
Atypical antipsychotics drugs also blocked dopamine receptors, but were more loosely 
bound to the receptors, and also blocked or partially blocked serotonin receptors and 
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other neurotransmitter receptors (Bitter,2006). For example, risperidone acted 
vigorously on serotonin receptors, while amisulpride did not have serotonergic activity 
(Mortimer,2003). On the other hand, aripiprazole was a mixed dopamine agonist and 
antagonist (i.e. partial antagonist), as well as displaying some serotonin 5-HT1A partial 
agonism and 5-HT2A antagonism. The additional effects of atypical antipsychotics on 
serotonin receptors might explain the benefits of the newer generation drugs on the 
‘negative symptoms’ of schizophrenia (Keck and McElroy,2003). 
While there were significant pharmacodynamic differences within the atypical 
antipsychotics, this class of medications could generally be said to have an increased 
affinity for serotonergic receptors (except amisulpride) over dopaminergic receptors 
compared to typical antipsychotics (Mortimer,2003). In addition, the blockade of 
dopaminergic receptors was more pronounced in the limbic system than in the basal 
ganglia. As a result, the atypical antipsychotics have significantly less EPS 
(Olin,2001).
 
In a study that examined both older and newer antipsychotics, it was found that the 
older traditional antipsychotics, such as chlorpromazine, haloperidol, fluphenazine and 
flupenthixol, bind more tightly than dopamine itself to the dopamine D2 receptor, with 
dissociation constant that were lower than that of dopamine (Seeman,2004). 
 
On the other hand, the atypical antipsychotics, including quetiapine, clozapine, 
olanzapine and ziprasidone, were noted to bind more loosely than dopamine to the 
dopamine D2 receptor and have higher dissociation constants than dopamine. By 
transiently occupying D2 receptors and then rapidly dissociating from them, atypicals 
allowed normal dopamine neurotransmission that keep prolactin levels normal, spare 
cognition and prevent EPS (Seeman,2004). 
 
1.11.4  Side effects 
1 Introduction  
 
34 
 
 
Antipsychotics were generally associated with a range of side effects. A significant 
number of patients in controlled drug trials discontinued antipsychotics partly due to 
adverse effects.  
 
1.11.4.1 Typical antipsychotics 
 
Many of the typical antipsychotics, such as flupenthixol, haloperidol, perphenazine, 
trifluoroperazine and thiothixene were much more potent at blocking dopamine 
receptors than chlorpromazine. Their increased potency however, was not related to 
increased efficacy, but to greater incidence and prevalence of EPS (Table 1.5) caused 
mainly by dopamine blockade of the basal ganglia (Bitter,2006).
 
 
Table 1.5: Extrapyramidal reactions caused by typical antipsychotics 
 
 
• Tardive psychosis 
• Acute dystonias 
• Akathisia 
• Parkinsonism (rigidity and tremor) 
• Tardive dyskinesia 
 
 
Other common side effects of the first generation drugs include neurological 
syndromes hyperprolactinaemia, anhedonia, sedation, disturbances of 
thermoregulation, cognitive impairment, cardiac arrhythmias, weight gain, diabetes 
and antimuscarinic effects (e.g. dry mouth, constipation and urinary retention) 
(Keks,1996). For these and other reasons, typical antipsychotics were increasingly 
being replaced by the newer atypical antipsychotics. 
 
1.11.4.2   Atypical antipyschotics 
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The newer atypical antipsychotic drugs were usually preferred for initial treatment 
over the older typical antipsychotics, as they were often better tolerated and associated 
with fewer neurological adverse events.  
Clozapine was the ‘gold standard’ of second generation antipsychotics. It has 
practically no EPS and was in fact, useful in the treatment of negative symptoms and 
depression in schizophrenia and in preventing suicidal behaviour in these patients 
(Kane and Correll,2010). However, the side effects of clozapine limit its use, 
especially the potentially life-threatening agranulocytosis. As such, clozapine could 
only be used in patients who comply with regular blood monitoring (Tandon,2011).  
Atypical antipsychotics were also more likely to induce weight gain and obesity-
related diseases. Diabetes, hypercholesterolaemia and the metabolic syndrome were 
the more frequent treatment-emergent events with second generation than with first 
generation antipsychotics (Bobes et al.,2007). Nevertheless, there were differences 
within the atypical antipsychotics. For instance, olanzapine appeared to cause 
decreased insulin sensitivity and weight gain more commonly than other atypical 
antipsychotics (McQuade et al.,2004; Lieberman et al.,2005). While amisulpride and 
ziprasidone caused less weight gain, they later increased the corrected QT interval on 
electrocardiogram (Isbister et al.,2006; Camm et al.,2012).
 
1.12  Non-pharmacological: Psychological Therapies 
Successful treatment of schizophrenia not only depended on a life-long 
pharmacological treatment regimen, but also on relevant psychological therapies. 
While medication helped control symptoms associated with schizophrenia (e.g. 
delusions and hallucinations), it could not help the person find a job, learn to be 
effective in social relationships, increase the individual's coping skills, help them learn 
to communicate and work well with others. 
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Educational and psychotherapeutic approaches helped in the recognition of early signs 
and symptoms of relapse, and compliance with drug treatment. Recognising early 
signs and symptoms of schizophrenia helped to prevent a relapse, and in selected high-
risk populations, it helped to start treatment as soon as the symptoms of schizophrenia 
were present (Roder et al.,2011). There are four major and distinct psychological 
treatment approach identified as supplement to pharmacological treatment.    
 
1.12.1 Social Skills Training 
 
Social skills training was widely recommended and used in the treatment of 
schizophrenia. It commonly used training modules for Social and Independent Living 
Skills developed by Liberman el al (2002; 2007). 
By practicing specific disorder-related social and instrumental skills such as basic 
conversation, medication management and community re-entry, individuals with 
schizophrenia might gradually overcome poor social competence and finally improved 
community integration (Bellack,2004). Recent study indicated that social skills 
training led to stable improvement in social functioning and decreased the 
hospitalisation due to relapse at follow-up (Pfammatter et al.,2006).   
1.12.2 Cognitive Remediation  
 
Majority of schizophrenia patients demonstrated poor performance of cognitive 
processing. The affected domains were processing speed, verbal learning, sustained 
attention, working memory, executive functioning and social cognition. Cognitive 
impairments were now recognized as important therapeutic target for schizophrenia 
patients (Wykes and van der Gaag,2001; Medalia and Lim,2004).  
The goal of cognitive remediation was to help the patients using information from 
their surroundings to make adaptive coping decision. The treatment goal was not to 
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‘cure’ schizophrenia, but to improve the patient’s ability to manage life problems, to 
function independently, and to be free of extreme distress and other psychological 
problems (Vita et al.,2011). Cognitive remediation was an intervention focusing on 
improvement of cognitive functioning by: 
(i) Applying repeated practice of cognitive tasks in a computerized or paper and 
pencil version. 
(ii)  Training of strategies for compensating cognitive impairments, either in the form 
of organizing information, e.g. categorization or adaptive strategies, which 
involved other aids in the environment of the schizophrenia patients e.g. posting 
reminders. 
One meta-analysis study findings supported the training of cognitive remediation has 
effects on attention, executive functioning, memory and social cognition (Pfammatter 
et al.,2006).    
1.12.3 Cognitive-behavioural therapy (CBT) of positive symptoms  
About one fourth to up to one half of all schizophrenia patients suffered from 
persisting both delusions and hallucinations or either one despite compliance (Bora et 
al.,2008).    
Cognitive behaviour therapy (CBT) evolved from behavioural theory and developed to 
focus more on cognitive models that based on the assumption of irrational beliefs, 
misinterpretations or thinking errors, reality distortion which presented as visual and 
auditory hallucinations (Hemsley,2005). These misjudgements might hamper the 
discrimination between external stimuli and internal intentions (Sprong et al.,2007). It 
was interesting to observe psychotic experiences could be induced in healthy subjects 
under certain conditions e.g. sleep deprivation, severe stress or through hypnosis 
(Frith,2004).  
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CBT for psychosis incorporated cognitive restructuring with an analysis of the quality 
of psychotic symptoms, their triggering events and their maintaining conditions. It 
would also teach patients to enhance the coping strategies in verbal challenge, 
empirical reality testing or reappraisal (Marcinko and Read,2004).  
A meta-analysis study of 17 randomized controlled trials showed CBT led to 
significant decline of persistent positive symptoms especially the reduction in the 
severity of hallucinations (Pfammatter et al.,2006).    
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1.12.4 Psychoeducational coping-oriented interventions with families and 
relatives’ groups  
 
Psychoeducational coping-oriented interventions with families have become a strongly 
supported evidence-based practice in the treatment of schizophrenia for many years 
(McFarlane et al.,2003; Murray-Swank and Dixon,2004). Expressed emotion (EE) was 
a measure of the family environment which referred to the attitudes of the family 
members toward the patient. The measurement reflected the quality of interaction 
patterns and nature of family relationships among the family caregivers and patients of 
schizophrenia. Patients from high EE homes have a poorer illness prognosis than the 
patients from low EE homes (Amaresha and Venkatasubramanian,2012; Wasserman et 
al.,2012).  
Psychoeducational in families of patients with schizophrenia can reduced the relapse 
rates of these patients (Pitschel-Walz et al.,2001; Pfammatter et al.,2006), positively 
influenced the course of the patient’s illness  (Corrigan et al.,1990; Ramirez Garcia et 
al.,2006), and help the families and patients to better cope with the mental illness 
(Sherman,2003; Chien,2008).  
1.12.5  Integrated psychological  therapy (IPT) 
 
Integrated psychological therapy (IPT) was a group based cognitive behaviour therapy 
for schizophrenia patients with the goal of improved social competence. The therapy 
combined neurocognitive and social cognitive interventions with social skills and 
problem-solving approaches (Roder et al.,2011). Studies have shown the effectiveness 
of IPT including as part of standard medical therapy for patients (Pfammatter et 
al.,2006; Briand et al.,2006).    
IPT was divided into 5 subprograms. The first subprogram targeted on basic 
impairments in neurocognition such as attention, verbal memory, cognitive flexibility 
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and concept formation. The second subprogram addressed deficits in social cognition 
e.g. social and emotional perception, emotional expression. The third subprogram 
focused on neurocognitive skills that directly impact on interpersonal communication, 
such as verbal fluency and executive functioning. The fourth and five subprograms 
emphasized on building patients’ social competence through practice of interpersonal 
skills and group based problem-solving exercises (Roder et al.,2011).           
1.13  Treatment Guidelines and Recommendations 
In general, internationally accepted treatment guidelines such as from American 
Psychiatric Association (APA,1997) and National Institute for Clinical Excellence 
(NICE,2010) recommended oral atypical antipsychotics as first-line medications for 
patients with newly diagnosed schizophrenia or in the acute phase of schizophrenia, 
mainly because of the decreased risk of EPS and tardive dyskinesia.  
The recommended dose was aim for both effective and least cause to side effects 
which might difficult to tolerate. The experience of unpleasant side effects might 
affect long-term adherence. Treatment guidelines recommended different lengths of 
treatment after the first episode of schizophrenia and after repeated episodes. The 
usual recommendation was at least 1 year of continuous treatment after the first 
episode, at least 5 years after the second episode, and long-term maintenance treatment 
after the third episode (NICE,2010).  
For those who have experienced repeated psychotic episodes, long-term (even life-
long) treatment was necessary, at the lowest effective therapeutic dose (Kane et 
al.,2011). It was crucial not to prematurely lower treatment dose or discontinue 
medication during the stabilization phase, as this might lead to a recurrence of 
symptoms and possible relapse (APA,1997). For most patients with schizophrenia in 
the stable phase, psychosocial interventions were recommended as a useful adjunctive 
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treatment to pharmacological treatment to help improve outcomes (Pfammatter et 
al.,2006). 
1.14   Rationale and Objectives of this study  
My study will focus on few important issues related to schizophrenia patients with 
metabolic syndrome including: 
1. Prevalence of Metabolic Syndrome in Schizophrenia Patients Receiving 
Antipsychotics in Malaysia. (Please refer to Chapter 2)  
2. Randomized Controlled Trial of the Safety and Efficacy of Aripiprazole Vs 
Ziprazidone in Schizophrenic Patients with Metabolic Syndrome. (Please refer 
to Chapter 3) 
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2   Prevalence of Metabolic Syndrome 
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Chapter TWO:  Prevalence of Metabolic Syndrome in Schizophrenia Patients 
Receiving Antipsychotics in Malaysia  
 
2.1   Abstract 
Introduction: Metabolic syndrome comprises a spectrum of medical disorders that 
increase the risk of developing type-2 diabetes and cardiovascular disease. It has been 
shown that the association of metabolic syndrome with psychiatric disorders 
particularly schizophrenia, was related associated with antipsychotic used. Atypical 
antipsychotics were reported to be associated with increased risk of hyperglycaemia 
and impaired glucose level, and subsequently increase the risk of the metabolic 
syndrome. 
Objectives: To determine the prevalence of metabolic syndrome and prevalence of 
coronary heart disease risk among schizophrenia patients receiving antipsychotics in 
Malaysia.  
Methodology:  
Design : This was a cross sectional study. 
Setting: The study was conducted at four mental institutions, two army 
hospitals and two general hospitals namely Hospital Bahagia 
Ulu Kinta, Perak, Hospital Permai Johor Bahru, Johor, Hospital 
Sentosa Kuching, Sarawak, Hospital Mesra Kota Kinabalu, 
Sabah, Hospital Terendak Melaka, Navy Hospital Lumut, 
Perak, University Malaya Medical Centre (UMMC), Kuala 
Lumpur and Hospital Sg. Petani, Kedah. 
Patients: Study population were schizophrenia patients aged between 18 
and 65 years old, who met the DSM-IV TR criteria for 
schizophrenia. Patients should receive antipsychotic treatment 
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for at least 1 year and were not on mood stabilizer or depot 
neuroleptics. 
Measures: Metabolic syndrome was defined by using the NCEP ATP III 
criteria-modified for Asian waist circumference. The 
cardiovascular heart disease risk was assessed by using 
Framingham function (10-year all coronary heart disease 
event). A structured questionnaire to assess: (i) 
sociodemographic and lifestyle background (ii) medical, 
psychiatry and family history (iii) physical examination and 
blood investigation for metabolic syndrome profile. 
 
Results:      A total of 270 patients were screened for metabolic syndrome. The 
prevalence of metabolic syndrome was 46.7%. The mean BMI value was 29.4 ± 5.1 
kg/m
2
 for patients with metabolic syndrome and 25.0 ± 5.6 kg/m
2 
for patient, without 
metabolic syndrome (p<0.05). The usage of commonest monotherapy atypical 
antipsychotics was olanzapine (42.2%) and chlorpromazine for typical antipsychotics 
(33.3%) in the metabolic syndrome group. The prevalence of diabetes mellitus after 
initiation of antipsychotics was 15.2%. There was statistically significant for all 
metabolic syndrome components between metabolic syndrome and non-metabolic 
syndrome groups i.e. Waist circumference (OR=34.8, 95% CI: 12.2, 99.4), HDL 
Cholesterol (OR=5.4, 95% CI: 3.2, 9.2), Triglycerides (OR= 8.6, 95% CI: 4.9, 15.2), 
BP (OR=5.5, 95% CI: 3.2, 9.3), FBS (OR= 11.4, 95% CI: 5.5, 23.6). Coronary heart 
disease 10-year risk was significantly higher in the metabolic syndrome patients. The 
prevalence of patients with high/very high cardiovascular event risk (Framingham ≥ 
10%) was 31.5% in the metabolic syndrome patients vs. 11.0% in the non-metabolic 
syndrome patients (OR = 3.7, 95% CI: 1.9, 7.1, p<0.0001).  
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Conclusion: The prevalence of metabolic syndrome in schizophrenia patients 
receiving antipsychotic in Malaysia was very high. It was associated with increased 
cardiovascular risk. Intervention measures are urgently needed to combat these 
problems. 
        
Keywords: prevalence, metabolic syndrome, schizophrenia, cardiovascular risk, body 
mass index. 
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2.2   Introduction 
Metabolic Syndrome 
The metabolic syndrome comprises a spectrum of medical disorders that increase the 
risk of developing type 2 diabetes (T2D) and cardiovascular disease (CVD). The 
metabolic syndrome is also commonly known as ‘syndrome X’ and ‘insulin resistance 
syndrome’ (Cho,2011). 
2.2.1 History 
The term ‘metabolic syndrome’ was introduced in the late 1950s. However it only 
became more commonly used in the late 1970s to explain the various risk factors 
associated with diabetes that had been described as early as the 1920s (Joslin,1921; 
Kylin,1923). In 1977, the term was used by Haller to describe the additive effects of a 
cluster of risk factors on atherosclerosis (Haller,1977). The risk factors were obesity, 
diabetes mellitus, hyperlipoproteinemia, hyperuricemia and hepatic steatosis. The term 
was also used by Singer (1977) to describe the associations of obesity, gout, diabetes 
mellitus and hypertension with hyperlipoproteinemia. 
In 1977 and 1978, Gerald B. Phillips developed the concept that risk factors for 
myocardial infarction overlap to form a "constellation of abnormalities" (i.e. glucose 
intolerance, hyperinsulinemia and hypertension) that was associated not only with 
heart disease, but also with aging, obesity and other clinical states (Phillips,1977; 
Phillips,1978). A decade later, Gerald Reaven proposed insulin resistance as the 
underlying factor, and named the cluster of abnormalities Syndrome X. However, 
abdominal obesity was not included as part of the syndrome at that time 
(Reaven,1988).   
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Today, the metabolic syndrome was used to define a group of metabolic abnormalities 
(i.e. diabetes or prediabetes, abdominal obesity, elevated lipid levels and blood 
pressure) associated with increased risks of T2D and CVD.  
 2.2.2 Prevalence   
The metabolic syndrome affects a great number of people. It was estimated that 
around 20%-25% of the world’s adult population have the metabolic syndrome 
(Alberti et al.,2006). In the recent National Health Survey in US, it was found that 
34.3% adults suffering from the metabolic syndrome, which was about 71.8 million 
adults (Ford et al.,2010). While most European studies found the prevalence of the 
metabolic syndrome to be within the range of 12%-38% (Pannier et al.,2006; Bernal-
Lopez et al.,2011; Mokáň et al.,2008; Fernández-Bergés et al.,2012; Szigethy et 
al.,2012).  
Study by Lee et al (2008) reported the prevalence of the metabolic syndrome in four 
Asia-Pacific populations using different definitions from the World Health 
Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), 
and International Diabetes Federation (IDF). It was found that Japanese had the lowest 
metabolic syndrome rates (3%-11%), followed by Korea (7%-29%), Australia (16%-
42%) and Samoa (17%-60%). 
Asians have a lower prevalence of the metabolic syndrome (5%-17.8%) (Lao et 
al.,2012; Kim et al.,2012; DECODA,2007; Lee et al.,2004). In Koreans, the reported 
prevalence rates of the metabolic syndrome, using the Asia Pacific criteria for obesity, 
were 13.1% (13.2% male, 13.1% female) (Lee et al.,2004). In addition, the odds ratio 
of the metabolic syndrome in those aged over 70 years against those aged 20-29 years 
was 13.8 (95% CI 8.2-23.2), and in women vs. men 1.4 (95% CI 1.2-1.5). In Thailand, 
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a prevalence of 15.2% was reported among Thai professional and office workers, and 
it was three times more common in men than in women (25.8% vs. 8.2%) 
(Lohsoonthorn et al.,2007).  
However, Malaysia has a much higher prevalence of metabolic syndrome compared to 
other Asian countries. Based on the WHO, ATP III, IDF and Harmonized definitions, 
the overall crude prevalence of metabolic syndrome in Malaysia was 32.1%, 34.3%, 
37.1% and 42.5%, respectively (Mohamud et al.,2011).  
Despite the generally lower incidence of metabolic syndrome in Asians, it should be 
noted that current evidence has shown a heightened risk for diabetes mellitus among 
Asian populations (Craig et al.,2007; Gupta and Kumar,2008).   
2.2.3 Impact of the metabolic syndrome   
While the metabolic syndrome itself poses serious health complications, it also places 
individuals at an increased risk for other serious medical conditions, such as 
cardiovascular mortality (Simons et al.,2011; Kondo et al.,2011).
 
The clustering of various metabolic abnormalities occurring in the same individual 
confers a significant additional cardiovascular risk, over and above the sum of the risk 
associated with each abnormality (Shin et al.,2009; Protopsaltis et al.,2007). Studies 
showed that the more components of the metabolic syndrome that were evident, the 
higher was the cardiovascular mortality rate (Hu et al.,2004). For instance, the 4-year 
risk of incident myocardial infarction among men ages 40-65 in the Prospective 
Cardiovascular Munster (PROCAM) study was increased 2.5 times in the presence of 
either T2D or hypertension, 8 times in the presence of both factors, and 19 times in the 
presence of both factors plus an abnormal lipid profile (Assmann et al.,2002).
  
  
2   Prevalence of Metabolic Syndrome 
 
49 
 
In a 10-year follow-up study of PROCAM (Assmann et al.,2002),  based on 325 acute 
coronary events among 5,389 men aged 35-65 years at recruitment into the study, a 
COX proportional hazards model was developed. Based on this model, eight 
independent risk predictors of coronary events were found. Among the risk variables, 
diabetes (HR=1.491, 95% CI: 1.095 -2.030), elevated systolic blood pressure 
(HR=1.010, 95% CI: 1.005 - 1.016), reduction in HDL-cholesterol level (HR=0.968, 
95% CI: 0.957 - 0.980) and triglycerides (HR=1.373, 95% CI: 11.056 - 1.785) were 
components of the metabolic syndrome. 
Individuals with the metabolic syndrome were twice as likely to die from and three 
times as likely to have a myocardial infarction or stroke compared with people without 
the syndrome. In addition, people with the syndrome had a five-fold greater risk of 
developing T2D (Stern et al.,2004). The cardiovascular complications of diabetes, 
which was also a leading cause of blindness, amputation and kidney failure, account 
for much of the social and financial burden of the disease (WHO,1994b). 
 
When comparing type 2 diabetic (T2D) patients with and without the metabolic 
syndrome, those with the syndrome (about 19.2%%) have a much greater risk for 
CVD than those without (about 7.5%) (Alexander et al.,2003). It has been shown in 
the US Third National Health and Nutrition Examination Survey (NHANES III) that 
the age-adjusted prevalence of coronary heart disease (CHD) was highest in patients 
with both T2D and the metabolic syndrome (19.2%), followed by patients with the 
syndrome but not T2D (13.9%) (Alexander et al.,2003). Among the risk variables, 
diabetes (OR=1.55, 95% CI: 1.07 –2.25), elevated blood pressure (OR=1.87, 95% CI: 
1.37 –2.56) and reduction in HDL-cholesterol level (OR=1.74, 95% CI: 1.18 - 2.58) 
were components of the metabolic syndrome. 
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In a follow-up by Isomaa and colleagues (2001), the risk of CHD and stroke was 
found to be tripled among subjects with the metabolic syndrome aged 35 to 70 years as 
compared with those who did not have the syndrome (p<0.001). Compared with 
subjects without the metabolic syndrome,
 
total mortality (18.0 vs. 4.6%, p<0.001) and 
cardiovascular mortality (12.0 vs. 2.2%; p<0.001) were increased in subjects
 
with the 
metabolic syndrome. Further analysis with a multiple regression analysis, Isomaa and 
colleagues reported metabolic syndrome (RR=1.81, 95% CI: 1.24 - 2.65) and 
microalbuminuria (RR=2.80, 95% CI: 1.62 - 4.83) as an indication of diabetic 
nephropathy were the strongest risk factor
 
for cardiovascular death.  
2.2.4 Risk factors and underlying factors 
While the pathophysiology of the metabolic syndrome was extremely complex and 
remained to be fully elucidated, currently both insulin resistance and central obesity 
were considered to be the significant underlying causes of this syndrome (Anderson et 
al.,2001; Nesto,2003). 
Insulin resistance 
Insulin resistance occured when body cells become less sensitive and eventually 
resistant to insulin. It resulted from inherited and acquired influences, and has been 
linked to increased risk of CHD (Meshkani and Adeli,2009; Miranda et al.,2005). 
Hereditary causes of insulin resistance include mutations of insulin receptors, glucose 
transporters and signalling proteins, although the common forms were largely 
unidentified. Acquired causes include physical inactivity, diet, medications, 
hyperglycaemia, increased free fatty acids and the aging process (Cho,2011). Insulin 
resistance played a major pathogenic role in the development of the metabolic 
syndrome, including: (Meshkani and Adeli,2009; Alberti et al.,2006)
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• Hyperinsulinaemia 
• T2D or glucose intolerance 
• Central obesity 
• Hypertension 
• Dyslipidaemia, chiefly manifested as a triad of low high-density lipoprotein-
cholesterol (HDL-C) together with increases in triglycerides and small, dense low-
density lipoprotein (sLDL) particles  
• Hypercoagulability characterized by an increased plasminogen activator inhibitor 1 
(PAI-1) level 
• A proinflammatory state, with increases in acute-phase reactants, such as C-
reactive protein (CRP) 
• A prothrombotic state, with increases in plasminogen activator inhibitor (PAI-1) 
and fibrinogen. 
Central obesity 
Obesity was associated with the metabolic syndrome, and was the most common cause 
of insulin resistance (Shand et al.,2009). Obesity contributed to hypertension, high 
serum cholesterol, low high-density lipoprotein-cholesterol and hyperglycaemia, and 
was independently associated with higher CVD risk (Kurukulasuriya et al.,2011; 
Zalesin et al.,2011).  
The risk of serious health consequences in the form of T2D, CHD and a range of other 
conditions had been shown to rise with an increase in body mass index (BMI) (Flint et 
al.,2010; Chung et al.,2012). A BMI greater than 25 kg/m
2
 increased the risk of 
metabolic syndrome (Lohsoonthorn et al.,2007). However, the waist circumference in 
people with central obesity was considered to be more indicative of the metabolic 
syndrome profile (Parikh et al.,2009).  
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2.2.5 Other risk factors   
Besides insulin resistance and obesity, various factors, including age, gender, family 
history, lifestyle and medications, play important roles in the development of the 
metabolic syndrome. The effect of the risk factors however, might vary depending on 
ethnic group (Tan et al.,2011).
 
Age 
The prevalence of metabolic syndrome increases with age, affecting less than 20% of 
people in their 20s and more than 50% of people in their 60s (Ford et al.,2010). 
However, it had been noted that the features of the metabolic syndrome were 
becoming evident in young children, where three or more components of the syndrome 
being present (Xu et al.,2012).   
Gender 
Metabolic syndrome was more evident in middle-aged men (Novak et al.,2011) but 
later women tend to assume increased cardiovascular risk after menopause (Pérez-
López et al.,2009). A study in US reported prevalence of the metabolic syndrome was 
more common in African American women than in African American men and in 
Mexican American women than in Mexican American men. However the metabolic 
syndrome affects more White men than White women (Salsberry et al.,2007).  
Genetic factors 
People with a sibling or parent with diabetes or with a personal history of diabetes, 
were at greater risk of developing the metabolic syndrome (Magnusson et al.,2012; 
Efstathiou et al.,2012).   
Ethnicity 
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Members of certain ethnic groups were at increased risk for the metabolic syndrome. 
Hispanics seem to be at greater risk for the syndrome than other races (Kolovou et 
al.,2007).
 
For example, in the US, Mexican Americans have the highest rate of 
metabolic syndrome (44.5%), followed by Caucasians (43.2%) and African Americans 
(32.5%) (Ford et al.,2010).  
Lifestyle  
Sedentary lifestyle and excess caloric intake predispose individuals to various medical 
disorders, including hypertension, hypercholesterolaemia and obesity, thereby 
contributing to the development of the metabolic syndrome (Cho,2011).  
Medications 
Some people were at risk for the metabolic syndrome due to medications that might 
cause gain in weight or changes in the blood pressure, cholesterol and blood sugar 
level. These medicines were most often used for inflammation and allergies (e.g. 
glucocorticoids) (Schacke et al.,2002) , HIV (e.g. protease inhibitors) (Boesecke and 
Cooper,2008), depression and other types of psychiatric diseases (e.g. atypical 
antipsychotics) (Fenton and Chavez,2006). 
Atypical antipsychotics were reported to be associated with increased risk of impaired 
glucose level and hyperglycaemia, and subsequently increase the risk of the metabolic 
syndrome (Newcomer et al.,2002). Nevertheless, it has been shown that psychiatric 
disorders including schizophrenia, were associated with an elevated risk of developing 
diabetes regardless of antipsychotic use (Henderson,2002). 
Patients with schizophrenia were at greater risk for metabolic dysfunctions than other 
individuals due to a number of reasons, including inactive lifestyle, poor dietary 
choices, and side effects of antipsychotic medications (Cohn,2009).  
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In a study conducted by Cohn and colleagues (2004) involving 240 subjects with 
schizophrenia or schizoaffective disorder, a prevalence of 42.6% and 48.5% were 
found in the male and female patients respectively, using the NCEP criteria. Cohn also 
reported equal prevalence for those under age 45 years (43.8%) and those ages 45 
years and over (45.8%). Using the same metabolic syndrome definition, studies of 
inpatients with schizophrenia have described the prevalence of metabolic syndrome 
ranging from 27% to 29 % (Teixeira and Rocha,2007; Rezaei et al.,2009) while in 
outpatients ranging from 25% to 35% (Bobes et al.,2007; Huang et al.,2009). 
2.2.6 Diagnostic criteria and classification 
There were a number of diagnostic criteria developed for the metabolic syndrome by 
different expert organizations. The most widely accepted ones were produced by the 
World Health Organization (WHO) (1999) (Table 2.1), the European Group for the 
Study of Insulin Resistance (EGIR) (Balkau and Charles,1999) (Table 2.2) and the 
National Cholesterol Education Program - Third Adult Treatment Panel (NCEP ATP 
III) (2001) (Table 2.3). NCEP ATP III definition was most commonly used in the US. 
Although all these existing guidelines agreed on the core components of the metabolic 
syndrome e.g. obesity, insulin resistance, dyslipidaemia and hypertension, they were 
difficult to use or sometimes produced conflicting results in the attempt to identify 
individuals with the metabolic syndrome in clinical practice (Alberti et al.,2006). 
Therefore, it has made direct comparisons of data difficult between studies because 
different definitions have been used to identify the metabolic syndrome. 
Although there was no single and universally accepted diagnostic tool for metabolic 
syndrome, NCEP ATP III and International Diabetes Federation (IDF)  more favours 
and easier to use in clinical practice. The latest International Diabetes Federation (IDF) 
definition of the metabolic syndrome addressed both clinical and research needs, 
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providing an accessible, diagnostic tool suitable for worldwide use (Table 2.4) (Alberti 
et al.,2006). Furthermore, The latest NCEP ATP III criteria (Grundy et al.,2005) and 
the IDF criteria provide different obesity cut-points for different ethnic groups (Table 
2.5) (Alberti et al.,2006).
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Table 2.1: WHO Diagnostic Criteria  
 
For a person to be defined as having the metabolic syndrome, they must have: 
• Diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or 
insulin resistance 
• Plus at least two of the following: 
Elevated blood 
pressure 
• ≥140/90 mmHg 
• Or on antihypertensive drugs 
Dyslipidaemia • Triglycerides ≥1.7 mmol/L 
• Or HDL-C 0.9 mmol/L in males, 1.0 mmol/L in 
females 
Central obesity • Waist:hip ratio >0.90 in males, >0.85 in females,  
• And/or body mass index >30 kg/m2 
Microalbuminuria • Urinary albumin excretion level of 20 mcg/min 
• Or albumin:creatinine ratio (ACR) ≥30 mg/g 
(WHO,1999) 
 
 
 
Table 2.2: EGIR Diagnostic Criteria  
 
For a person to be defined as having the metabolic syndrome, they must have: 
• Insulin resistance, defined as the top 25% of the fasting insulin values among 
non-diabetic individuals 
• Plus at least two of the following: 
Elevated blood 
pressure 
• ≥140/90 mmHg 
• Or on antihypertensive drugs 
Dyslipidaemia • Triglycerides ≥2.0 mmol/L 
• And/or HDL-C 1.0 mmol/L, or treated for 
dyslipidaemia 
Central obesity Waist circumference ≥94 cm in males, ≥80 cm in females 
Raised fasting plasma 
glucose (FPG) 
FPG ≥6.1 mmol/L 
(Balkau and Charles,1999) 
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Table 2.3: NCEP ATP III Diagnostic Criteria  
 
For a person to be defined as having the metabolic syndrome, they must have: 
• At least three of the following: 
Elevated blood 
pressure 
• ≥130/85 mmHg 
Dyslipidaemia • Triglycerides ≥1.695 mmol/L (150 mg/dL) 
• Or HDL-C <40 mg/dL in males, <50 mg/dL in females 
Central obesity Waist circumference ≥102 cm (40 inches) in males, ≥88 cm 
(36 inches) in females 
Raised fasting plasma 
glucose (FPG) 
FPG ≥6.1 mmol/L (110 mg/dL) 
(NCEP,2001) 
 
 
Table 2.4: The IDF Diagnostic Criteria  
 
For a person to be defined as having the metabolic syndrome, they must have: 
• Central obesity (defined as waist circumference* with ethnicity specific 
values) 
• Plus at least two of the following: 
Raised triglycerides 150 mg/dL (1.7 mmol/L)  
or specific treatment for this lipid abnormality 
Reduced HDL-C <40 mg/dL (1.03 mmol/L) in males 
<50 mg/dL (1.29 mmol/L) in females 
or specific treatment for this lipid abnormality 
Raised blood pressure Systolic BP 130 mmHg or diastolic BP 85 mmHg 
or treatment of previously diagnosed hypertension 
Raised fasting plasma 
glucose (FPG) 
FPG 100 mg/dL (5.6 mmol/L),  
or previously diagnosed type 2 diabetes 
If above 5.6 mmol/L (100 mg/dL), oral glucose tolerance 
test is strongly recommended, but is not necessary to 
define presence of the syndrome 
*If BMI is >30 kg/m
2
, central obesity can be assumed and waist circumference does not need 
to be measured.(Alberti et al.,2006) 
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Table 2.5: Country-/ethnic-specific values for waist circumference  
 
Country/ethnic group Waist circumference (as measure of central obesity) 
Europids Male: 94 cm; Female: 80 cm 
South Asians Male: 90 cm; Female: 80 cm 
Chinese Male: 90 cm; Female: 80 cm 
Japanese Male: 90 cm; Female: 80 cm 
These are pragmatic cut-points and better data are required to link them to risk. Ethnicity 
should be the basis for classification, not country of residence.(Alberti et al.,2006)  
 
 
2.2.7 Antipsychotics and Metabolic Syndrome  
 
While physicians today were familiar with the risk of diabetes amongst patients, there 
were still many physicians unaware those psychiatric disorders such as schizophrenia, 
also place patients at an increased risk for other serious medical comorbidities 
(Lieberman,2004; Subashini et al.,2011).  
The development of the metabolic syndrome in patients suffering from schizophrenia 
was indeed a serious concern today. Patients with schizophrenia were at greater risk 
for metabolic dysfunctions than other individuals due to a number of reasons, 
including inactive lifestyle, poor dietary choices and side effects of antipsychotic 
medications (Meyer et al.,2008; Vancampfort et al.,2011).
 
2.2.8   Prevalence of Metabolic Syndrome with Antipsychotics Treatment  
The metabolic adverse effects of atypical antipsychotics have received particular 
attention in the recent years. Certain atypical antipsychotics were recognised to be 
associated with greater incidence of metabolic syndrome than others (ADA-APA-
AACE,2004; Picchioni and Murray,2007). While the metabolic syndrome itself was a 
serious health risk and medical complication, some studies suggested that the 
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syndrome might place patients at an increased risk of cardiovascular disease (Isomaa 
et al.,2001; Goff et al.,2005).
 
 
Emerging data indicated that the metabolic syndrome was much more prevalent 
among schizophrenia patients (Heiskanen et al.,2003; Basu et al.,2004; Cohn et 
al.,2004). Heiskanen and colleagues (2003) were amongst the earliest study quantify 
the prevalence of the metabolic syndrome among the mentally ill using the National 
Cholesterol Education Program (NCEP) criteria. Their data was drawn from a sample 
of 35 Finnish schizophrenic outpatients, and showed a prevalence of 37%, which was 
2-4 times higher than the prevalence reported for the general population in eastern 
Finland (Table 2.6).  
Basu and colleagues (2004)
 
also noted a prevalence of 42.4% out of 33 outpatients 
with schizoaffective disorder enrolled in a clinical trial (mean age 44.5 years). That 
rate was almost two times the prevalence for the cohort ages 40-49 years in the Third 
National Health and Nutrition Examination Survey (NHANES III) (Table 2.6).  
In a larger study by conducted by Cohn and colleagues (2004) involving 240 subjects 
with schizophrenia and schizoaffective disorder, a prevalence of 42.6% was found in 
the male patients and 48.5% female patients using the NCEP criteria. Cohn also 
reported equal prevalence for those under age 45 years (43.8%) and those ages 45 
years and over (45.8%). Their findings were a complete contrast to that observed in 
the general population that shown the prevalence of metabolic syndrome increased 
with age (Table 2.6).   
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Table 2.6   Prevalence of Metabolic Syndrome in Schizophrenia Patients with ATP 
NCEP III definition  
 
Study Study description N 
Mean Age, 
Years Prevalence 
     
Heiskanen 
(2003) 
35 Finnish outpatients with 
schizophrenia. 
Female:16  
Male : 19 
44.5 37.1% 
     
Basu 
(2004) 
33 outpatients with 
schizophrenia or 
schizoaffective disorder  
Female: 19  
Male:14 
44.5 42.4% 
     
Cohn 
(2004) 
240 Canadian subjects with 
schizophrenia or 
schizoaffective disorder, two 
thirds outpatients. 
Female: 84  
Male: 156  
43.3 44.7% 
     
Heiskanen et al.,2003 ;Basu et al.,2004 ;Cohn et al.,2004 
 
In recent studies, the prevalence of metabolic syndrome among schizophrenia with 
antipsychotics treatment has not much change from the earliest studies, ranging from 
34.4% to 49.6% (Kraemer et al.,2011; Subashini et al.,2011; Grover et al.,2012), 
except for Japan 27.5% (Sugawara et al.,2010). Low prevalence was also noted for 
schizophrenia patients who never received antipsychotic drug, ranging from 3.9% to 
24.7% (Padmavati et al.,2010; Kraemer et al.,2011; Mitchell et al.,2011).  
A meta-analysis has included 77 publications shown the overall rate of metabolic 
syndrome was 32.5% (95%CI: 30.1%, 35.0%). Waist circumference was the most 
useful in predicting high rate of metabolic syndrome with a sensitivity of 79.4% and a 
specificity of 78.8% (Mitchell et al.,2011).    
2.2.9 Metabolic side effects of antipsychotic medication 
The onset of either one or all of the metabolic side effects associated with the second 
generation antipsychotics such as obesity, impaired glucose tolerance or diabetes and 
dyslipidaemia would increase the probability of patients developing the metabolic 
syndrome and also cardiovascular disease (Goff et al.,2005). 
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2.2.10 Weight Gain and Obesity 
Atypical antipsychotics have been frequently reported as causing a higher increase in 
weight gain than conventional antipsychotics (Bustillo et al.,1996; Citrome et 
al.,2011). There was considerable evidence, particularly in patients with 
schizophrenia, that treatment with the atypical antipsychotics could cause a rapid 
increase in body weight in the first few months of therapy (Zhang et al.,2004).  
There was however, considerable variability in weight gain caused by the various 
atypical antipsychotics (Wirshing et al.,1999). In a study conducted by Allison et al 
(1999), patients were on standard doses of 5 atypical antipsychotics for 10 weeks and 
weight gain for each drug was calculated. Weight gain associated with ziprasidone 
(0.04 kg), risperidone (2.10 kg), sertindole (2.92 kg), olanzapine (4.15 kg) and 
clozapine (4.45 kg). Subjects receiving placebo has mean lost weight of 0.74 kg.  
Another prospective study by Meyer el al (2001) reported mean weight increased 
during the first year of therapy with clozapine 5.3-6.3 kg, olanzapine 6.8-11.8 kg, 
risperidone 2.0-2.3 kg, quetiapine 2.8-5.6 kg, ziprasidone and aripiprazole less than 
0.9 kg. 
The mechanisms responsible in weight gain associated with atypical antipsychotic 
were not fully understood. It is suspected to be related to the changes in leptin and 
insulin level (Zhang et al.,2004), which might alter hunger and satiety in people taking 
atypical antipsychotics, from the result through binding of atypical drugs to serotonin, 
norepinephrine, dopamine and particularly histamine-H1 receptors. All of these 
receptors have been implicated in the control of body weight (ADA-APA-
AACE,2004). 
2   Prevalence of Metabolic Syndrome 
 
62 
 
Weight gain and changes in body composition might account for many of the 
metabolic complications associated with atypical antipsychotic therapy, such as insulin 
resistance, pre-diabetes, diabetes and dyslipidaemia (ADA-APA-AACE,2004). Even 
without the development of the metabolic syndrome or diabetes, significant weight 
gain associated with antipsychotic treatment might compromise a patient’s health by 
contributing to comorbid conditions, such as hypertension and coronary artery disease 
(Daumit et al.,2008).  
2.2.11 Hyperglycaemia and Impaired Glucose Tolerance 
Atypical antipsychotics could increase the risk of hyperglycaemia and impaired 
glucose levels, and subsequently lead to the risk of metabolic syndrome. 
Abnormalities in glucose regulation were first reported in patients with schizophrenia 
and bipolar disorder prior to the introduction of antipsychotic medications, with early 
reports indicating a pattern of insulin resistance in untreated patients (Meduna et 
al.,1942). Ryan et al (2003)  also reported impaired fasting glucose tolerance in first-
episode, drug-naïve patients with schizophrenia. These patients were also more insulin 
resistant and have higher levels of plasma glucose, insulin and cortisol than healthy 
comparison subjects. 
Patients treated with olanzapine and clozapine have higher fasting and postprandial 
insulin levels than patients treated with conventional antipsychotics, even after 
adjusting for body weight (ADA-APA-AACE,2004). Individual cases have shown 
marked hyperglycaemia in patients taking clozapine and olanzapine (Koro et al.,2002; 
Sernyak et al.,2003). 
One possible mechanism for hyperglycaemia was effect on pancreatic β- cell function 
that lead to impairment of insulin action and insulin resistance (Best et al.,2005). 
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Drug-induced insulin resistance might occur because of weight gain or a change in 
body fat distribution, or by a direct effect on insulin sensitive target tissues (ADA-
APA-AACE,2004). 
2.2.12  Diabetes 
Treatment with antipsychotic medications was also associated with exacerbation of 
existing type 1 and type 2 diabetes, new onset of type 2 diabetes mellitus, as well as 
diabetic ketoacidosis (Henderson,2001; Cohen and Correll,2009). Numerous case 
reports have documented the onset of exacerbation of diabetes, including the 
occurrence of hyperglycaemia crises, following initiation of therapy with many of the 
atypical antipsychotics (ADA-APA-AACE,2004).
 
The onset of diabetes tended to occur within the first few months of the treatment. A 
meta-analysis of 45 published cases of new-onset diabetes and diabetic ketoacidosis 
over a 21-year period found the highest increase of new diabetes cases within the first 
1 to 3 months after the initiation of atypical antipsychotic treatment (Jin et al.,2002). 
Despite limitations in study design, data consistently showed an elevated risk for 
diabetes in patients treated with clozapine or olanzapine compared with patients 
receiving treatment with the first generation antipyschotics or with other atypical 
antipsychotics (ADA-APA-AACE,2004). The risk of new onset type 2 diabetes 
associated with use taking risperidone and quetiapine was also noted by Lambert et al 
(2006). Aripiprazole and ziprasidone have relatively limited epidemiological data, but 
clinical trial experience with these drugs thus far has not shown an increased risk for 
diabetes (Blonde et al.,2008; Yood et al.,2009).
 
 
The concern about glucose intolerance, diabetes mellitus and diabetic ketoacidosis 
associated with atypical antipsychotic therapy has culminated in Food and Drug 
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Administration (FDA) mandating changes in the drug labelling, which contains 
warnings for hyperglycaemia and diabetes for all atypical antipsychotics (FDA,2004).   
2.2.13 Dyslipidaemia 
An additional related consequence of atypical antipsychotic use was their effect on 
serum lipids. The available evidence suggested that changes in serum lipids were in 
accordance with body weight changes. Clozapine and olanzapine, which produces the 
greatest weight gain, were associated with the greatest increases in total cholesterol, 
low-density lipoprotein (LDL) cholesterol and triglycerides, and with decreased high-
density lipoprotein (HDL) cholesterol (ADA-APA-AACE,2004). 
Aripiprazole and ziprasidone, which were associated with the least amount of weight 
gain, did not appear to be associated with a worsening of serum lipids, while 
risperidone and quetiapine have intermediate effects on lipids (Casey,2004). 
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Table 2.7  Atypical Antipsychotics and Metabolic Effects   
 
Drug Weight gain Risk for diabetes Worsening lipid profile 
Clozapine +++ + + 
Olanzapine +++ + + 
Risperidone ++ D D 
Quetiapine ++ D D 
Aripiprazole* +/- - - 
Ziprasidone* +/- - - 
+ = increase effect; - = no effect; D = discrepant results., *Newer drugs with limited long-term 
data 
(ADA-APA-AACE,2004) 
2.2.14 Management of antipsychotic-related metabolic syndrome 
Simple monitoring and management tips could aid physicians in managing obese 
schizophrenia patients, or those with the metabolic syndrome. Some guidance about 
this issue was provided in the consensus statement developed by a panel consisting of 
the American Diabetes Association, the American Psychiatric Association, the 
American Association of Clinical Endocrinologists, and the North American 
Association for the Study of Obesity (ADA-APA-AACE,2004). 
In summary, the panel recommended the following: 
1. Risk-benefit assessment when starting atypical antipsychotics 
2. Patient, family and caregiver education. 
3. Baseline screening. 
4. Regular monitoring. 
5. Referral to specialised services, when appropriate. 
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2.2.15 Risk-benefit assessment 
The choice of atypical antipsychotics for a specific patient depended on many factors. 
The implications of developing treatment-induced metabolic disease should be an 
important consideration (ADA-APA-AACE,2004).
 
Amongst the currently available atypical antipsychotics, clozapine was clearly the 
most effective antipsychotic. However, clozapine was only indicated after other 
medication have failed or in patients at high risk for suicidal behaviour, largely 
because it can cause agranulocytosis (Agid et al.,2007; Meltzer,2005). 
 
A number of factors should be considered when selecting among the antipsychotic 
medications (ADA-APA-AACE,2004). These include: 
• The nature of the patient’s psychiatric conditions 
• The specific target signs and symptoms 
• Past history of drug response 
• Patient preference 
• History of treatment adherence 
• Medication effectiveness 
• Psychiatric and medical comorbidities 
• The availability of appropriate formulations 
• The need for special monitoring 
• The cost of and access to medications. 
 
Given the serious health risks, patients taking atypical antipsychotics should receive 
appropriate baseline screening and ongoing monitoring (De Hert et al.,2011). 
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2.2.16 Patient, family and caregiver education 
Patients, family members and caregivers need to know that treatment with some 
atypical antipsychotics might be associated with significant weight gain and a 
heightened risk of developing diabetes and dyslipidaemia. Healthcare professionals, 
patients, family members and caregivers should also be aware of the signs and 
symptoms of diabetes, and especially those associated with the acute decompensation 
of diabetes, such as diabetic ketoacidosis (Li and Arthur,2005). 
 
2.2.17 Baseline screening 
When prescribing an atypical antipsychotic, baseline screening and follow-up 
monitoring was essential in order to lower the possibility of developing CVD, diabetes 
or other diabetes complications (De Hert et al.,2011). 
The ADA-APA panel recommended that baseline screening measures (Table 2.8) be 
obtained before, or as soon as clinically feasible right after the initiation of any 
antipsychotic medication (ADA-APA-AACE,2004):
 
1. Personal and family history of obesity, diabetes, dyslipidaemia, hypertension, or 
CVD 
2. Weight and height  
3. Waist circumference  
4. Blood pressure; 
5. Fasting plasma glucose 
6. Fasting lipid profile. 
 
These assessments could determine if the patient was overweight (BMI 25.0-19.9) or 
obese BMI (30), has pre-diabetes (fasting plasma glucose 100-125 mg/dl) or diabetes 
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(FBS  126 mg/dl), hypertension (BP >140/90mmHg) or dyslipidaemia. If any of 
these conditions were identified, appropriate treatment should be initiated. 
For patients with or at higher risk for diabetes and in those treated with other 
medications that might increase these risks, it might be preferable to initiate treatment 
with an atypical antipsychotics that have a lower propensity for weight gain and 
glucose intolerance (Freudenreich et al.,2007). 
2.2.18 Regular monitoring 
Careful monitoring of at-risk patients might aid in the prevention of metabolic 
syndrome as well as the management of any potential symptoms should they occur. 
The patient’s weight should be reassessed at 4, 8 and 12 weeks after initiating or 
changing atypical antipsychotic therapy, and quarterly thereafter at the time of routine 
visits (ADA-APA-AACE,2004) (Table 2.8). 
Fasting plasma glucose, lipid levels and blood pressure should also be assessed 3 
months after initiation of antipsychotic medications. Thereafter, blood pressure and 
plasma glucose values should be obtained annually or more frequently in those who 
have a higher baseline risk for the development of diabetes or hypertension. In those 
with a normal lipid profile, repeat testing should be performed at 5-year intervals or 
more frequently if clinically indicated (ADA-APA-AACE,2004) (Table 2.8). 
If a patient gains 5% of his or her initial weight at any time during therapy, one 
should consider switching to more weight-neutral antipsychotic medications (ADA-
APA-AACE,2004). When switching from one antipsychotic drug to another, it was 
preferable to discontinue the current medication gradually. 
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For people who developed worsening glycaemia or dyslipidaemia while on 
antipsychotic therapy, the panel recommended considering switching to an atypical 
agent that has not been associated with significant weight gain or diabetes. The blood 
pressure, lipid and glycaemic goals of therapy for people with diabetes applied equally 
to those who also have psychiatric disorders. However, all goals need to be 
individualised (ADA-APA-AACE,2004). 
Table 2.8 Monitoring Protocol for Patients on Atypical Antipsychotics* 
 Baseline 4 
weeks 
8 
weeks 
12 
weeks 
Quarterly Annually Every 
5 
years 
Personal/family 
history 
       
Weight (BMI)        
Waist 
circumference 
       
Blood pressure        
Fasting plasma 
glucose 
       
Fasting lipid 
profile 
       
*More frequent assessments may be warranted based on clinical status, (ADA-APA-
AACE,2004) 
 
2.2.19 Referral to specialised services 
The ADA-APA panel recommended that nutrition and physical activity counselling 
have to be provided for all patients who are overweight or obese, particularly if they 
were starting treatment with a second-generation antipsychotic that was associated 
with significant weight gain. Referral to a healthcare professional or program with 
expertise in weight management might also be necessary (ADA-APA-AACE,2004).  
 
All patients with abnormal glucose or lipid levels should be referred to specialised 
clinicians. Immediate care or consultation was required for patients with symptomatic 
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or severe hyperglycaemia, symptomatic hypoglycaemia, or glucose levels 60 mg/dl, 
even in the absence of symptoms. In short, treatment with atypical antipsychotics 
might increase the patient’s risk of metabolic syndrome and diabetes. Therefore, 
physicians needed to be proactive when treating patients with schizophrenia. 
In South East Asia, especially in Malaysia, there was paucity of data on the prevalence 
of metabolic syndrome and cardiovascular risk among schizophrenia patients. A study 
performed by Rahman et al (2009) among 51 patients with primary psychotic and 
mood disorder found that the prevalence of metabolic syndrome was 37.2%. 
The objective of the present study was to determine the prevalence of metabolic 
syndrome among schizophrenia patients receiving antipsychotics in Malaysia. The 
present study also sought to determine the prevalence of coronary heart-disease risk 
among these patients. 
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2.2.20  RESEARCH QUESTION 
What was the prevalence of metabolic syndrome among schizophrenia patient?  
2.2.21  STUDY OBJECTIVES 
(i) Primary Objective  
To determine the prevalence of metabolic syndrome among schizophrenia 
patients in Malaysia.  
(ii) Secondary objective 
(a) To describe the demographic, lifestyle, medical and psychiatric history 
according to the metabolic syndrome status among schizophrenia patients. 
(b) To describe the characteristics of antipsychotic treatment and other medication 
according to the metabolic syndrome status among schizophrenia patients. 
(c) To determine the prevalence of hypertension, diabetes mellitus and 
hyperlipidemia among schizophrenia patients after initiation of monotherapy 
antipsychotics. 
(d) To determine the prevalence of metabolic syndrome and its component among 
schizophrenia patients treated with monotherapy atypical antipsychotics.   
(e) To determine the prevalence of metabolic syndrome and its component among 
schizophrenia patients treated with monotherapy typical antipsychotics.  
(f) To determine the prevalence of metabolic syndrome component according to 
metabolic syndrome status among schizophrenia patients.   
(g) To determine the prevalence of cardiovascular risk factors (CVRFs), coronary 
heart disease (CHD) risk according to metabolic syndrome status among 
schizophrenia patients.   
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2.3   Methodology 
2.3.1. Study design  
This study was a descriptive cross sectional study.  
2.3.2. Setting and study period 
The study was conducted at four mental institutions, two army hospitals and two 
general hospitals namely Hospital Bahagia Ulu Kinta, Perak, Hospital Permai Johor 
Bahru, Johor, Hospital Sentosa Kuching, Sarawak, Hospital Mesra Kota Kinabalu, 
Sabah, Hospital Terendak Melaka, Navy Hospital Lumut, Perak, University Malaya 
Medical Centre (UMMC), Kuala Lumpur and Hospital Sg. Petani, Kedah from June 
2008 until September 2011. 
2.3.3. Study population 
Study population were schizophrenia patients aged between 18 and 65 years old, who 
met the DSM-IV TR criteria for schizophrenia. 
i). Inclusion criteria 
Patients received antipsychotic treatment for at least 1 year. 
ii). Exclusion criteria 
 Patient with history of diabetes mellitus and hypertension prior to the treatment 
of schizophrenia. 
 Patients who were on mood stabilizer. 
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2.3.4. Sample size and sampling procedure 
This study was used as a screening for randomised controlled trial study in Chapter 3. 
Therefore universal sampling was used for the recruitment of this study subjects. 
Out of 527 patients that were screened during study period, 485 patients fulfilled the 
DSM-IV TR criteria for schizophrenia. Three hundred and twenty five schizophrenia 
patients agreed to be interviewed and part of metabolic syndrome parameters were 
taken but only 270 consented for fasting blood investigations and full metabolic 
syndrome profile. The socidemographic characterictic of patients with fasting blood 
taking (n=270) and with no fasting taking (n=55) is in Table 2.15.      
2.3.5. Study variables 
(a) Dependent variable 
Metabolic syndrome    
(b) Independent variables 
Sociodemographic variables  
i). Age  
ii). Sex  
iii). Ethnicity    
iv). Occupation 
v). Educational level 
vi). Marital status 
vii). Body mass index (BMI) 
viii). Care setting 
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Lifestyle, medical and psychiatric history  
i). Smoking status  
ii). Duration of quit smoking   
iii). Physical activity   
iv). Medical history   
v). Family history   
vi). Psychiatric history 
Characteristic of treatment  
i). Current antipsychotic 
ii). Typical antipsychotics (monotherapy) 
iii). Atypical antipsychotics (monotherapy) 
iv). Concomitant medication 
v). Other medication 
Metabolic syndrome criteria 
i). Waist circumference 
ii). HDL cholesterol 
iii). Triglyceride 
iv). Blood pressure 
v). Fasting glucose  
Cardiovascular risk factors   
i). Age   
ii). Smoking status   
iii). Diabetes mellitus   
iv). HDL cholesterol    
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v). Systolic blood pressure   
vi). Diastolic blood pressure   
2.3.6. Operational definitions 
There were two definitions for metabolic syndrome. The first one was Modified 
National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) with 
Asian values for waist circumference (Grundy et al.,2005) and second one was 
modified IDF with South Asian values for waist circumference (Alberti et al.,2006) 
(Table 2.6).   
The operational definitions for variables and scale were described in detail in ANNEX 
“A”. 
 
Table 2.6: Definitions of Metabolic Syndrome  
 NCEP ATP III* IDF** 
Waist circumference 
(cm) 
 
Male ≥ 90, female ≥ 80 
 
 
Male ≥ 90, female ≥ 80 
Blood pressure 
(mmHg) 
≥ 130/85   
or on drug treatment for hypertension   
≥ 130/85   
or treatment of previous diagnosed 
hypertension   
HDL (mg/dL) < 40 mg/dL(1.03 mmol/L) in males 
< 50 mg/dL(1.29 mmol/L) in females 
or on drug treatment for reduced HDL-C   
< 40 mg/dL(1.03 mmol/L) in males 
< 50 mg/dL(1.29 mmol/L) in females 
or specific treatment for this lipid abnormality  
TG (mg/dL) ≥ 150 mg/dL(1.7 mmol/L) 
or on drug treatment for elevated 
triglyceride   
≥ 150 mg/dL(1.7 mmol/L) 
or specific treatment for this lipid abnormality  
Glucose (mg/dL) ≥ 100 mg/dL(5.6 mmol/L) 
Or on drug treatment for elevated 
glucose   
≥ 100 mg/dL(5.6 mmol/L) 
or previous diagnosed type 2 diabetes   
   *NCEP ATP III - Modified National Cholesterol Education Program Adult Treatment Panel 
                            - Metabolic Syndrome is any 3 of 5 criteria, Asian values for waist circumference  
                 **IDF - International Diabetes Federation, South Asian values for waist circumference 
                            - Metabolic Syndrome is central obesity plus any 2 of 5 criteria 
                            - If BMI is > 30kg/m2, central obesity can be assumed and waist circumference does  
                              not  need to be measured  
 
 
2   Prevalence of Metabolic Syndrome 
 
76 
 
2.3.7. Study instrument 
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a short structured 
diagnostic interview for DSM-IV TR for the Major Axis I psychiatric disorder (D.V. 
Sheehan et al.,1998).The M.I.N.I. was available in local language (D.V.  Sheehan et 
al.,1998). 
Framingham Coronary Heart Disease (CHD) 10-year risk score was developed by 
National Heart, Lung and Blood Institute (NHLBI) in U.S. through Framingham Heart 
Study (Wilson et al.,1998). The CHD 10-year risk was calculated separately for men 
and women using CHD score sheet. Variables required were age, total cholesterol or 
LDL cholesterol, HDL cholesterol, blood pressure, diabetes and smoking status. The 
risk score was given in percentage. The interpretation of CHD 10-year risk was the 
number of people out of 100 people probably has a heart attack in the next 10 years.    
2.3.8. Data collection methods 
All patients with schizophrenia were approached during the study period. Patients who 
fulfilled study criteria were briefed on the study and written consent was obtained. A 
face-to-face interviewed was conducted using a screening structured questionnaire and 
the Mini International Neuropsychiatric Interview (M.I.N.I.).  
The screening structured questionnaire consisted of three sections: (i) 
sociodemographic and lifestyle background (ii) medical, psychiatry and family history  
(iii) physical examination and blood investigation for metabolic syndrome profile.  
Patient was given an appointment date and were asked for minimum of 8 hours fasting 
since last meal for the blood investigation. Secondary data pertaining to date onset of 
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illness, patient’s treatment and medication, diagnosis of hypertension, diabetes 
mellitus and hyperlipidemia were obtained from patient’s case note.   
2.3.9. Data Management 
The data were checked before ending each interview session and before compilation 
to ensure completeness. Raw data obtained were coded and entered into Statistical 
Package for Social Sciences (SPSS) Version 16.0. Cleaning for wrong entry and 
outliers were done before the analysis.   
2.3.10. Pre-test 
A pre-test of the questionnaires was done on 5 patients who were attending the 
psychiatric clinic, UMMC. These respondents were excluded from the study. Some 
corrections were made after the pre-test to facilitate patients’ understanding of the 
questionnaires. 
2.3.11. Ethical consideration 
Ethical approval was obtained from Medical Ethics Committee of UMMC and 
Medical Research and Ethics Committee, Ministry of Health. Before any interview, 
patients were informed regarding the nature and purpose of the study and the 
respondents were given the assurance that all information given will be treated with 
confidentiality. A written consent was obtained from the patients prior the interviews.  
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2.3.12. DATA ANALYSIS 
i). Univariate analyses 
For categorical variables, they were described in the form of frequencies and 
percentages. For continuous independent variables, they were summarized and 
described as means, standard deviations, median and interquartile range.  
ii). Bivariate analysis   
Pearson’s Chi-square test and Fisher’s exact test were used to determine the possible 
association of significant variables to the occurrence of metabolic syndrome. 
Continuous data and comparison of two means were analyzed using the t-test. Skewed 
continous data and comparison of median was analysed using non parametric test. 
Subsequently the continuous variables were recategorised and further tested by 
Pearson’s Chi-square test. For bivariate analysis of BMI, only normal, overweight and 
obese categories were considered in the analysis. Normal category was chosen as 
reference group and underweight category was excluded for the analysis. The 
individual prevalence of the cardiovascular risk factors and the prevalence of 
metabolic syndrome components were estimated by calculating the corresponding 
95% confidence interval (95% CI). Framingham risk score in the metabolic syndrome 
and non-metabolic syndrome groups were compared using parametric tests (Student’s 
t test) or non-parametric test (Mann-Whitney U test), according to the distribution of 
the variables. The risk score of the patients were further classified according to the 
category “low” CHD risk (Framingham < 10%) and “high/ very high” CHD risk 
(Framingham > 10%) within 10 years.  
In addition, the mean of Framingham risk score was also compared according to 
patients’ age group with and without metabolic syndrome. The multiple comparisons 
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were analyzed using Two-Way Interaction in Three-Way Anova with Bonferroni 
correction and adjusting for sex. The SPSS version 16.0 statistical package was used 
throughout. An alpha level of significance p< 0.05 was set for all analyses. 
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2.4   Results  
Study population and socio demographic characteristics  
For the study, 527 patients were screened, of whom 485 patients fulfilled the DSM-IV 
TR criteria for schizophrenia. Three hundred and twenty five schizophrenia patients 
agreed to be interviewed and metabolic syndrome parameters were taken except for 
blood investigation. Only 270 patients consented for fasting blood investigations and 
full metabolic syndrome profile. 
The prevalence of metabolic syndrome among the recruited patients based on modified 
NCEP ATP III definition (Grundy et al.,2005) and modified IDF (Alberti et al.,2006) 
were 46.7% and 45.9% respectively. Table 2.7 displayed the socio demographic 
characteristics of the study population. The metabolic syndrome group had higher 
mean age, a larger proportion of female, unemployed individual and patients from 
psychiatric institution. Among schizophrenia patients, an association between BMI 
and metabolic syndrome was significant based on modified NCEP ATP III definition.  
There was statistically significant difference of the mean BMI between metabolic 
syndrome and non-metabolic syndrome among schizophrenia patients on 
antipsychotics. The mean BMI for metabolic syndrome was higher than non-metabolic 
syndrome groups (29.4 ± 5.1 vs. 25.0 ± 5.6).  Majority of the patients with metabolic 
syndrome had significantly higher prevalence of overweight (39.7% vs. 24.3%) and 
obesity (40.5% vs. 17.4%) compared to the non-metabolic syndrome group.  
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Table 2.7: Demographics and Characteristics of Schizophrenia Patient  
 
Characteristics 
Patients with metabolic 
syndrome (n=126) 
  n  (%) 
Patients without metabolic  
syndrome (n=144) 
  n  (%) 
 
p value 
    
Age(year)mean ± SD  40.7 ± 11.3 39.5± 11.8 P=0.472* 
Age group (n =270 )    
< 20
‡
 2(1.6) 2(1.4) P=0.500 
20 – 29 18(14.3) 34(23.6)  
30 – 39 44(34.9) 40(27.8)  
40 – 49 29(23.0) 32(22.2)  
50 – 59  26(20.6) 27(18.8)  
> 60 7(5.6) 9(6.2)  
    
BMI( kg/m
2
) mean ± SD 29.4 ± 5.1 25.0± 5.6 p<0.001*  
BMI
¶
(n =256)    
Underweight(<18.5) 0(0) 14(9.7) p<0.001 
Normal( 18.5 – 24.9) 25(19.8) 70(48.6)  
Overweight( 25 – < 30) 50(39.7) 35(24.3)  
Obese(≥ 30) 51(40.5) 25(17.4)  
    
Sex (n =270 )    
Male
‡
 74(58.7) 100(69.4) p=0.670 
Female  52(41.3) 44(30.6)  
    
Race (n = 270 )    
Malay
‡
 53(42.1) 53(36.8) P=0.747 
Chinese 44(34.9) 58(40.3)  
Indian 15(11.9) 15(10.4)  
others 14(11.1) 18(12.5)  
    
Marital status (n=259)    
Married
‡
 42(33.9) 35(25.9) P=0.398 
Single 70(56.4) 90(66.7)  
Divorced 8(6.5) 6(4.4)  
widowed 4(3.2) 4(3.0)  
    
Education level(n=234)     
No formal education
‡
 2(1.7) 5(4.3) P=0.683 
Primary  21(17.8) 20(17.3)  
Secondary  86(72.9) 81(69.8)  
Tertiary  9(7.6) 10(8.6)  
    
Occupation (n=249)    
Employed
‡
  33(27.0) 55(43.3) P=0.003 
Unemployed  83(68.0) 67(52.8)  
Housewife 6(4.9) 5(3.9)  
    
Care setting (n=270)    
General hospital
‡
 68(54.0) 92(63.9) P=0.098 
Institution  58(46.0) 52(36.1)  
    
Chi square test, *t-test, ‡ Reference group, BMI
¶ 
excluded underweight- Chi square test based on category 
normal (reference group), overweight and obese. Metabolic syndrome status was based on modified 
NCEP ATP III definition.  
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Lifestyle  
Most of the schizophrenia patients in this study did not practice healthy lifestyle 
habits. The prevalence of current smokers was higher than former smokers in the 
metabolic syndrome group (24.8% vs. 20.5%). Very small proportion of former 
smokers admitted the duration of quit smoking. Among the current and former 
smokers, majority smoked less than 20 sticks cigarettes/day and majority of the 
patients have sedentary lifestyle with hardly any physical activity for both groups 
(Table 2.8).   
Medical and Psychiatric History  
Among the screened patient, 8 patients had history of hypertension and 3 patients had 
history of diabetes mellitus before antipsychotics treatment. These patients were 
excluded from the analysis of this study.   
The metabolic syndrome group had a larger proportion of patients developed 
hypertension and diabetes mellitus after initiation of antipsychotics, female patients 
with history of gestational diabetes and family history of diabetes. Among 
schizophrenia patients, there was association between the occurrence of diabetes 
mellitus after initiation of antipsychotics and metabolic syndrome. There was also 
statistically significant difference between metabolic syndrome and non-metabolic 
syndrome patients in the mean age of onset of illness. The age of onset for 
schizophrenia in metabolic syndrome patients was slightly older than non-metabolic 
syndrome patients (28.7 ± 9.3 vs. 25.5 ± 7.4).  
There were no statistically significant differences between metabolic syndrome and 
non-metabolic syndrome patients with respect to mean year duration of illness, mean 
number of relapse and history of relapse (Table 2.8). 
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Table 2.8: Lifestyle, medical and psychiatric history according to the metabolic 
syndrome status 
 
Characteristics 
Patients with 
metabolic syndrome 
(n=126) 
Patients without 
metabolic syndrome 
(n=144) 
P value 
 n   (%) n   (%)  
    
Smoking n=117 n=130  
Never
‡
 64(54.7) 62(47.7) P=0.211 
Former smoker < 20 sticks/day 20(17.1) 18(13.8)  
Former smoker ≥ 20 sticks/day 4(3.4) 3(2.3)  
Current smoker < 20 sticks/day 17(14.5) 35(27.0)  
Current smoker ≥ 20 sticks/day 12(10.3) 12(9.2)  
    
Duration of quitting smoking n=8 n=4  
≥ 10 years
‡
 7(87.5) 2(50.0) P=0.082 
5 - 9 years 0(0.0) 2(50.0)  
1 – 4 years  1(12.5) 0(0.0)  
< 1 year 0(0.0) 0(0.0)  
    
Physical activity n=118 n=131  
Never
‡
  56(47.5) 58(44.3) P=0.840 
Rarely 28(23.7) 25(19.1)  
1 -3 times/month 4(3.4) 5(3.8)  
1-2 times /week 9(7.6) 12(9.2)  
3 -4 times /week 8(6.8) 13(9.9)  
≥ 5 times /week 13(11.0) 18(13.7)  
    
Medical and family history     
Hypertension after initiation of 
antipsychotics(n=233) 
14/115(12.2) 6/118(5.1) P=0.053 
Diabetes mellitus after initiation of 
antipsychotics(n=231) 
17/112(15.2) 6/119(5.0) P=0.010 
History of gestational diabetes 
(female)(n=38)  
2/25(8.0) 1/13(7.7) P=0.973 
Family history of 
hypertension(n=219) 
39/107(36.4) 45/112(40.2) P=0.570 
Family history of diabetes(n=219) 31/109(28.4) 27/110(24.5) P=0.514 
Parent obese(n=225) 13/111(11.7) 15/114(13.2) P=0.742 
Siblings obese(n=225)  13/111(11.7) 14/114(12.3) P=0.896 
    
Psychiatric history    
Age of onset(year),mean ± 
SD(n=177) 
28.7(9.3) 25.5(7.4) P=0.014* 
Duration of illness (year) ,mean ± SD 
(n=260) 
10.9(9.3) 10.0(7.8) P=0.403* 
History of relapse(n=264) 42(33.9) 51(36.4) P=0.763 
No of relapse, mean ± SD 0.9(1.6) 0.8(1.5)  
(n=263)  Median (interquatile range)  0.0(0.0 -1.0) 0.0(0.0 -1.0) P=0.522** 
    
. 
 
Chi square test, *t-test, **Mann-Whitney U test, ‡ Reference group. Metabolic syndrome status was 
based on modified NCEP ATP III definition 
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Characteristics of treatment with antipsychotics and other medications   
Table 2.9 showed the characteristics of treatment with antipsychotics and other 
concomitant medications. The majority of patients were treated with only one 
antipsychotic (75.9%). For the overall use of antipsychotic, the proportion of atypical 
antipsychotics monotherapy used was the highest in both metabolic syndrome and 
non-metabolic syndrome groups (50.8% vs. 58.3%). Followed by typical 
antipsychotics monotherapy used in both groups (21.4% vs. 20.8). 
With respect to patients with typical monotherapy antipsychotic treatment in the 
metabolic syndrome group, chlorpromazine had the highest proportion (33.3%) of 
followed by sulpiride and perphenazine (18.5%). While in patients received atypical 
monotherapy antipsychotic treatment, olanzapine had the highest proportion followed 
by risperidone (42.2% vs. 32.8%). None of the patients prescribed on amisulpride has 
metabolic syndrome.  
For the overall schizophrenia patients, antipsychotics were combined with 
anticholinergics (31.5%), benzodiazepines (15.9%), antidepressants (13.0%). In 
addition, 4.8% was being treated for diabetes, 4.4% of patient took antihypertensive 
medication and 5.9% of patients took lipid-lowering medication. There was no 
significantly difference in the distribution of concomitant and other medications 
between metabolic syndrome and non-metabolic syndrome group. 
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Table 2.9: Characteristics of treatment with antipsychotic and other medication   
Characteristics Patients with 
metabolic 
syndrome (n=126) 
Patients without 
metabolic syndrome    
(n=144) 
P value 
 N    (%) N    (%)  
Current antipsychotic     
Atypical antipsychotics (monotherapy) ‡ 64(50.8) 84(58.3) P=0.339 
Typical antipsychotics (monotherapy) 27(21.4) 30(20.8)  
Combination of Typical and Atypical 
Antipsychotics 
15(11.9) 11(7.7)  
Combination of Typical  Antipsychotics 14(11.1) 9(6.2)  
Combination of Atypical Antipsychotics 6(4.8) 10(7.0)  
    
Typical antipsychotics(monotherapy)     
Chlorpromazine 9(33.3) 10(33.3)  
Sulpiride 5(18.5) 6(20.0)  
Perphenazine 5(18.5) 5(16.7) P=0.960 
Haloperidol‡  3(11.2) 5(16.7)  
Trifluoperazine 2(7.4) 1(3.3)  
Flupenthixol decanoate 2(7.4) 1(3.3)  
Fluphenazine decanoate 1(3.7) 2(6.7)  
    
Atypical antipsychotics(monotherapy)     
Olanzapine‡ 27(42.2) 26(31.0) P=0.390 
Risperidone 21(32.8) 29(34.5)  
Paliperidone 11(17.2) 16(19.0)  
Clozapine 2(3.1) 1(1.2)  
Quetiapine 1(1.6) 2(2.4)  
Aripiprazole 2(3.1) 6(7.1)  
Amisulpride 0(0) 4(4.8)  
    
Concomitant medication     
Anticholinergic 41(32.5) 44(30.6) P=0.726 
Benzodiazepine 25(19.8) 22(15.3) P=0.324 
antidepressants 16(12.7) 19(13.2) P=0.904 
    
Other medication    
Anti diabetic medication 8(6.3) 5(3.5) P=0.271 
Blood pressure lowering 6(4.8) 6(4.2) P=0.813 
Lipid-lowering medication  6(4.8) 10(6.9) P=0.449 
    
Chi square test, ‡ Reference group, Metabolic syndrome status was based on modified NCEP ATP III 
definition. 
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Prevalence of hypertension, diabetes mellitus and hyperlipidemia after 
initiation of monotherapy antipsychotic 
For the prevalence of hypertension, diabetes mellitus and hyperlipidemia among 
schizophrenia patients after initiation of monotherapy antipsychotic, the denominator 
includes patient without blood investigation for metabolic syndrome parameters. 
Among the typical antipsychotics, sulpiride has the highest prevalence of 
hypertension, diabetes mellitus and hyperlipidemia after initiation of monotherapy 
antipsychotic (9.1% for all prevalence respectively). As for the intra muscular 
injection antipsychotics, fluphenazine decanoate has the highest prevalence of 
hyperlipidemia (3.3%). 
 
For schizophrenia patients on atypical antipsychotics, the highest prevalence of 
hypertension and hyperlipidemia after initiation of monotherapy antipsychotic was 
aripiprazole (12.5% for both respectively), whereas paliperidone has the highest 
prevalence of diabetes mellitus (3.4%) (Table 2.10).  
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Table 2.10: Prevalence of hypertension, diabetes mellitus and hyperlipidemia after initiation of monotherapy antipsychotic among 
schizophrenia patients  
 Typical antipsychotics 
 Haloperidol(n=8) Perphenazine(n=13) Sulpiride(n=11) Trifluoperazine (n=3) Chlorpromazine(n=19) Flupenthixol 
decanoate (n=3) 
Fluphenazine 
decanoate (n=3) 
 Prevalence n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
              
Hypertension 0(0.0) 0.0-32.4 1(7.7) 1.4-33.3 1(9.1) 1.6-37.7 0(0.0) 0.0-56.2 0(0.0) 0.0-16.8 0(0.0) 0.0-56.2 0(0.0) 0.0-56.2 
Diabetes mellitus 0(0.0) 0.0-32.4 1(7.7) 1.4-33.3 1(9.1) 1.6-37.7 0(0.0) 0.0-56.2 0(0.0) 0.0-16.8 0(0.0) 0.0-56.2 0(0.0) 0.0-56.2 
Hyperlipidemia  0(0.0) 0.0-32.4 1(7.7) 1.4-33.3 1(9.1) 1.6-37.7 0(0.0) 0.0-56.2 0(0.0) 0.0-16.8 1(3.3) 6.2-79.2 0(0.0) 0.0-56.2 
               
 Atypical antipsychotics 
 Olanzapine (n=61) Clozapine (n=14) Risperidone (n=64) Quetiapine (n=7) Amisulpride (n=4) Paliperidone (n=29) Aripiprazole (n=8) 
 Prevalence n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
               
Hypertension 2(3.3) 0.9-11.2 0(0.0) 0.0-21.5 3(4.7) 1.6-12.9 0(0.0) 0.0-35.4 0(0.0) 0.0-49.0 2(6.9) 1.9-22.0 1(12.5) 2.2-47.1 
Diabetes mellitus 2(3.3) 
 
0.9-11.2 0(0.0) 0.0-21.5 2(3.1) 0.86-10.7 0(0.0) 0.0-35.4 0(0.0) 0.0-49.0 1(3.4) 0.6-17.2 0(0.0) 0.0-32.4 
Hyperlipidemia 1(1.6) 0.29-8.7 0(0.0) 0.0-21.5 5(7.8) 3.4-17.0 0(0.0) 0.0-35.4 0(0.0) 0.0-49.0 2(6.9) 1.9-22.0 1(12.5) 2.2-47.1 
The denominator for hypertension, diabetes mellitus and hyperlipidemia include patients without blood investigation for metabolic syndrome components 
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Table 2.11 showed the prevalence of metabolic syndrome and its components among 
schizophrenia patients treated with monotherapy atypical antipsychotics. Among the 
metabolic syndrome component, waist circumference has the highest proportion 
compare to other components for all atypical antipsychotics except for aripiprazole. 
All patients with monotherapy clozapine (n=3) and quetiapine (n=3) had metabolic 
syndrome components for waist circumference and blood pressure. Olanzapine had the 
highest prevalence of triglyceride and HDL cholesterol (37.7% vs. 58.5%).   
For patients treated with monotherapy typical antipsychotics, waist circumference was 
the highest proportion among the metabolic syndrome components for all typical 
antipsychotics except for haloperidol. Perphenazine has the highest prevalence of 
blood pressure and triglyceride (70.0% vs. 50.0%). Flupenthixol decanoate has the 
highest prevalence of HDL cholesterol (66.7%) and Trifluoperazine has the highest 
prevalence of fasting blood sugar (66.7%) (Table 2.12).    
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Table 2.11: Prevalence of metabolic syndrome(MetS) and its components among schizophrenia patients treated with monotherapy atypical 
antipsychotics 
 Atypical antipsychotics 
 Olanzapine (n=53) Clozapine (n=3) Risperidone (n=50) Quetiapine (n=3) Amisulpride (n=4) Paliperidone (n=27) Aripiprazole (n=8) 
MetS Prevalence n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
              
NCEP ATP III* 27(50.9) 37.9-63.9 2(66.7) 20.8-93.9 21(42.0) 29.4-55.8 1(33.3) 6.2-79.2 0(0.0) 0.0-49.0 11(40.7) 24.5-59.3 2(25.0) 7.2-59.1 
               
MetS components prevalence              
               
Waist circumference               
Male ≥90 cm , 
female ≥80 cm 
44(83.0) 
 
70.8-90.8 3(100) 43.9-100 46(92.0) 81.2-96.9 3(100) 43.9-100 1(25.0) 4.6-69.9 23(85.2) 67.5-94.1 1(12.5) 2.2-47.1 
               
BP( ≥130/85 mmHg) 25(47.2) 
 
34.4-60.3 3(100) 
 
43.9-100 22(44.0) 31.2-57.7 3(100) 43.9-100 1(25.0) 4.6-69.9 11(40.7) 24.5-59.3 3(37.5) 13.7-69.4 
               
HDL(male< 40 mg/dL 
,female< 50mg/dL) 
31(58.5) 
 
45.1-70.7 1(33.3) 6.2-79.2 23(46.0) 33.0-59.6 1(33.3) 6.2-79.2 0(0.0) 0.0-49.0 10(37.0) 21.5-55.8 3(37.5) 13.7-69.4 
               
Triglyceride 
(≥150mg/dL) 
20(37.7) 
 
25.9-51.2 1(33.3) 6.2-79.2 18(36.0) 24.1-49.9 1(33.3) 6.2-79.2 0(0.0) 0.0-49.0 9(33.3) 18.6-52.2 4(50.0) 21.5-78.5 
               
Glucose(100 mg/dL) 15(28.3) 
 
18.0-41.6 1(33.3) 6.2-79.2 12(24.0) 14.3-37.4 1(33.3) 6.2-79.2 0(0.0) 0.0-49.0 9(33.3) 18.6-52.2 1(12.5) 2.2-47.1 
NCEP ATP-III* has Asian values for waist circumference 
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Table 2.12: Prevalence of metabolic syndrome(MetS) and its components among schizophrenic patients treated with monotherapy typical 
antipsychotics 
 Typical antipsychotics 
 Haloperidol(n=8) Perphenazine(n=10) Sulpiride(n=11) Trifluoperazine (n=3) Chlorpromazine(n=19) Flupenthixol 
decanoate (n=3) 
Fluphenazine 
decanoate (n=3) 
MetS Prevalence n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
              
NCEP ATP III* 3(37.5) 13.7-69.4 5(50.0) 23.7-76.3 5(45.5) 21.3-72.0 2(66.7) 20.8-93.9 9(47.4) 27.3-68.3 1(33.3) 6.2-79.2 2(66.7) 20.8-93.9 
               
MetS components prevalence              
               
Waist circumference              
Male ≥90 cm , 
female ≥80 cm 
4(50.0) 21.5-78.5 10(100) 72.3-100 10(90.9) 62.3-98.4 3(100.0) 43.9-100 12(63.2) 41.0-80.9 3(100.0) 43.9-100 3(100.0) 43.9-100 
               
BP( ≥130/85 mmHg) 1(12.5) 
 
2.2-47.1 7(70.0) 39.7-89.2 3(27.3) 9.8-56.6 2(66.7) 20.8-93.9 6(31.6) 15.4-54.0 2 (66.7) 20.8-93.9 2(66.7) 20.8-93.9 
               
HDL(male< 40 mg/dL 
,female< 50mg/dL) 
4(50.0) 21.5-78.5 6(60.0) 31.3-83.2 6(54.5) 28.0-78.7 1(33.3) 6.2-79.2 10(52.6) 31.7-72.7 1(33.3) 6.2-79.2 2(66.7) 20.8-93.9 
               
Triglyceride 
(≥150mg/dL) 
3(37.5) 13.7-69.4 5(50.0) 23.7-76.3 4(36.4) 15.2-64.6 1(33.3) 6.2-79.2 8(42.1) 23.1-63.7 1(33.3) 6.2-79.2 1(33.3) 6.2-79.2 
               
Glucose(100 mg/dL) 2(25.0) 
 
7.2-59.1 1(10.0) 1.8-40.4 3(27.3) 9.8-56.6 2(66.7) 20.8-93.9 6(31.6) 15.4-54.0 0(0.0) 0.0-56.2 1(33.3) 6.2-79.2 
NCEP ATP-III* has Asian values for waist circumference 
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In Table 2.13, there was statistically significant for all metabolic syndrome 
components between metabolic syndrome and non-metabolic syndrome groups (Waist 
circumference OR=34.8 (95% CI: 12.2, 99.4), HDL Cholesterol OR=5.4 (95% CI: 3.2, 
9.2), TG OR= 8.6 (95% CI: 4.9, 15.2), BP- OR=5.5 (95% CI: 3.2, 9.3), FBS OR= 11.4 
(95% CI: 5.5, 23.6).  
Among the metabolic syndrome components, the prevalence of waist circumference 
was the highest in both metabolic syndrome and non-metabolic syndrome groups 
(98.4% vs. 50.7%) followed by HDL cholesterol (72.6% vs. 30.9%). The prevalence 
of fasting blood glucose was the lowest in both the metabolic syndrome and non-
metabolic syndrome groups (51.6% vs. 6.2%). 
There was statistically significant difference for median (Mann-Whitney U test) of 
fasting blood glucose, triglycerides and HbA1c between metabolic syndrome and non-
metabolic syndrome groups. In addition, there was statistically significant difference 
for mean of waist circumference and HDL Cholesterol by gender. The mean waist 
circumference for male was higher than female in metabolic syndrome group (102.4 ± 
9.8 cm vs. 96.7 ± 10.8 cm). There was also significant difference for mean for total 
cholesterol, systolic and diastolic blood pressure between metabolic syndrome and 
non-metabolic syndrome groups. 
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Table 2.13:  Prevalence of Metabolic Syndrome components according metabolic 
syndrome status  
Metabolic Syndrome  
Component 
Metabolic  
Syndrome(n=126) 
Non Metabolic  
Syndrome(n=144) 
Overall (n=270) p 
n(%) 95% CI n(%) 95% CI n(%) 95% CI  
Waist circumference (Male 
≥90 cm , female ≥80 cm)
 
 
124(98.4) 94.4-99.6 73(50.7) 42.6-58.7 197(73.0) 67.4-77.9 p<0.001 
HDL
#
 (Male< 40 mg/dL 
,female < 50mg/dL) 
90(72.6) 64.1-79.7 42(30.9) 23.7-39.1 132(50.8) 44.7-56.8 p<0.001 
Triglyceride 
#
(≥150mg/dL) 84(67.7) 59.1-75.3 21(15.4) 10.3-22.5 105(40.4) 44.7-56.8 p<0.001 
BP( ≥130/85 mmHg)
 
 77(61.1) 52.4-69.2 36(25.0) 18.6-32.7 113(41.9) 36.1-47.8 p<0.001 
Fasting glucose(≥100 mg/dL) 65(51.6) 42.9-60.1 9(6.2) 3.3-11.5 74(27.4) 22.4-33.0 p<0.001 
        
Laboratory test parameters  95% CI  95% CI  95% CI  
Fasting blood glucose(mg/dL)        
Mean(SD)  110.5(37.9) 103.9-117.2 89.2(21.3) 85.7-92.7 99.2(31.9) 95.3-103.0  
Median (Interquartile range) 100.8 (88.2-113.4) 86.4 ( 81.0-91.8) 90.0 (82.8-100.8 ) p<0.001** 
        
Triglycerides (mg/dL)        
Mean(SD)  214.1(57.0) 185.5-242.6 116.9(57.0) 107.2-126.6 163.2(127.9) 147.6-178.9  
Median (Interquartile range) 171.8 (125.8-245.3) 113.8 ( 81.5-138.2) 132.9 ( 97.4-186) p<0.001** 
        
HbA1c(%)        
Mean(SD)  6.4(1.7) 6.1-6.7 5.5(0.7) 5.4-5.6 5.9(1.3) 5.8-6.1  
Median (Interquartile range)     5.9 (5.6-6.5)                 5.4 (5.2-5.8)                     5.6 (5.3-6.1) p<0.001** 
        
 Mean(SD) 95% CI Mean(SD) 95% CI Mean(SD) 95% CI  
        
Total Cholesterol (mg/dL) 216.1(46.5) 207.8-224.3 202.2(41.3) 195.2-209.2 208.8(44.3) 203.4-214.2 p<0.001* 
LDL Cholesterol (mg/dL) 136.6(40.4) 129.1-144.0 131.1(40.4) 124.2-138.0 133.6(40.4) 128.6-138.6 P=0.287* 
HDL Cholesterol(mg/dL)        
Male 37.9(6.8) 36.3-39.5 46.0(13.0) 43.3-48.6 42.5(11.5) 40.7-44.2 p<0.001* 
Female 44.5(10.7) 41.5-47.5 52.8(13.6) 48.5-57.1 48.2(12.7) 45.5-50.8 P=0.001* 
        
Other parameters Mean(SD) 95% CI Mean(SD) 95% CI Mean(SD) 95% CI  
Waist circumference         
Male 102.4(9.8) 100.1-104.7 87.5(13.8) 84.7-90.2 93.9(13.9) 91.9-95.8 p<0.001* 
Female 96.7(10.8) 93.7-99.7 88.6(13.7) 84.4-92.8 91.7(13.1) 89.4-94.0 P=0.002* 
Systolic BP(mm Hg) 127.0(16.7) 124.0-130.0 117.4(17.4) 114.5-120.2 121.6(18.2) 119.7-123.6 p<0.001* 
Diastolic BP(mm Hg) 83.8(12.7) 81.6-86.1 77.1(11.9) 75.1-79.1 80.7(13.0) 79.3-82.1 p<0.001* 
        
Chi square test, *t-test ,** Mann-Whitney U test,
 #
the denominator for Triglycerides and HDL 
Cholesterol N=260   
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In Table 2.14 showed the prevalence of cardiovascular risk factors. The individual 
prevalences of each cardiovascular risk factor differed significantly between metabolic 
syndrome and non-metabolic syndrome groups were present of diabetes mellitus 
(OR=5.9, 95% CI:  2.4, 15.1), raised of total cholesterol (OR=1.8, 95% CI:  1.1, 3.0), 
reduction in HDL cholesterol (OR=2.9, 95% CI:  1.7, 5.1) and increased in diastolic 
blood pressure (OR=3.1, 95% CI:  1.7, 5.7). 
Prevalence of patients with high and very high risk of CHD in 10 years (Framingham) 
in the metabolic syndrome group was 31.5% and 11.0% in the non-metabolic 
syndrome group. The difference was statistically significant. There was also 
statistically significant difference in the Framingham risk median score for metabolic 
syndrome and non-metabolic syndrome groups (6.5% vs. 4.0%, respectively). In the 
metabolic syndrome group, the mean of Framingham risk score was 7.6, which meant 
that about 7.6 of 100 people with this level of risk may have a heart attack in the next 
10 years. In the non-metabolic syndrome group, the mean of Framingham risk score 
was 5.0, which meant about 5 of 100 people with this level of risk may have a heart 
attack in the following 10 years (Table 2.14).  
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Table 2.14:  Prevalence of CVRFs and CHD risk (Framingham) according to metabolic 
syndrome status  
 Metabolic  
Syndrome(n=126) 
Non Metabolic  
Syndrome(n=144) Overall (n=270) 
p 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI  
Cardiovascular risk factors(CVRFs)        
Age≥40(male) or≥45(female) years 58(46.0) 37.6-54.7 64(44.4) 36.6-52.6 122(45.2) 39.4-51.2 P=0.794 
Smoker  
29(23.0) 16.5-31.1 47(32.6) 25.5-40.7 76(28.1) 23.1-33.8 P=0.079 
Diabetes (known diagnosis or 
glucose ≥126 mg/dL)  
26(20.6) 14.5-28.5 6(4.2) 1.9-8.8 32(11.9) 8.5-16.3 p<0.001 
Total cholesterol
# 
≥ 200 mg/dL 
80(64.5) 55.8-72.4 68(50.0) 41.7-58.3 148(56.9) 50.9-62.8 P=0.018 
HDL cholesterol
#
 (male< 45 or 
female< 50mg/dL) 
99(79.8) 71.9-86.0 78(57.4) 49.0-65.4 177(68.1) 62.2-73.4 p<0.001 
SBP ≥140 or ≥ 130 mmHg (Diabetes 
,prior cardiovascular or kidney 
disease) 
28(22.2) 15.9-30.2 22(15.3) 10.3-22.1 50(18.5) 14.3-23.6 P=0.143 
DBP ≥90 or ≥ 80 mmHg 
(Diabetes,prior cardiovascular or 
kidney disease) 
42(33.3) 25.7-42.0 20(13.9) 9.2-20.5 62(23.0) 18.4-28.3 p<0.001 
 
       
Risk of CHD in 10 years(Framingham)        
Mean (SD) 7.6(6.4) 6.5-8.8 5.0(4.4) 4.3-5.8 6.3(5.6) 5.6-7.0  
Median (Interquartile range)             6.5 (2.5-11.0)             4.0 (1.0-7.0)               4.0 (1.0-9.0) p<0.001** 
Patients with high & very high risk  
(≥10%) of CHD in 10 years 
(Framingham) 
 
n(%) 95% CI n(%) 95% CI n(%) 95% CI  
39(31.5) 23.9-40.1 15(11.0) 6.8-17.4 54(20.8) 16.3-26.1 p<0.001 
Chi square test, *t-test,** Mann-Whitney U test,
 #
the denominator for Total and HDL Cholesterol N=260   
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Table 2.15: Demographics and Characteristics of Schizophrenia Patient with and 
without fasting blood investigation  
 
Characteristics 
Patients with Blood taken 
(n=270) 
  n  (%) 
Patients without blood 
taken (n=55) 
  n  (%) 
 
p value 
    
Age(year)mean ± SD  39.9 ± 11.6 42.0± 11.5 P=0.225* 
Age group (n =270 )    
< 20
‡
 4(1.5) 0(0) P=0.899 
20 – 29 52(19.3) 9(16.4)  
30 – 39 84(31.1) 16(29.1)  
40 – 49 61(22.6) 14(25.5)  
50 – 59  53(19.6) 13(23.5)  
> 60 16(5.9) 3(5.5)  
    
BMI( kg/m
2
) mean ± SD 27.0 ± 5.8  24.7± 5.1 P=0.006*  
BMI
¶
(n =256)    
Underweight(<18.5) 14(5.2) 6(10.9) P=0.083 
Normal( 18.5 – 24.9) 95(35.2) 23(41.8)  
Overweight( 25 – < 30) 85(31.5) 19(34.6)  
Obese(≥ 30) 76(28.1) 7(12.7)  
    
Sex (n =270 )    
Male
‡
 174(64.4) 23(41.8) p=0.002 
Female  96(35.6) 32(58.2)  
    
Race (n = 270 )    
Malay
‡
 106(39.3) 9(16.4) P<0.001 
Chinese 102(37.8) 32(58.2)  
Indian 30(11.1) 12(21.8)  
others 32(11.8) 2(3.6)  
    
Marital status (n=259)    
Married
‡
 77(29.7) 17(30.9) P=0.790 
Single 160(61.8) 33(60.0)  
Divorced 14(5.4) 2(3.6)  
widowed 8(3.1) 3(5.5)  
    
Education level(n=234)     
No formal education
‡
 7(3.0) 1(2.3) P<0.001 
Primary  41(17.5) 6(14.0)  
Secondary  167(71.4) 21(48.8)  
Tertiary  19(8.1) 15(34.9)  
    
Occupation (n=249)    
Employed
‡
  88(35.4) 18(36.7) P=0.843 
Unemployed  150(60.2) 28(57.1)  
Housewife 11(4.4) 3(6.2)  
    
Care setting (n=270)    
General hospital
‡
 160(59.3) 54(98.2) P<0.001 
Institution  110(40.7) 1(1.8)  
    
Chi square test, *t-test, ‡ Reference group, BMI
¶ 
excluded underweight- Chi square test based on category 
normal (reference group), overweight and obese. Metabolic syndrome status was based on modified 
NCEP ATP III definition.  
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Figure 2.1 Risk score of CHD (Framingham) according to patients age group 
and metabolic syndrome status   
*corrected by Bonferroni formula (p<0.008) for multiple comparisons and adjusted for sex, CHD - coronary heart 
disease, MetS – metabolic syndrome 
 
 
There was greater increased of mean score of CHD risk for all age groups in the 
metabolic syndrome as compared to non-metabolic syndrome groups. The significant 
difference of mean score CHD risk was for all age group except for more than 60 
years old (Figure 2.1).   
 
 
* 
* 
* * * 
* 
* 
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2.5   Discussion 
Prevalence of Metabolic Syndrome Treated with Antipsychotics 
The main aim of this study was to estimate the prevalence of metabolic syndrome in 
schizophrenia patients who were treated with antipsychotic medications for at least 
one year.  The results of the present study showed that 46.7% of the patients met the 
criteria for metabolic syndrome as defined by NCEP ATP III guidelines. This rate was 
considerably greater than the 34.3% prevalence found in the general Malaysian 
population (Mohamud et al.,2011) and the 10-20% prevalence reported among Asian 
population (Nestel et al.,2007). 
The higher prevalence of metabolic syndrome among schizophrenia patients has been 
frequently reported in other studies. Study conducted by Cohn and colleagues (2004) 
found prevalence of 42.6% in the male patients and 48.5% female patients using the 
same criteria. A Japanese study reported the prevalence of 48.1% of metabolic 
syndrome in outpatient with schizophrenia (Sugawara et al.,2011).  
There were several reasons why schizophrenia was associated with higher rate of the 
metabolic syndrome. Certain lifestyles, such as sedentary habits, high-fat and high-
carbohydrate diets, were common in people with severe mental illness and were 
associated with the metabolic syndrome (Brown et al.,1999; Davidson et al.,2001a). 
Schizophrenia might also predispose individuals to physiological changes that 
increased the risk of developing metabolic syndrome, e.g. abnormalities in glucose 
regulation with a pattern of insulin resistance, which have been described in 
schizophrenic patients even before the development of the illness and the use of 
antipsychotic agents (Kasanin,1926; Meduna et al.,1942).  Some antipsychotics were 
also associated with higher rates of developing metabolic syndrome. These 
medications may cause weight gain or changes in the blood pressure, cholesterol and 
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blood sugar level (Fenton and Chavez,2006). Atypical antipsychotics had been 
associated with increased risk of hyperglycaemia and impaired glucose level, and 
subsequently increased the risk of metabolic syndrome (Kamran et al.,1994; Ober et 
al.,1999; Newcomer et al.,2002). In the present study 42.2% of the olanzapine patients, 
32.8% of the patients on risperidone and 17.2% of the patients on paliperidone had 
metabolic syndrome. 
Cardiovascular Risk 
The results of the present study showed that the presence of metabolic syndrome was 
associated with high coronary heart disease risk. We found a significant difference in 
the cardiovascular risk between patients with and without metabolic syndrome. The 
data obtained in our study appeared to be consistent with that to the Cardiovascular, 
Lipid and Metabolic Outcomes Research in Schizophrenia Study in Spain (Bobes et 
al.,2007), which reported high cardiovascular risk in patients treated with 
antipsychotic drugs as defined by the Framingham score. Further, in a study of 367 
adults treated with atypical antipsychotics, Correll et al (2006) reported that the 
metabolic syndrome was present in 137 (37.3%) of patients and was significantly 
associated with the 10-year risk of CHD events. In addition, Holt el al (2010) found 
12% of the study patients had a greater than 20% risk of a CHD event within the next 
10 years.    
Metabolic Syndrome Component 
In our study, we observed statistically significant difference for all metabolic 
syndrome components between metabolic syndrome and no-metabolic syndrome 
groups. Notably, the mean fasting blood sugar level in the metabolic syndrome group 
was clearly impaired while the mean fasting blood sugar for the non-metabolic 
syndrome group was normal (110.5 mg/dL vs. 89.2 mg/dL). The male patients in the 
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non-metabolic syndrome group had normal mean HDL cholesterol level compared to 
those in the metabolic syndrome group. Further, the mean triglyceride level in the 
metabolic syndrome group almost doubled that of the non-metabolic syndrome group 
(214.1 mg/dL vs. 116.9 mg/dL). 
The most common findings in our patients with metabolic syndrome were abnormal 
waist circumference (98.4%), followed by low HDL cholesterol level (72.6%), raised 
triglyceride level (67.7%) and elevated blood pressure (61.1%).While elevated fasting 
blood glucose was the least frequent abnormality. Our data substantiates the findings 
from study by Kato and colleagues (2004), where the most common metabolic 
syndrome criteria reported in their study population were abnormal waist 
circumference, followed by dyslipidemia and elevated blood pressure, while the least 
prevalent metabolic component was elevated fasting blood glucose. 
Mental health professionals should consistently measure and monitor waist 
circumference and blood pressure, two components of metabolic syndrome, which are 
easily assessed in clinic setting. In our sample, 98.4% of patients with metabolic 
syndrome had abnormal waist circumference and 61.1% had elevated blood pressure. 
Abnormalities of either waist circumference or blood pressure warrant screening for 
other components of the syndrome. 
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Body Mass Index (BMI) 
The mean BMI was significantly higher in patients with metabolic syndrome 
compared to those without metabolic syndrome (p<0.05), with the mean BMI value of 
29.4 ± 5.1 kg/m
2
 in patients with metabolic syndrome. When our patients were 
categorised according to weight status, there was statistically significant higher 
proportion of overweight (39.7% vs. 24.3%) and obese patients (40.5% vs. 17.4%) in 
the metabolic syndrome groups than in the non-metabolic syndrome groups. These 
results concurred with the findings from the Cardiovascular, Lipid and Metabolic 
Outcomes Research in Schizophrenia Study (CLAMORS) (Bobes et al.,2007) in 
which the prevalence of general obesity and abdominal adiposity was also high in their 
schizophrenia outpatients with metabolic syndrome. The study recorded a two-fold 
higher rate of obesity in metabolic syndrome subjects compared to non-metabolic 
syndrome subjects (55.2% vs. 22.7%).  The high prevalence of obesity and abdominal 
adiposity in our study also corroborates the data from the CATIE study (McEvoy et 
al.,2005). 
Limitations 
The current study has few limitations. Firstly, it was a cross sectional study. Although 
the metabolic syndrome was frequent in this group of patients, causal pathway could 
not be inferred. Secondly, there was no reference population without psychopathology. 
However, there were national rates available from the nationwide survey (Mohamud et 
al.,2011). Thirdly, the prevalence of hypertension, diabetes mellitus and 
hyperlipidemia after initiation of antipsychotics were described with current 
antipsychotics used, however this might be not true as the mean duration of 
schizophrenia about 10 years, and patients were on several antipsychotics before 
current antipsychotics. Nevertheless, if the current antipsychotics have property of 
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metabolic syndrome neutral and the duration of treatment for at least one year, it 
should be sufficient to observe the reversibility of the metabolic syndrome parameters 
causing by previous antipsychotics.  
Despite these limitations, our findings were consistent with higher rate of the 
metabolic syndrome found in the schizophrenia population.  
2.6   Conclusions 
The prevalence of metabolic syndrome in schizophrenia patients receiving 
antipsychotic in Malaysia was very high. Our data adds to the mounting evidence that 
schizophrenia patients are at increased risk for developing metabolic syndrome. The 
high prevalence of the syndrome underscores an urgent need to formulate a 
comprehensive intervention measures to combat these problems. 
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Chapter THREE:  Randomized Controlled Trial of the Safety and Efficacy 
of Aripiprazole Vs Ziprazidone in Schizophrenic 
Patients with Metabolic Syndrome 
 
3.1   Abstract  
Introduction: Atypical antipsychotics were reported to be associated with increased 
risk of hyperglycaemia and hyperlipidemia, and subsequently increase the risk of the 
metabolic syndrome. However, aripiprazole and ziprasidone have a favourable 
metabolic profile.   
Objectives:  i) To determine the improvement and reversibility of metabolic 
syndrome, its components and lipid profiles after switching to aripiprazole or 
ziprasidone. ii) To determine the safety and efficacy of aripiprazole and ziprasidone in 
the treatment of schizophrenia patients with metabolic syndrome. 
Methodology:  
Design: This was a double blind randomized controlled trial.   
Setting: The study was conducted at four mental institutions and four general 
hospitals.  
Patients: Study population were patients aged between 18 and 65 years old, with 
a current Diagnostic and Statistical Manual of Mental Disorders-IV 
Text Revision (DSM-IV TR) diagnosis of schizophrenia.  
Intervention: Eligible patients were randomised either to aripiprazole or ziprasidone. 
The dose of aripiprazole and ziprasidone, can be either increased or 
reduced based on clinical assessment. The total daily dosage of 
ziprasidone ranges from 80mg - 160mg.The total daily dosage of 
aripiprazole ranges from 10mg - 30 mg.   
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Measures: Metabolic syndrome was defined by using the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) 
criteria-modified for Asian waist circumference. For baseline and 
follow-up evaluation, the outcome measures included body mass index 
(BMI), waist circumference, blood pressure (BP), fasting blood sugar 
(FBS), lipid profile, adverse effects monitoring and clinical rating 
scale such as Positive and Negative Symptoms Scale (PANSS), 
Clinical Global Impression Scale (CGI), Abnormal Involuntary 
Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and Simpson 
Angus Scale (SAS). Intention-to-treat was used for the data analysis. 
Generalized Estimating Equation (GEE) and Mixed-Effects Model 
Repeated-Measures (MMRM) analysis was utilized to examine 
changes in outcome measures over time with the treatment of 
aripiprazole and ziprasidone. 
 
Results: A total of 527 schizophrenia patients were screened, 175 patients were 
recruited for the study. 51.4% (90/175) of patients was randomized to aripiprazole and 
48.6% (85/175) to ziprasidone. There was improvement in the prevalence of metabolic 
syndrome from baseline to 6-month after switching to aripiprazole or ziprasidone; 
(aripiprazole 58.9% vs. 30.0%, ziprasizone 51.8% vs. 15.3%, p<0.05), 14.4% of 
patients had resolved metabolic syndrome after switching to aripiprazole and 18.8% of 
patients had resolved metabolic syndrome after switching to ziprasidone. There was 
improvement in the prevalence of all metabolic syndrome component from baseline to 
6-month after switching to aripiprazole or ziprasidone; waist circumference 
(aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), HDL cholesterol 
(aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), triglycerides 
(aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), BP (aripiprazole 41.1% 
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vs. 25.6%, ziprasizone 32.9% vs. 20.0%) , FBS (aripiprazole 42.2% vs. 20.0%, 
ziprasizone 25.9% vs. 8.2%, p<0.05). There was statistically significant improvement 
in PANSS, CGI, BARS and SAS after switching to aripiprazole or ziprasidone. The 
commonest side effects reported were EPS and insomnia for both treatment groups.    
Conclusion: Switching to aripiprazole or ziprazidone was effective in reversing the 
metabolic syndrome and its components among schizophrenia patients who had 
metabolic syndrome. Aripiprazole and ziprasidone were efficacious and safe in the 
treatment of schizophrenia patients with metabolic syndrome.  
 
Keywords: Randomized controlled trial, schizophrenia, aripiprazole, ziprasidone, 
safety, efficacy. 
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3.2   Introduction  
It has been known that patients with schizophrenia were at greater risk for type 2 
diabetes, cardiovascular disease (CVD) and early mortality associated with CVD, as 
compared to the general population (Osborn et al.,2008; Hennekens,2007; Roshanaei-
Moghaddam and Katon,2009). Numerous reports have also associated the 
development of insulin resistance (Houseknecht et al.,2007; Chintoh et al.,2009) and 
type 2 diabetes (Jin et al.,2004; Smith et al.,2008) with long-term treatment with 
certain atypical antipsychotic drugs.     
Not all antipsychotic agents carry the same adverse metabolic risk. Of the atypical 
antipsychotics, aripiprazole and ziprasidone were associated with a lower metabolic 
risk (ADA-APA-AACE,2004; Newcomer,2005). Both ziprasidone and aripiprazole 
were known to be the second generation atypical antipsychotics that were least likely 
to cause dyslipidaemia, and in fact might improve the lipid profile of patients switched 
from another antipsychotic drug to one of these agents (Spurling et al.,2007; 
Greenberg and Citrome,2007). 
Therefore, switching patients with schizophrenia who require long-term treatment with 
antipsychotic drugs to either aripiprazole or ziprasidone appeared to be a rational 
choice to lessen the metabolic effects (e.g. obesity, hyperglycaemia, dyslipidaemia) 
induced by the antipsychotics. The evidence for supporting this strategy has mostly 
come from small observational studies (Alptekin et al.,2009; Schorr et al.,2008; 
Takeuchi et al.,2010), short-term randomised studies (Pae et al.,2009), retrospective 
chart review (Spurling et al.,2007), or post-hoc analysis of pooled data from 
randomised efficacy trials (Weiden et al.,2003; Weiden et al.,2008). 
In particular, switching to aripiprazole or ziprasidone from antipsychotics with greater 
tendency to cause weight gain and metabolic dysregulation (e.g. olanzapine, clozapine, 
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quetiapine) has been shown to reduce body weight, triglyceride and LDL-cholesterol 
levels (Weiden et al.,2008; Casey et al.,2003; Cetin and Karagozoglu,2007; Montes et 
al.,2007; Newcomer et al.,2008). More recently, the results from a 12-month, 
prospective, randomised, open-label study by Chen et al (2012) suggested that, 
switching existing antipsychotic treatment to either aripiprazole or ziprasidone in 
stable patients with schizophrenia, schizoaffective disorder or bipolar disorder 
improved the metabolic profile of those patients over the long-term. 
3.2.1   Atypical Antipyschotics: Aripiprazole and Ziprasidone 
3.2.2. Aripiprazole 
Aripiprazole, the sixth atypical antipsychotic of its kind, was approved by the Food 
and Drug Administration (FDA) in 2002 for the treatment of schizophrenia. It later 
also received FDA approval for the treatment of acute manic and mixed episodes 
associated with bipolar disorder, as well as treatment of depression (BMS,2007). The 
introduction of aripiprazole, which was classified as a D2 partial agonist, was an 
interesting development in this area of schizophrenia treatment.   
3.2.3 Pharmacology 
Aripiprazole was chemically characterised as a quinolinone derivative. The clinical 
benefits of aripiprazole in treating schizophrenia could be attributed partly to the 
drug's unique mechanism of action on dopamine and serotonergic receptors. While all 
previously available antipsychotics were antagonists at D2 receptors, aripiprazole was 
said to be a partial agonist at these receptors (Burris et al.,2002), exhibiting both pre-
synaptic dopamine autoreceptor agonistic activity and post-synaptic D2 antagonistic 
activity (Kikuchi et al.,1995). When dopamine levels were high (e.g. in the limbic 
regions in schizophrenia), aripiprazole acted as an antagonist, while at the same time 
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worked as an agonist in other regions where dopamine levels were low (e.g. in the 
prefrontal cortex in schizophrenia). For this reason, aripiprazole was also claimed to 
be a ‘dopamine stabilizer’ (Stahl,2001). 
Although it was commonly believed that aripiprazole mediates its antipsychotic 
through partial agonism at the D2 dopamine receptor, it was more likely that its 
primary mechanism of action was functional selectivity at the D2 receptor (Urban et 
al.,2007). Studies have shown that aripiprazole has an affinity about 100 times higher 
for D2 than D1 receptors in rat stratium in vitro (Inoue et al.,1997), and has a high 
affinity for the D2 receptor (Burris et al.,2002). Some type of differential modulation 
of dopaminergic activity might also occur in the mesolimbic, mesocortical, and basal 
ganglia target fields in the brain (Tanahashi et al.,2012).  
Besides its functional selectivity at the D2 receptor, aripiprazole was also an antagonist 
at the serotonin 5-HT2A receptors (Burris et al.,2002), a common trait of all atypical 
antipsychotics,  as well as a partial agonist at the serotonin 5-HT1A receptors (Jordan et 
al.,2002). The 5-HT2A antagonism was one potential mechanism by which aripiprazole 
(and all atypical antipsychotic agents) helped alleviate negative symptoms associated 
with schizophrenia (e.g. flattened affect, alogia, anhedonia, emotional and social 
withdrawal). It has also been reported that 5-HT2A blockade might offer certain 
amount of protection from the extrapyramidal symptoms associated with extensive D2 
blockade (Kapur and Remington,1996; Meltzer et al.,1989). High-affinity blockade of 
D2 receptors and increased in D2 receptor density were thought to be associated not 
only with undesirable extrapyramidal symptoms (EPS), but also with the development 
of tardive dyskinesia (Blanchet et al.,2012).
 
The 5-HT1A agonistic action of aripiprazole, on the other hand, might offer extra help 
in mediating EPS when D2 blockade was complete. This was accomplished through 
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the inhibitory actions on serotonergic neurons, which lead to an increased in 
dopaminergic transmission in the stratium, thus reducing EPS (Jordan et al.,2002). 
This pharmacological action of aripiprazole has led some specialists to describe this 
drug as the first of a new class of atypical antipsychotic agents, termed ‘dopamine-
serotonin system stabilizer’ (McQuade et al.,2004). As for other neuroreceptors, 
aripiprazole exhibited moderate affinity for histamine and alpha-adrenergic receptors, 
and no appreciable affinity for cholinergic muscarinic receptors (Green,2004). 
3.2.4 Pharmacokinetics 
i) Absorption and distribution 
Aripiprazole displayed linear kinetics, with its steady-state plasma concentrations 
achieved after 2 weeks with once-daily dosing. After multiple oral doses, maximum 
plasma concentration (Cmax) occurs 3-5 hours after administration without food 
(Molden et al.,2006).  
The bioavailability of aripiprazole oral tablets was about 90%. Administration with 
food does not significantly affect Cmax or area under the curve (AUC), but delay the 
time to reach Cmax by 3 hours for the parent compound, and by 12 hours for 
dehydroaripiprazole, its major metabolite (Bristol-Myers,2002).
 
Aripiprazole and dehydroaripiprazole were 99% protein-bound at therapeutic 
concentrations (Molden et al.,2006). No clinically relevant effects of aripiprazole on 
the pharmacokinetics of warfarin (a highly protein-bound drug) have been reported 
when the two agents were administered concurrently (Bristol-Myers,2002).
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ii) Metabolism and Elimination 
Aripiprazole has undergone extensive hepatic metabolisation, with a mean terminal 
half-life of 60 hours (range 48-68 hours) 14 days after administration. Aripiprazole has 
an elimination half-life of approximately 75 hours (Winans,2003). The active major 
metabolite of aripiprazole was dehydroaripiprazole, with elimination half-life of about 
94 hours. The parent compound was excreted only in traces – less than 1% and 18% 
eliminated in the urine and faeces, respectively (Winans,2003; Molden et al.,2006).  
Aripiprazole was metabolised via three pathways: dehydrogenation, hydroxylation and 
N-dealkylation. Cytochrome P450 (CYP) enzymes 3A4 and 2D6 were responsible for 
the dehydrogenation and hydroxylation processes, while N-dealkylation appears to be 
catalyzed solely by CYP3A4. At steady state, dehydroaripiprazole, the major 
metabolite, represents about 40% of the AUC and has an affinity similar to that of 
aripiprazole for D2 receptors (Bristol-Myers,2002).  
In poor metabolisers of CYP2D6, aripiprazole plasma concentration increased by 
about 80%, while dehydroaripiprazole decreased by 30%. In patients with mild and 
moderate hepatic insufficiency, AUC of aripiprazole increased by 31% and 8%, 
respectively. However, AUC of aripiprazole decreased by 20% in those with severe 
hepatic insufficiency. In patients with severe renal impairment (creatinine clearance 
<30 ml/min), the AUC for aripiprazole was decreased by 15%, and for 
dehydroaripiprazole was increased by 7%.
 
These differences observed in patients with 
renal or hepatic impairment, however, did not warrant dosage adjustments (Bristol-
Myers,2002). 
iii) Drug Interactions 
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Results from in vivo studies support in vitro findings that aripiprazole did not affect 
pharmacokinetic parameters of drugs metabolized by CYP2C9, CYP2C19, CYP2D6, 
and CYP3A4. Dosages of aripiprazole 10-30 mg/day showed no significant effects on 
metabolism of dextromethorphan (CYP2D6 and CYP3A4 substrate), warfarin 
(CYP2C19 and CYP2C9 substrate) or omeprazole (CYP2C19 substrate) (Bristol-
Myers,2002).
 
Administration of aripiprazole after 13 days of administration of the potent CYP2D6 
inhibitor quinidine (166mg/day) increased the AUC of aripiprazole by 112% and of 
dehydroaripiprazole by 52%. The AUC also increased by 63% and 77% for 
aripiprazole and dehydroaripiprazole, respectively, after administration of 
ketoconazole (200 mg/day), a potent CYP3A4 inhibitor (Bristol-Myers,2002).  
Population pharmacokinetic analysis of data from several phase II and III studies did 
not demonstrate any clinically relevant effects from co-administration of substrates 
and inhibitors of CYP2D6 and CYP3A4 on aripiprazole pharmacokinetics. However, 
the manufacturer recommended reducing the dosage of aripiprazole to half the normal 
dosage when administered concomitantly with ketoconazole or quinidine (Bristol-
Myers,2002).
 
Co-administration of carbamazepine, a potent CYP3A4 inducer, with aripiprazole 
resulted in decreased of approximately 70% in Cmax and AUC of both aripiprazole and 
dehydroaripiprazole. Adding carbamazepine to aripiprazole would necessitate 
doubling the aripiprazole dosage; further dosage adjustments should be based on 
clinical evaluation (Bristol-Myers,2002).
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Co-administration of aripiprazole with valproate at steady state resulted in a 25% 
decrease in Cmax and AUC of aripiprazole. Lithium did not show any substantial 
effects on aripiprazole pharmacokinetics (Citrome et al.,2005). 
iv)  Dosage and administration 
The recommended dosage of aripiprazole for an acute exacerbation of schizophrenia 
was 10-30 mg/day administered as a single daily dose, with or without food (Bristol-
Myers,2002).  
3.2.5. Side effects 
Standard dosages of aripiprazole 10-30 mg/day were generally well tolerated. The 
tolerability profile of aripiprazole was broadly similar to that observed with placebo in 
short-term trials in patients with acute relapse of schizophrenia or schizoaffective 
disorder, as well as in a 26-week trial in patients with chronic stable schizophrenia 
(Swainston Harrison and Perry,2004). 
The most common side effects of aripiprazole reported in patients with schizophrenia 
and schizoaffective disorder include:
 
• Headache 
• Agitation 
• Anxiety 
• Insomnia 
• Dyspepsia 
• Nausea 
• Light headedness 
• Blurred vision 
• Akathisia 
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i) EPS 
Aripiprazole was generally associated with a placebo-level incidence of EPS and EPS-
related adverse events. In a 52-week trial, there were significantly fewer aripiprazole 
recipients experiencing EPS-related adverse events compared with haloperidol 
recipients. Changes in severity of EPS were minimal and usually no different from 
those observed with placebo.  
There was also less severe EPS in aripiprazole-treated patients than in haloperidol-
treated patients in a long-term trial. In short-term trials, treatment-emergent tardive 
dyskinesia was reported in only 0.2% of patients receiving aripiprazole, an incidence 
comparable to that seen in placebo recipients (0.2%) (de Oliveira et al.,2009).  
ii) Cardiovascular and metabolic effects 
Studies have shown that aripiprazole has a low propensity to cause clinically 
significant weight gain, prolactin elevation or corrected QT (QTc) interval 
prolongation in patients with schizophrenia or schizoaffective disorder. There were 
also no clinically marked differences in mean changes from baseline in diabetes and 
dyslipidaemia parameters between aripiprazole-treated patients or placebo recipients 
in a 26-week, placebo-controlled trial (Swainston Harrison and Perry,2004).  
3.2.6 Clinical trials on efficacy and tolerability 
The efficacy and tolerability of aripiprazole has been demonstrated in patients with 
schizophrenia or schizoaffective disorder. Multicentre clinical trials indicated 
aripiprazole to be well tolerated and significantly more efficacious than placebo and 
comparable with other atypical antipsychotics (Kane et al.,2002; Bowles and 
Levin,2003; Potkin et al.,2003).  
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i) Short-term studies 
Short-term clinical trials showed that, when compared with placebo, treatment with 
aripiprazole (10-30 mg/day) led to significant improvement in positive and negative 
symptom scores, as well as in Clinical Global Impression Severity of Illness (CGI-S) 
scores, in patients with acute relapse of chronic schizophrenia or schizoaffective 
disorder.  Aripiprazole has also been shown to significantly more effective than 
placebo in reducing relapse rate in patients with stable chronic schizophrenia in a 26-
week, randomised trial (Swainston Harrison and Perry,2004).  
A 4-week, double-blind, randomised study comparing aripiprazole (15 mg/day) and 
risperidone (6 mg/day) was conducted in Chinese patients with schizophrenia or 
schizoaffective disorder in Taiwan. Results showed that both the aripiprazole and 
risperidone groups showed statistical improvement from baseline in Positive and 
Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and CGI-
S scores at study endpoint (p<0.001). However aripiprazole was associated with 
significantly less EPS liability (p<0.005) and less serum prolactin level elevation than 
risperidone (p<0.001) (Chan et al.,2007).  
ii) Long-term studies 
A 26-week, multicentre, randomised, double-blind study  was conducted to compare 
aripiprazole and olanzapine in patients with schizophrenia who were in acute relapse 
and required hospitalisation. While both treatment groups achieved comparable 
clinically meaningful improvements on efficacy measures, a greater proportion of 
patients in the olanzapine group exhibited clinically significant weight gain as 
compared with the aripiprazole group. By end of study, 37% of olanzapine recipients 
had experienced significant weight gain compared with 14% of aripiprazole recipients 
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(p<0.001). In fact at week 26, there was a mean weight loss of 1.37 kg with 
aripiprazole compared with a mean increase of 4.23 kg with olanzapine among 
patients who remained on therapy (p<0.001). Changes in fasting plasma levels of total 
cholesterol, high-density lipoprotein cholesterol, and triglycerides were also 
significantly different between the two treatment groups, with worsening of the lipid 
profile among olanzapine-treated patients. The observed effects on weight and lipids 
indicate a potentially lower metabolic and cardiovascular risk in patients treated with 
aripiprazole compared with those treated with olanzapine (McQuade et al.,2004). 
When compared with olanzapine (10-15 mg/day) in a non-blind, 26-week trial, 
patients with chronic schizophrenia receiving aripiprazole (30mg/day) experienced 
similar (general cognitive function) or better (verbal learning) changes from baseline 
in the neurocognitive parameters as compared with olanzapine-treated patients 
(Swainston Harrison and Perry,2004). 
When compared with haloperidol in a 52-week trial involving patients with acute 
relapse of schizophrenia, the response rates at study end was higher in the aripiprazole 
group (77%) than in the haloperidol group (73%) (Swainston Harrison and 
Perry,2004).  
Clearly, aripiprazole has an apparent advantage over existing antipsychotics in terms 
of safety and tolerability (Bowles and Levin,2003; Marder et al.,2003; Crismon et 
al.,2003), given its beneficial profile in terms of a low potential for body weight gain 
and changes in metabolic indices.   
3.2.7 Ziprasidone 
Ziprasidone was the fifth atypical antipsychotic to gain FDA approval in February 
2001. In the United States, ziprasidone was approved for the treatment of 
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schizophrenia. The intramuscular injection form of ziprasidone was approved for acute 
agitation in schizophrenic patients. Ziprasidone has also received approval for acute 
treatment of mania and mixed states associated with bipolar disorder (FDA,2001).   
3.2.8 Pharmacology 
Ziprasidone was an antipsychotic with combined dopamine and serotonin receptor 
antagonist activity. It also has a high affinity for alpha-adrenergic receptors and a 
medium affinity for histamine receptors. The exact mechanism of action of 
ziprasidone was unknown. However, it was believed that the drug’s antipsychotic 
activity was mediated primarily by antagonism at dopamine receptors, specifically D2 
(Seeger et al.,1995).  
The most potent action of ziprasidone was at the 5-HT2A site. This atypical 
antipsychotic has perhaps the most selective affinity for 5-HT2A receptors compared 
with most clinically available antipsychotic agents. This powerful antagonism of 5-
HT2A receptors in the brain might limit the EPS associated with dopamine receptor 
blockade and also improved efficacy against negative symptoms of schizophrenia 
(Seeger et al.,1995).  
On the other hand, antagonism at histaminic and alpha-adrenergic receptors was likely 
to explain some of the side effects of ziprasidone (e.g. sedation, orthostasis) 
(Green,2001). Ziprasidone has weak anticholinergic activity, suggesting a low 
potential for impairing cognitive abilities (Byerly et al.,2001). This might indicate an 
advantage in the elderly who were prone to anticholinergic cognitive effects. 
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3.2.9 Pharmacokinetics 
i) Absorption and distribution 
Ziprasidone tended to show linear pharmacokinetics. The mean Cmax and AUC 
increased with increasing dose, with apparent dose-proportionality between the 20 mg 
and 60 mg dose levels (Miceli et al.,2000).  
The systemic bioavailability of ziprasidone was 100% when administered 
intramuscularly. Ziprasidone was well absorbed after oral administration, reaching 
peak plasma concentrations in 6 to 8 hours. The absolute bioavailability of a 20 mg 
dose under fed conditions was approximately 60%. In the presence of food, the 
absorption of ziprasidone was increased up to two-fold. The mean terminal half-life of 
ziprasidone was about 7 hours within the proposed clinical dose range (FDA,2006). 
After a single dose intramuscular administration, the peak serum concentration 
typically occurred at about 60 minutes or earlier. Steady-state plasma concentrations 
were achieved within 1-3 days. Exposure increased in a dose-related manner and 
following 3 days of intramuscular dosing, little accumulation was observed 
(FDA,2006). 
Ziprasidone absorption was not optimally achieved when administered without food. 
The bioavailability of the drug was only 50%-60% when administered without food. 
At lower doses, ziprasidone might have a higher affinity for the serotonin and 
norepinephrine transmitter systems. This might be a risk factor for mania when used in 
patients with bipolar disorder. No dose adjustment was required in patients with mild-
to-moderate renal impairment or mild-to-moderate hepatic impairment (FDA,2006).
 
ii) Metabolism and elimination 
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Ziprasidone was highly protein-bound (> 99%) and was hepatically metabolised by 
aldehyde oxidase. The drug was thoroughly metabolised with <1% being excreted 
unchanged in faeces or urine. Ziprasidone did not change into active metabolites. 
Ziprasidone was primarily metabolised by CYP3A4 in human liver microsomes and 
did not, at clinically effective doses, appeared to mediate drug interactions with 
simultaneously administered CYP substrates (FDA,2006). 
 
One study on extensive metaboliser subjects found that ziprasidone did not inhibit the 
clearance of drugs metabolised by the 2D6 isoenzyme of cytochrome P450 (CYP2D6). 
Unlike clozapine and olanzapine, ziprasidone was not metabolised by CYP1A2, and 
cigarette smoking (a CYP1A2 inducer) was unlikely to affect its metabolism (Wilner 
et al.,2000).
 
iii) Drug interactions 
 
Medications that induced (e.g. carbamazepine) or inhibited (e.g. ketoconazole) 
CYP3A4 have been shown to decrease and increase, respectively, blood levels of 
ziprasidone (FDA,2006). There were no significant interactions with lithium in healthy 
subjects taking a moderate dose of lithium and ziprasidone.(Apseloff et al.,2000) The 
drug has also no interaction with aluminium and magnesium hydroxide antacids or 
cimetidine (FDA,2006).
 
iv)    Dosage and administration 
 
Ziprasidone was available in oral and intramuscular forms for administration. The oral 
form of ziprasidone was the hydrochloride salt, ziprasidone hydrochloride, while the 
intramuscular form was the mesylate salt, ziprasidone mesylate trihydrate, which was 
provided as a lyophilized powder (FDA,2006). 
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Initial evidence suggested an effective dosage range of ziprasidone at 80-160 mg/day 
(Daniel et al.,1999). Rapid-acting intramuscular fixed doses of ziprasidone at 5-20 mg 
have also been well tolerated , and not associated with EPS, dystonia or excessive 
sedation (Green,2001).
 
3.2.10 Side effects 
Ziprasidone was generally well tolerated. The most frequent side-effects associated 
with ziprasidone were (Daniel et al.,1999):
 
• Mild or moderate headache 
• Mild dyspepsia 
• Nausea 
• Dizziness 
• Transient somnolence 
Ziprasidone was shown to have a very low liability for inducing movement disorders 
and weight gain (Daniel et al.,1999). According to a meta-analysis study, weight gain 
attributable to ziprasidone therapy was only 0.44 kg on average (Allison et al.,1999). 
Another systematic review also concluded that ziprasidone did not appear to be linked 
to weight gain (Taylor and McAskill,2000). A Cochrane review for ziprasidone by 
Bagnall et al (2000) concluded that ziprasidone might be an effective antipsychotic 
with less EPS than haloperidol, but it also might cause more nausea and vomiting. 
Ziprasidone also has important advantages in the sense that it was not associated with 
clinically significant adverse changes in cholesterol, triglycerides or glycemic control. 
In fact, patients might experience moderate improvement in these measures when 
switching to ziprasidone from a different antipsychotic agent. The tolerability profile 
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of ziprasidone might thus be quite valuable in the treatment of some patients 
(Greenberg and Citrome,2007).  
Ziprasidone was associated with transient prolactin elevation, which was not dose 
related, and which attenuates as treatment continues (Miceli et al.,2000). Ziprasidone 
was not anticholinergic, and therefore only infrequently causes EPS or postural 
hypotension (Greenberg and Citrome,2007).
 
Nevertheless, ziprasidone has been associated with an increased mortality in elderly 
patients with dementia-related psychosis. It might also prolong the electrocardiogram 
QTc interval in some patients, and increases the risk of a type of heart arrhythmia 
known as torsades de pointes. As such, it has been advised that ziprasidone should be 
used cautiously in patients simultaneously taking medication that were likely to 
interact with ziprasidone or increase the QTc interval (FDA,2006).   
3.2.11 Clinical trials on tolerability and efficacy 
 
The efficacy and tolerability of ziprasidone has been demonstrated in a number of 
studies involving patients with schizophrenia or schizoaffective disorder. When 
compared with chlorpromazine and haloperidol, ziprasidone appeared to have some 
limited clinical advantages over the two typical antipsychotics in ameliorating 
negative symptoms of schizophrenia (Greenberg and Citrome,2007).
 
Ziprasidone has also demonstrated comparable antipsychotic efficacy to other atypical 
antipsychotics, but exhibited a more favourable metabolic parameter profile 
(Greenberg and Citrome,2007; G. M. Simpson et al.,2004; Bartko et al.,2006).
 
i) Short-term studies 
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Ziprasidone was compared with olanzapine in a 6-week, multicentre, double-blind, 
parallel-design and flexible-dose trial. The study results showed that, while both 
antipsychotics were efficacious in improving symptoms and global illness severity, 
and were well tolerated, ziprasidone was less associated with changes in the metabolic 
parameters compared with olanzapine. Body weight, total cholesterol, triglycerides 
and low-density lipoprotein cholesterol were noted to significantly increase in the 
olanzapine group, but not in the ziprasidone group. Olanzapine, but not ziprasidone, 
was also associated with significant increased in fasting insulin level (G. M. Simpson 
et al.,2004).   
Another short-term 8 weeks randomised, double-blind study compared ziprasidone 
(40-80 mg b.i.d) with risperidone (3-5 mg b.i.d) in patients with acute exacerbation of 
schizophrenia and schizoaffective disorder. Again, both agents were comparable in 
terms of improving psychotic symptoms and tolerability. However, ziprasidone 
demonstrated a lower Movement Disorder Burden score and fewer incidence of 
prolactin elevation and clinically relevant weight gain compared with risperidone 
(Addington et al.,2004).  
ii) Long-term studies 
Ziprasidone has been shown to be well tolerated and beneficial for long-term treatment 
in terms of improving severity of symptoms and general functioning in patients 
undergoing usual care.  
In an open-label, large-scale, naturalistic trial conducted by Ratner et al(2007) 
unstable schizophrenia patients with persistent symptoms or troublesome side effects 
were treated with ziprasidone (40-160 mg/day) for 12 months. Improvement in 
PANSS factors and global functioning was observed among patients who had 
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completed the study. The response rate remained high at 43.8% when a cut-off of 20% 
improvement of PANSS total scores was used. The most common side effects of 
ziprasidone were fatigue, sleep disturbances and headache, but the treatment did not 
appear to be associated with weight gain. 
In Phase 2 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
for schizophrenia, ziprasidone did not match the clinical performance of olanzapine 
and risperidone, but appeared to be comparable to quetiapine in overall effectiveness. 
The researchers suggested that the rate of dose titration and the dose achieved might 
have an important influence on the efficacy profile of ziprasidone (Greenberg and 
Citrome,2007).  
iii) Switch studies 
Studies looking at switching from other antipsychotics to ziprasidone have also 
demonstrated improvements of psychopathology and negative symptoms in 
schizophrenia patients.  
A study by Daniel et al(1999)  looked at switching from olanzapine to ziprasidone in 
58 outpatients over a short period. They found that ziprasidone was associated with 
improvements in attention, vigilance, verbal learning and memory after 6 weeks of 
therapy with ziprasidone. 
 In patients with schizophrenia who were already treated with conventional or other 
atypical antipsychotics, but had to be switched due to unsatisfactory efficacy or poor 
tolerance, a 12-week therapy with ziprasidone resulted in significant improvements on 
all major symptoms measures and subscales. At least 50% of patients were rated much 
or very much improved on CGI-I 12 weeks later. The mean SAS score was also 
significantly reduced during the ziprasidone treatment period. In addition, during the 
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12-week treatment, the body weight of the patients was significantly reduced by an 
average of 1.2 kg (p=0.002) (Bartko et al.,2006).   
Therefore, ziprasidone might be considered a first-line drug option in the treatment of 
schizophrenia. Nevertheless, in view of the differences among antipsychotic 
medications, drug selection should be guided by the patient's individual characteristics 
and situation. 
 
3.3    Systematic review on efficacy and safety of aripiprazole and 
ziprasidone as treatment of metabolic syndrome components and 
metabolic syndrome among schizophrenia patients   
 
3.3.1. Methods 
3.3.2. Search strategy  
This systematic review included literature published between January 2000 and 
October 2012.  An electronic search on the following databases was carried out:  
PUBMED, Web of Science, OVID Medline (R), the Cochrane Central Register of 
Controlled Trials and the Cochrane Database of Systematic Review, using the search 
terms: 
i). Aripiprazole   
ii). Ziprasidone 
iii). Schizophrenia 
iv). Metabolic    
Where Medical Subject Headings (MeSH) terms were available, they were exploded 
and combined. Reference lists from retrieved papers were also searched. Reference 
lists of the all papers were checked for the potential publications.  
3.3.3. Type of studies  
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Only publications in English for randomized clinical trials were included if: 
(a) Aripiprazole at any dose compared with any other antipsychotics or  placebo 
(b) ziprasidone at any dose compared with any other antipsychotics or  placebo  
(c) aripiprazole compared with ziprasidone  
 Types of participant 
Male or female patients, age ≥ 18 years old, any ethnic origin, who was diagnosed 
schizophrenia and other form of schizophrenia without mood stabilizer .e.g. 
schizoaffective disorder.  
3.3.4.  Types of interventions 
(a) The treatment group was aripiprazole or ziprasidone and the comparison 
groups were either any antipsychotic drugs or placebo or non-drug treatment. 
(b) The treatment group was between aripiprazole and ziprasidone 
3.3.5.  Types of outcome measures  
(a) Efficacy findings using clinical rating scales – PANSS total, positive, negative 
subscale and Brief Psychiatry Rating Scale (BPRS), CGI-I and CGI-S 
(b) Metabolic syndrome rate      
(c) Parameters included mean or median changes in lipids(mg/dL), Fbs (mg/dL), 
SBP and DBP (mmHg), waist circumference (cm), weight(kg)  
3.3.6.   Data extraction 
Two reviewers were involved in identifing potentially relevant abstracts and 
assessment of full papers for inclusion and methodological quality. Any disagreement 
was discussed and resolved the discrepancy. 
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Information was extracted on data source such as study design, participants, 
interventions, summary results at the endpoint. Publication reported on efficacy using 
rating scales without reporting any of these parameters were excluded from the 
systematic review: mean or median changes in lipids (mg/dL), Fbs (mg/dL), SBP & 
DBP (mmHg), waist circumference (cm), weight (kg), metabolic syndrome rate. 
The data were summarized into three systematic review tables: 
i). Aripiprazole versus other antipsychotics    
ii). Ziprasidone versus other antipsychotics    
iii). Aripiprazole versus ziprasidone         
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3.3.7. Results 
A total of 15 RCT studies for aripiprazole, 17 RCT studies for ziprasidone and 2  RCT 
studies for aripiprazole and ziprasidone were identified by the search and cross-
referencing strategies.  
 
Figure 3.1   Flow chart showing the article-identification process for 
aripiprazole as treatment in schizophrenia patients  
 
 
 
 
  
 
 
 
 
 
 
Figure 3.2   Flow chart showing the article-identification process for 
ziprasidone as treatment in schizophrenia patients  
   
 
 
 
 
  
 
 
Papers not meeting inclusion criteria =5  
4 include schizoaffective disorder with mood 
stabilizer(Potkin et al.,2003; Casey et al.,2003; 
Kinon et al.,2008; Newcomer et al.,2008) and 1 
results not clearly stated(Sarin et al.,2004) 
  
 
 
Final number of paper 
included in the study = 10 
Total number of potential 
relevant papers = 15 
Final number of paper 
included in the study = 17 
Total number of potential 
relevant papers = 17 
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Figure 3.3   Flow chart showing the article-identification process for 
aripiprazole and ziprasidone as treatment in schizophrenia patients  
 
 
 
 
  
 
 
Papers not meeting inclusion criteria =1  
 include schizoaffective disorder with 
mood stabilizer and bipolar disorder 
(Chen et al.,2012)  
 
 
Final number of paper 
included in the study = 1 
Total number of potential 
relevant papers = 2 
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Table 3.1   Systematic review on the aripiprazole as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Pigott et al.(2003) 
26-week, 
Randomized,double-blind  
Schizophrenia on 
antipsychotic  
age≥18 years old 
310 patients 
Aripiprazole15mg/day(n=155) 
Placebo(n=155) 
Discontinuation rate 
Aripiprazole 54.2%,Placebo 71% 
PANSS total, positive subscale and 
BPRS, CGI-I and CGI-S (p<0.05) 
PANSS negative subscale(p>0.05) 
TG: aripipzazole -37.2, placebo -2.9  
HDL-C: aripiprazole +2.0 ,placebo +0.89  
LDL-C: aripiprazole -5.1,placebo -2.9 
Fbs: aripiprazole +0.13,placebo +2.1 (p=NS) 
Weight : aripipzazole -1.26,placebo -0.87 
 (p<0.05) 
Reported by L’Italien et al,(2007) Metabolic 
syndrome rate: Placebo 26.9%, Aripiprazole 
22.1%(p=NS) 
Incidence Metabolic syndrome : Placebo 
10.4%, Aripiprazole 3.2%(p<0.05) 
 
Marder et al.(2003) 
Pooled of 4-6-week, five 
randomized,double-blind 
Schizophrenia on 
antipsychotic except 
clozapine, Schizoaffective 
disorder not on mood 
stabilizer 
age≥18 years old 
1539 patients 
Aripiprazole 2-
30mg/day(n=926) 
Haloperidol  5 -
20mg/day(n=200) 
Placebo(N=413)  
Discontinuation rate 
Aripiprazole 46%,Haloperidol 42%, 
placebo 56%   
BARS,SAS and AIMS(p>0.05 
aripiprazole vs. placebo) 
TC(median): aripiprazole +1.0, haloperidol 
+8.0,placebo +3.0(p=NS) 
Fbs(median): aripiprazole +0.13,placebo +2.1 
(p=NS) 
Weight : aripiprazole +0.71,haloperidol +0.56, 
placebo -0.1 (p<0.05 aripiprazole vs. placebo) 
McQuade et al.(2004) 
26-week, 
Schizophrenia on 
antipsychotic except 
clozapine 
Aripiprazole15-
30mg/day(n=156) 
Olanzapine 10-
Discontinuation rate 
Aripiprazole 75%,Olanzapine 70%  
Mean CGI and PANSS total -both 
TG: olanzapine +79.4,aripipzazole+6.5 
(p<0.05) 
HDL-C: olanzapine -3.39, aripiprazole 
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Table 3.1   Systematic review on the aripiprazole as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Randomized,double-blind  age≥18 years old 
317 patients 
20mg/day(n=161) treatment arms improved 
 
+3.61(p<0.05) 
TC: olanzapine +16.3, aripiprazole  
-1.13(p=NS) 
LDL-C: olanzapine +2.27, aripiprazole  
-3.86(p=NS) 
Weight :olanzapine +4.23,aripipzazole 
-1.37 (p<0.001) 
Chrzanowski et 
al.(2006) 
52-week, 
Randomized,open-label 
extension study(Pigott et 
al.,2003)  
Schizophrenia previously 
from RCT aripiprazole vs. 
placebo 
age≥18 years old 
214 patients 
Aripiprazole15-
30mg/day(n=104) 
Olanzapine 5-
20mg/day(n=110) 
Discontinuation rate 
Aripiprazole 37%,Olanzapine 26%  
PANSS total, positive and negative 
subscales, CGI-I and CGI-S -both 
treatment arms improved(p=NS) 
 
TG: (p=NS) between groups 
HDL-C: a slight worsening with olanzapine 
versus a small improvement with aripiprazole 
(p<0.05) 
TC: greater increase with olanzapine versus 
aripiprazole (p<0.001) 
LDL-C: worsening with olanzapine versus 
improvement with aripiprazole(p<0.001) 
  
Fbs: aripiprazole -1.4,olanzapine +12.0 (p=NS) 
Weight: aripiprazole +0.04,olanzapine +2.54(p<0.001) 
Reported by L’Italien et al(2007) Metabolic 
syndrome rate: olanzapine 36.7%, Aripiprazole 
25.3%(p<0.05) 
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Table 3.1   Systematic review on the aripiprazole as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Incidence Metabolic syndrome : olanzapine 
20.6%, Aripiprazole 8.9%(p=NS) 
 
Kerwin et al.(2007) 
26-week, 
Randomized,open-label 
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
555 patients 
Aripiprazole10-
30mg/day(n=284) versus 
standard of care(SOC-
atypical antipsychotics 
n=271) 
-Risperidone 2-16mg/day 
-Olanzapine 5-20mg/day 
-Quetiapine 100-800mg/day 
Discontinuation rate 
Aripiprazole 42.3%,SOC 38.7%  
CGI-I and CGI-S -both treatment arms 
improved(p=NS) 
 
*presented as proportion of patients with 
potentially clinically relevant  
TG: aripipzazole(47.8%),SOC(59.7%) (p<0.05) 
HDL-C: aripipzazole(30.4%),SOC(35.1%) 
(p=NS) 
TC: aripipzazole(52.9%),SOC(70.2%) (p<0.05) 
LDL-C: aripipzazole(39.1%),SOC(60.0%) 
(p<0.05) 
Fbs: aripipzazole(25.2%),SOC(26.5%) (p=NS) 
Weight : aripipzazole -1.3, SOC+-1.4(p=NS) 
  
Chan et al.(2007) 
4-week, 
Randomized,double-blind  
Schizophrenia on 
antipsychotic except 
clozapine, Schizoaffective 
disorder not on mood 
stabilizer 
age≥18 years old 
83 patients 
Aripiprazole15mg/day(n=49) 
Risperidone 6mg/day(n=34) 
Discontinuation rate 
Aripiprazole 22%,Risperidone 29%  
PANSS total, positive and negative 
subscales, CGI-I and CGI-S -both 
treatment arms improved(p=NS) 
 
TC: aripiprazole -3.1,risperidone +19.2,  
 (p=NS) 
Fbs: aripipzazole +4.1,risperidone -2.7 (p=NS)   
Weight:  aripipzazole +0.9,risperidone +1.5 
(p=NS) 
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Table 3.1   Systematic review on the aripiprazole as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
McEvoy et al.(2007) 
6-week, 
Randomized,double-blind, 
discontinued RCT, entered 
open-label   
Schizophrenia on 
antipsychotic  
age≥18 years old 
420 patients 
Aripiprazole10mg/day(n=106) 
Aripiprazole15mg/day(n=106) 
Aripiprazole20mg/day(n=106) 
Placebo (n=108) 
Discontinuation rate 
Placebo 72.2%, Aripiprazole10mg 
59.4% 
Aripiprazole15mg 69.8%, Aripiprazole 
20mg 63.0% 
 
PANSS total, positive,negative 
subscale and BPRS, CGI-I and CGI-S 
(p<0.05) 
Weight : Placebo -0.64, Aripiprazole10mg  
+0.46, Aripiprazole15mg -0.17, Aripiprazole 
20mg +0.31(p=NS) 
 
Repoted by L’Italien et al,(2007)Metabolic 
syndrome rate: Placebo 23.4%, Aripiprazole 
18.2%(p=NS) 
 
Incidence Metabolic syndrome : Placebo 
25.0%, Aripiprazole 6.7%(p<0.05) 
 
   
   
Kane et al.(2009) 
28-week, 
Randomized,double-blind 
 
Schizophrenia on 
antipsychotic  
age≥18 years old 
566 patients 
Aripiprazole10-
30mg/day(n=285) 
Olanzapine 10-
20mg/day(n=281) 
Discontinuation rate 
Aripiprazole 50.2%,Olanzapine 42.7%  
PANSS total, positive subscales 
(p<0.05) Olanzapine superior than 
aripiprazole 
 PANSS negative subscales, CGI-I 
and CGI-S -both treatment arms 
improved(p=NS) 
 
*Least-squares mean change  
TG: olanzapine +25.66,aripipzazole -17.52 
(p<0.001) 
HDL-C: olanzapine -1.70, aripiprazole 
+1.43(p=0.006) 
TC: olanzapine +4.09, aripiprazole -9.85 
 (p<0.001) 
LDL-C: olanzapine +1.74, aripiprazole -6.72   
 (p=0.003) 
Fbs: olanzapine +4.87, aripiprazole +0.90 
(p=0.045) 
Weight :olanzapine +3.4,aripipzazole +0.3 
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Table 3.1   Systematic review on the aripiprazole as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
 (p<0.001) 
Fleischhacker et 
al.(2009) 
52-week, 
Randomized,double-blind  
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
703 patients 
Aripiprazole15-
30mg/day(n=355) 
Olanzapine 10-
20mg/day(n=348) 
Discontinuation rate 
Aripiprazole 61%,Olanzapine 53%  
PANSS total,CGI-I and CGI-S and -
both treatment arms improved 
(p<0.05). Olanzapine superior than 
aripiprazole  
 
TG: olanzapine +10.5,aripipzazole -25.2 
(p<0.05) 
HDL-C: olanzapine +4.8, aripiprazole +5.4 
(p=NS) 
TC: olanzapine +5.8, aripiprazole -17.0 
 (p<0.001) 
LDL-C: olanzapine +2.2, aripiprazole -17.0  
 (p<0.001) 
Fbs: (p=NS) between groups 
Weight(adjusted mean change):olanzapine 
+4.74,aripipzazole +0.32 (p<0.001) 
Macfadden et al.(2010) 
104-week, 
Randomized,rater-blinded, 
open label  
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
349 patients 
Aripiprazole10-
30mg/day(n=172) 
IM Risperidone 25-
50/biweekly(n=177) 
Discontinuation rate 
Aripiprazole 28.4%,IM Risperidone 29.6%  
PANSS total -both treatment arms 
improved(p=NS) 
 
TG: aripiprazole -0.1,risperidone +0.03,  
 (p=NS) 
 
TC: aripiprazole -0.3,risperidone -0.1,  
 (p=NS) 
Rbs(not fasting): aripipzazole -0.2, risperidone 
+0.3 (p=NS)   
Weight:  aripipzazole +1.6,risperidone +2.6 
(p=NS) 
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Arato et al.(2002) 
52-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic   
age≥18 years old 
294 patients 
Ziprasidone 40mg/day (n=72) 
Ziprasidone 80mg/day (n=68) 
Ziprasidone 160mg/day 
(n=67) 
Placebo (n=71) 
 
Discontinuation rate 
Ziprasidone 40mg/day 58%, Ziprasidone 
80mg/day 57%, Ziprasidone 160mg/day 
55%, Placebo 86% 
 PANSS total,positive and negative 
subscales, CGI-S (p<0.05) for 
ziprasidone different doses compared 
with placebo 
Weight: Ziprasidone 40mg/day -2.7, 
Ziprasidone 80mg/day -3.2, Ziprasidone 
160mg/day -2.9, Placebo -3.6(p=NS) 
  
Simpson et al.(2004) 
6-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
269 patients 
Ziprasidone 80-160mg/day 
(n=136) 
Olanzapine 5-20mg/day 
(n=133) 
Discontinuation rate 
Ziprasidone 48.5%, Olanzapine 36.8%  
PANSS total,positive and negative 
subscales, CGI-S and CGI-I- both 
treatment arms improved(p=NS) 
 
TG(median): Ziprasidone -2.0, Olanzapine 
+26.0,  (p<0.05) 
HDL-C: ziprasidone  vs. olanzapine (p=NS) 
TC(median): Ziprasidone -1.0, Olanzapine 
+19.5, (p<0.05) 
LDL-C(median): ziprasidone  -1.0, 
olanzapine +13.0 (p<0.05) 
Fbs(median): Ziprasidone +1.0, Olanzapine 
+1.0 ,  (p=NS) 
 weight : Ziprasidone  vs. Olanzapine   
(p<0.001) olanzapine weight change greater 
than ziprasidone  
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Simpson et al.(2005) 
52-week, 
Randomized,double-blind 
extension study(G. M. 
Simpson et al.,2004) 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
126 patients 
Ziprasidone 80-160mg/day 
(n=55) 
Olanzapine 5-20mg/day 
(n=71) 
Discontinuation rate 
Ziprasidone 69.1%, Olanzapine 70.4% 
PANSS total,positive and negative 
subscales, CGI-S and CGI-I- both 
treatment arms improved(p=NS) 
TC(median): Ziprasidone -1.0, Olanzapine 
+13.0, (p=NS) 
LDL-C(median): ziprasidone  +9.0, 
olanzapine +17.0 (p=NS) 
weight : Ziprasidone -0.82 , Olanzapine 
+4.97  (p<0.001)  
Addington et al.(2004) 
8-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
296 patients 
Ziprasidone 80-160mg/day 
(n=149) 
Risperidone  2-6mg/day 
(n=147) 
 
Discontinuation rate 
Ziprasidone 36.9%, Risperidone 29.3%  
PANSS total and negative subscales, 
CGI-S and CGI-I - both treatment arms 
improved(p=NS) 
  
Weight increase (≥7% of body 
weight)(p<0.05) 
Risperidone 16.0%, ziprasidone 8.2% 
Weight decrease (≥7% of body 
weight)(p<0.05) 
Risperidone 2.4%, ziprasidone 7.4% 
Breier et al.(2005) 
28-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
548 patients 
Ziprasidone 80-160mg/day 
(n=271) 
Olanzapine 10-20mg/day 
(n=277) 
 
Discontinuation rate 
Ziprasidone 57.6%, Olanzapine 40.4%  
PANSS total, general psychopathology 
,positive and negative subscales, CGI-S 
(p<0.001) olanzapine better than 
ziprasidone  
  
TG: olanzapine +34.5,ziprasidone -21.3 
(p<0.05) 
HDL-C: olanzapine -2.3, ziprasidone  +0.8 
(p<0.001) 
 TC: olanzapine +3.1, ziprasidone  -12.8 
 (p<0.001) 
LDL-C: olanzapine +0.8, ziprasidone  -10.4  
 (p<0.001) 
Fbs: olanzapine +5.0, ziprasidone  -0.18  
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
 (p<0.001) 
Weight:olanzapine +3.06, ziprasidone  -1.12 
(p<0.001) 
Lieberman et al.(2005) 
72-week, 
Randomized,double-blind 
(CATIE phase 1)   
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
1493 patients 
Ziprasidone 80-160mg/day 
(n=185) 
Olanzapine 7.5-30mg/day 
(n=336) 
Quetiapine 200-800mg/day 
(n=337) 
Risperidone 1.5-6mg/day 
(n=341) 
Perphenazine 8-24mg/day 
(n=261) 
 
Discontinuation rate 
Ziprasidone 79%, Olanzapine 64%,  
Quetiapine 82%, Risperidone 74%, 
Perphenazine 75% 
PANSS total and CGI (p<0.05) 
 
*Exposure-adjusted mean 
*TG: Ziprasidone -16.5, Olanzapine +40.5,  
Quetiapine +21.2, Risperidone -2.4, 
Perphenazine +9.2(p<0.001) 
*TC: Ziprasidone -8.2, Olanzapine +9.4, 
Quetiapine +6.6, Risperidone -1.3,  
Perphenazine +1.5(p<0.001) 
*Fbs: Ziprasidone +2.9, Olanzapine +13.7 ,  
Quetiapine +7.5 , Risperidone +6.6, 
Perphenazine +5.4(p=NS) 
Weight : Ziprasidone -0.7, Olanzapine +4.3, 
Quetiapine +0.5, Risperidone +0.4, 
Perphenazine -0.9(p<0.001) 
Brook et al.(2005) 
6-week, 
Randomized,single-blinded 
 
Schizophrenia or 
schizoaffective not on mood 
stabilizer 
Aged 18-70 years 
572 patients 
IM Ziprasidone 10-40mg for 
initial 3 days followed by oral 
Ziprasidone 80-160mg/day  
(n=429) 
 IM Haloperidol 2.5-10mg for 
initial 3 days followed by oral 
Haloperidol 5-20mg/day         
Discontinuation rate 
IM Phase:Ziprasidone 0.9%, Haloperidol 
2.2% 
Oral Phase:Ziprasidone 31.0%, 
Haloperidol 31.9% 
BPRS, BPRS-derived measures and 
Weight: Ziprasidone  +0.25,  
Haloperidol -0.15  
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
(n=138) COVI Anxiety Scale -Ziprasidone better 
than haloperidol (p<0.05) 
 CGI-S and CGI-I(P=NS)  
Stroup et al.(2006) 
24-week, Randomized, 
double –blind (CATIE phase 
2)   
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
444 patients 
Ziprasidone 80-160mg/day 
(n=137) 
Olanzapine 7.5-30mg/day 
(n=68) 
Quetiapine 200-800mg/day 
(n=63) 
Risperidone 1.5-6mg/day 
(n=70) 
 
Discontinuation rate 
Ziprasidone 77%, Olanzapine 67%,  
Quetiapine 84%, Risperidone 64% 
PANSS total (p=0.005) except 
risperidone(p=NS) 
PANSS positive subscale (p<0.05) 
PANSS negative and psychopathology 
subscale, CGI(p=NS) 
*Exposure-adjusted mean 
*TG: Ziprasidone -3.5, Olanzapine +94.1,  
Quetiapine +39.3, Risperidone -5.2, 
(p<0.001) 
*TC: Ziprasidone -10.7, Olanzapine +17.5, 
Quetiapine +6.5, Risperidone -3.1,  
(p<0.001) 
*Fbs: Ziprasidone +0.8, Olanzapine +13.8 ,  
Quetiapine +1.2 , Risperidone +6.9, (p=NS) 
Average weight change/month : Ziprasidone 
-0.8, Olanzapine +0.6, Quetiapine +0.3, 
Risperidone -0.1 (p<0.001) 
Olie et al.(2006) 
12-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic  
age≥18 years old 
123 patients 
Ziprasidone 80-160mg/day 
(n=60) 
Amisulpride 50-200mg/day 
(n=63) 
 
Discontinuation rate 
Ziprasidone 14.6%, amisulpride 10.6%  
PANSS total, negative subscale and 
BPRS,CGI-S (p<0.001) overall 
amisulpride better than ziprasidone  
Weight increase (>7% of body 
weight)(p<0.05) 
Amisulpride 17.9%, ziprasidone 8.8% 
Weight decrease (>7% of body 
weight)(p<0.05) 
Amisulpride 5.4%, ziprasidone 7.0% 
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Kinon et al.(2006) 
24-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
394 patients 
Ziprasidone 80-160mg/day 
(n=192) 
Olanzapine 10-20mg/day 
(n=202) 
Discontinuation rate 
Ziprasidone 70%, Olanzapine 55% 
PANSS total - both treatment arms 
improved(MMRM,p=NS) 
CDSS, MADRS and GAF -olanzapine 
better than ziprasidone(p<0.05) 
. 
TG: Ziprasidone -9.47, Olanzapine +13.6,  
(p<0.05) 
HDL-C: ziprasidone  -0.5 ,olanzapine -1.8 
(p=NS) 
TC: Ziprasidone -11.7, Olanzapine -2.27, 
(p=NS) 
LDL-C: ziprasidone  -7.3, olanzapine -4.41  
 (p=NS) 
Fbs: Ziprasidone +0.14, Olanzapine +2.85 ,  
(p=NS) 
 weight : Ziprasidone -1.65, Olanzapine 
+2.53,  (p<0.001) 
Kane et al.(2006) 
12-week, 
Randomized,double-blind 
Schizophrenia , treatment 
resistant with haloperidol 
age≥18 years old 
306 patients 
Ziprasidone up to160mg/day 
(n=152) 
Chlorpromazine up 
to1200mg/day (n=154) 
Discontinuation rate 
Ziprasidone 10.5%, Chlorpromazine 
12.3%  
PANSS total - both treatment arms 
improved(p=NS) 
PANSS negative subscale  and CGI-S 
(p<0.05) Ziprasidone superior than 
Chlorpromazine 
Weight increase (≥7% of body 
weight)(p<0.05) 
Chlorpromazine 13.8%, ziprasidone 5.1% 
Weight decrease (≥7% of body 
weight)(p<0.05) 
Chlorpromazine  1.8%, ziprasidone 10.2% 
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Meyer et al.(2008) 
12-week, Randomized, 
double –blind (CATIE 
prospective data from 
phase 1)  
 
Schizophrenia on 
antipsychotic except 
clozapine 
age≥18 years old 
281 patients 
Ziprasidone 80-160mg/day 
(n=31) 
Olanzapine 7.5-30mg/day 
(n=74) 
Quetiapine 200-800mg/day 
(n=67) 
Risperidone 1.5-6mg/day 
(n=54) 
Perphenazine 8-24mg/day 
(n=52) 
 
To demonstrate the rate of metabolic 
syndrome and metabolic effect 
comparing baseline and 3-month study 
visit     
MetS       Baseline,  3-month 
Olanzapine: 41.9%, 51.4% 
  MetS       Baseline,  3-month 
Risperidone:   37.0%, 42.6% 
Quetiapine :    38.8%,43.3% 
Ziprasidone:    48.4%,38.7% 
Perphenazine: 42.3%,38.5% 
waist : Ziprasidone 0.0, Olanzapine +1.8, 
Quetiapine +1.8, Risperidone +1.0,  
Perphenazine -1.0(p<0.001) 
systolic: Ziprasidone -0.5, Olanzapine -0.9, 
Quetiapine -1.7, Risperidone -1.4,  
Perphenazine -2.9(p=NS) 
Diastolic: Ziprasidone -0.6, Olanzapine +0.1, 
Quetiapine -0.3, Risperidone -1.4,  
Perphenazine -1.3(p=NS) 
HDL-C: ziprasidone  -0.1 ,olanzapine -2.3, 
Quetiapine -1.0, Risperidone -0.7,  
Perphenazine -0.1 (p=NS) 
Fbs: Ziprasidone -1.1, Olanzapine +0.5 , 
Quetiapine +2.7, Risperidone +4.7,  
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Perphenazine +1.4   (p=NS) 
TG: Ziprasidone -32.1, Olanzapine +21.5, 
Quetiapine +11.9, Risperidone -18.4,  
Perphenazine +11.5  (p=0.016) 
 
Cutler et al.(2008) 
4-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic. 
age18-65 years old 
606 patients 
Ziprasidone 160mg/day 
(n=151) 
Iloperidone 24mg/day 
(n=303) 
Placebo (n=152) 
 
Discontinuation rate 
Ziprasidone 34%, Iloperidone 35%, 
placebo  40% 
PANSS positive, negative subscale and 
general psychopathology, CGI-S and 
BPRS 
 Ziprasidone and Iloperidone were 
improved when compared to placebo 
except for PANSS general 
psychopathology 
TG: Ziprasidone +4.6, Iloperidone +0.8, 
placebo +19.5 
TC: Ziprasidone +4.1, Iloperidone +8.1, 
placebo -0.5  
Fbs: Ziprasidone +4.7,lloperidone 
+7.9,placebo +3.2 
 Weight : Ziprasidone +1.1, lloperidone +2.8, 
placebo +0.5   
Weight increase (≥7% of body weight) 
Ziprasidone 7%,Iloperidone 21%,placebo 
3% 
Lawson et al.(2009) 
Pooled of 4-6-week, four 
randomized, double-blind  
Schizophrenia and 
schizoaffective disorder not 
on mood 
stabilizer(comparing Black 
and White patients) 
age≥18 years old 
Ziprasidone 10-200mg/day      
(n=702) 
Haloperidol (n=85) 
Placebo(n=273) 
Discontinuation rate 
Ziprasidone 49.4%,Haloperidol 48.2%,   
Placebo 63.7% 
PANSS total and negative subscale, 
BPRS,CGI-S and CGI-I : Ziprasidone 
better than placebo, Black patients 
TG: Ziprasidone -8.82,  placebo -15.52  
TC : Ziprasidone  -7.79, placebo -7.57 
Random glucose: Ziprasidone +0.68, 
placebo +0.65 
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
1060 patients significantly improve than White patients 
p<0.05  
Weight: Ziprasidone +0.96, placebo -0.4 
 
Sacchetti et al.(2009) 
18-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic. 
age≥18 years old 
147 patients 
 
Ziprasidone 80-160mg/day 
(n=73) 
Clozapine 250-600mg/day 
(n=74) 
Discontinuation rate 
Ziprasidone 38.4%, Clozapine 38.4% 
PANSS positive, negative and general 
psychopathology subscales, CGI-S and 
CGI-I scale, CDSS,GAF scale and DAI-
10 scale 
- Clinical scales for both treatment arms 
improved when compared  to each 
other(p=NS),the difference for CGI-I was 
not significant for both arms 
TC(median):Ziprasidone -5.0, Clozapine 
+2.0(p<0.05) 
HDL(median):Ziprasidone +8.0, Clozapine 
+2.0 
LDL(median):Ziprasidone -6.0, Clozapine 
+4.0(p<0.05) 
TG(median):Ziprasidone -15.0, Clozapine 
+10.0(p<0.05) 
Fbs(median):Ziprasidone 0.0, Clozapine 
+6.0(p<0.05) 
Weight : Ziprasidone -2.6 ± 4.7, Clozapine 
+0.8 ±4.6kg 
  
Potkin et al.(2011) 
3-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
307 patients 
Ziprasidone 160mg/day 
(n=153) 
Lurasidone 120mg/day 
(n=154) 
Discontinuation rate 
Ziprasidone 30.7%, Lurasidone 32.5%  
PANSS total, positive and negative 
subscale, general psychopathology  and 
CGI-S : both treatment arms 
improved(p=NS) 
TG(median): Ziprasidone 0.0, lurasidone 
0.0,  (p=NS) 
TC(median): Ziprasidone -5.0, lurasidone -
6.0, (p=NS)  
Fbs(mean): Ziprasidone +4.8,lurasidone +4.7 
,(p=NS) 
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Table 3.2   Systematic review on the ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
  Weight(median) : Ziprasidone -0.29, 
lurasidone -0.16   (p=NS)  
Grootens et al.(2011) 
8-week, 
Randomized, double-blind 
Schizophrenia on 
antipsychotics, 
schizoaffective and 
schizophreniform disorder 
not on mood stabilizer 
age≥18 years old 
74 patients 
Ziprasidone 80-160mg/day 
(n=39) 
Olanzapine 10-20mg/day 
(n=35) 
Discontinuation rate 
Ziprasidone 28.2%,Olanzapine 17.1% 
PANSS total, positive, negative subscale 
and general psychopathology, CGI-S 
and CGI-I, CDSS, HQLS 
both treatment arms improved(p=NS) 
 
TC:Olanzapine+18.5, Ziprasidone-9.3 
TG: Olanzapine +36.0, Ziprasidone  -18.4 
Systolic: Olanzapine+0.7, Ziprasidone-0.9 
Diastolic: Olanzapine+0.7, Ziprasidone+3.1 
Fbs: Olanzapine+1.08, Ziprasidone 1.8  
Weight:Olanzapine +6.8,Ziprasidone +0.1 
Weight increase (≥7% of body weight) 
Olanzapine 64.5%,Ziprasidone 3.3% 
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Table 3.3   Systematic review on the aripiprazole and ziprasidone as treatment in schizophrenia patients 
Study design Study Subjects Intervention Summary of results at endpoint 
   Efficacy  Changes in lipids(mg/dL), Fbs(mg/dL), 
SBP&DBP(mmHg),waist circumference(cm), 
weight(kg),metabolic syndrome 
Zimbroff et al.(2007) 
4-week, 
Randomized,double-blind 
Schizophrenia on 
antipsychotic , 
Schizoaffective disorder not 
on mood stabilizer 
age≥18 years old 
256 patients  
 
aripiprazole 10-30mg/day 
(n=129) 
Ziprasidone 80-160mg/day 
(n=127) 
 
Discontinuation rate 
Aripiprazole 30.5%, Ziprasidone 32%  
 PANSS total, positive and negative 
subscales, CGI-S - both treatment arms 
improved (MMRM,p=NS) 
  
TG(median): Ziprasidone +6.0, aripiprazole -
3.0 
HDL-C: ziprasidone 0, aripiprazole 0 
TC(median): Ziprasidone -2.0, aripiprazole -
6.0 
LDL-C(median): ziprasidone  -1.0, 
aripiprazole -4.0  
Fbs(median): Ziprasidone +2.0, aripiprazole 
+3.0 
 weight : Ziprasidone +0.45,aripiprazole 
+0.45 
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3.3.9. Research Question 
Is aripiprazole has similar efficacy and safety with ziprasidone in the treatment of 
schizophrenia patients with metabolic syndrome and metabolic syndrome 
components? 
3.3.10. Study Objectives  
3.3.10.1    Primary Objective  
To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
reversing metabolic syndrome among the schizophrenia patients. 
3.3.10.2    Secondary objective 
i). To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
reversing metabolic syndrome components among the schizophrenia patients. 
ii). To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
reducing metabolic syndrome parameters among the schizophrenia patients. 
iii). To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
improving psychotic symptoms among schizophrenia patients with metabolic 
syndrome components by using CGI-S, PANSS total and subscales.  
iv). To determine the safety of aripiprazole and ziprasidone in the treatment of 
schizophrenia patients with metabolic syndrome components by using BARS, SAS 
and AIMS. 
v). To describe the adverse events of aripiprazole and ziprasidone in the of treatment 
schizophrenia patients with metabolic syndrome components.  
3.3.10.3     Tertiary objective 
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i). To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
improving weight, body mass index (BMI), and total cholesterol and LDL 
cholesterol among the schizophrenia patients. 
ii). To determine the efficacy of aripiprazole is not less effective than ziprasidone in 
improving the prevalence of cardiovascular risk factors (CVRFs) and coronary 
heart disease (CHD) risk among the schizophrenia patients.   
iii). To determine the efficacy of aripiprazole and ziprasidone by using the 
discontinuation rate as the outcome measure.  
 
3.3.11. Hypotheses  
3.3.11.1      Hypothesis for primary objective:   
i). The proportion of reversed metabolic syndrome for aripiprazole-treated patients 
will be non-inferior to the proportion of reversed metabolic syndrome for 
ziprasidone-treated patients between baseline, week 4, week 8, week 12, week 16, 
week 20 and week 24.  
3.3.11.2      Hypothesis for secondary objective:   
i). The proportion of reversed metabolic syndrome components for aripiprazole-
treated patients will be non-inferior to the proportion of reversed metabolic 
syndrome components for ziprasidone-treated patients between baseline, week 4, 
week 8, week 12, week 16, week 20 and week 24.  
ii). There will be no difference in the least squares(LS) mean change of metabolic 
syndrome parameters between aripiprazole and ziprasidone-treated patients at 
baseline, week 4, week 8, week 12, week 16, week 20 and week 24.  
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iii). There will be no difference in the least squares(LS) mean change of rating scales 
such as PANNS total, PANSS positive and negative subscales, CGI-S, BAS, SAS, 
AIMS between aripiprazole and ziprasidone-treated patients at baseline, week 4, 
week 8, week 12, week 16, week 20 and week 24. 
3.3.11.3      Hypothesis for tertiary objective:   
i). There will be no difference in the least squares(LS) mean change of weight, BMI, 
total cholesterol and LDL cholesterol between aripiprazole and ziprasidone-treated 
patients at baseline, week 4, week 8, week 12, week 16, week 20 and week 24.  
ii). The proportion of cardiovascular risk factors (CVRFs) and coronary heart disease 
(CHD) risk for aripiprazole-treated patients will be non-inferior to the proportion 
in the ziprasidone-treated patients between baseline, week 4, week 8, week 12, 
week 16, week 20 and week 24.  
iii). There will be no difference in the discontinuation rate between aripiprazole-
treated and ziprasidone-treated patients.  
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3.4  Methods  
3.4.1. Study Population 
The study population included male or female with current DSM-IV TR diagnoses of 
schizophrenia.  
3.4.2. Inclusion Criteria 
i). Having at least one component of metabolic syndrome.   
ii). Male or female, aged 18 – 65 years.  
iii). Having at least one year treatment of current antipsychotic treatment. 
iv). Patients who were treated with antihypertensive, antidiabetic or antihyperlipidemia 
prior the study, and the treatment was initiated ≥ 3 months prior to screening with 
no dosage changes 30 days before study recruitment.       
v). Able to provide written informed consent and to comply with all study procedures.  
vi). Using a barrier (diaphragm or condom) with spermicide, intrauterine device (IUD), 
or complete abstinence as a method of birth control (if a woman of child-bearing 
capacity).  
3.4.3. Exclusion Criteria 
i). Serious medical illnesses that potentially progress to life-threatening medical 
illness which may compromise patient safety or study conduct. 
ii). Patients who are currently treated with clozapine. 
iii). Patients who are currently treated with atypical antipsychotic either ziprasidone or 
aripiprazole.  
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iv). Known hypersensitivity or allergy to aripiprazole or ziprasidone. 
v). Patient with history of diabetes mellitus or hypertension prior to the treatment of 
schizophrenia. 
vi). Patient who was suicidal or homicidal. 
vii). Female who is positive on a urine pregnancy test or lactating. 
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3.4.4. Study Design 
This study was a 6-month randomized double-blind parallel clinical trial.  
Figure 3.4   The overall study design for randomized controlled trial between 
aripiprazole and ziprasidone in the treatment of metabolic syndrome 
components and metabolic syndrome 
 
 
 
 
3.4.5. Study Period 
The study period was from April 2008 until April 2012. Data was collected from May 
2009 to September 2011.  
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3.4.6. Location of Study 
This study was conducted at the outpatient psychiatric clinic in University Malaya 
Medical Centre (UMMC), Army Hospital namely Hospital Terendak Melaka and 
Hospital Tentera Laut Lumut, Perak, Hospital from Ministry of Health e.g Hospital 
Sungai Petani, Kedah, Hospital Bahagia, Ulu Kinta Perak, Hospital Permai, Johor, 
Hospital Mesra Kota Kinabalu, Sabah and Hospital Sentosa Kuching Sarawak.  
3.4.7. Study Variables 
The study variables that were considered for analysis in this study population were as 
follows: 
(Operational definitions in ANNEX A) 
3.4.8. Primary Study Endpoints  
i). The proportion of reversed metabolic syndrome among schizophrenia patients 
after treated with either aripiprazole or ziprasidone. 
Patients were scheduled for research evaluation visits on week 4, week 8, week 12, 
week 16, week 20 and week 24.   
3.4.9. Secondary Study Endpoint  
i). The proportion of reversed metabolic syndrome components among schizophrenia 
patients after treated with either aripiprazole or ziprasidone. 
ii). The least squares (LS) mean change of metabolic syndrome parameters among 
schizophrenia patients after treated with either aripiprazole or ziprasidone. 
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iii). The least squares (LS) mean change of rating scales such as PANNS total, 
PANSS positive and negative subscales, CGI-S, BAS, SAS, AIMS among 
schizophrenia patients after treated with either aripiprazole or ziprasidone. 
iv). To describe all side effects reported by patients during the study. 
Patients were scheduled for research evaluation visits on week 4, week 8, week 12, 
week 16, week 20 and week 24.   
3.4.10. Tertiary Study Endpoint 
i). The least squares (LS) mean change of weight, BMI, total cholesterol and LDL 
cholesterol among schizophrenia patients after treated with either aripiprazole or 
ziprasidone. 
ii). The proportion of cardiovascular risk factors (CVRFs), coronary heart disease 
(CHD) risk among schizophrenia patients after treated with either aripiprazole or 
ziprasidone. 
iii). The discontinuation rate between aripiprazole-treated and ziprasidone-treated 
patients.  
Patients were scheduled for research evaluation visits on week 4, week 8, week 
12, week 16, week 20 and week 24.   
3.4.11. Descriptive Variables  
Sociodemographic Variables 
i). Age  
ii). Sex  
iii). Race 
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iv). Occupational   
v). Educational level 
vi). Marital status 
Medical and Psychiatric History   
i). History of Smoking  
ii). Physical activities   
iii). History of hypertension and diabetes mellitus   
iv). History of gestational diabetes   
v). Age of onset for schizophrenia   
vi). Duration of schizophrenia 
vii). Current medication 
viii). Previous medication 
ix). History of weight after antipsychotics treatment 
x). History of hospitalization due to relapse  
xi). Number of relapse 
Family History 
i). History of hypertension 
ii). History of Diabetes Mellitus 
iii). Parent obese 
iv). Sibling obese 
3.4.12. Study Instruments 
3.4.12.1  Structured Questionnaires 
A structured questionnaire was used which consisted of three sections. The first 
section was to assess the demographic data of the study population. The second 
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section was to assess medical and psychiatric history. The third section was to obtain 
the family medical history.  
3.4.12.2.    Major Axis I Psychiatric Disorder Assessment  
MINI International Neuropsychiatric Interview (M.I.N.I.)  
M.I.N.I. is a face-to-face structured interview for the Major Axis I psychiatric disorder 
in DSM-IV and ICD-10. M.I.N.I. is used as a short structured diagnostic interview for 
DSM-IV or ICD-10 psychiatric disorders for the Major Axis I psychiatric disorder 
(D.V. Sheehan et al.,1998). It has been widely used in international clinical trials and 
epidemiological studies (Joling et al.,2008; van't Veer-Tazelaar et al.,2009). The 
M.I.N.I was available in local language for Malaysian population (D.V.  Sheehan et 
al.,1998). 
3.4.12.3.  Efficacy Assessment  
i) Positive and Negative Symptoms Scale(PANSS)  
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for 
measuring symptom severity of patients with schizophrenia (Kay et al.,1987). It refers 
to the two types of symptoms in schizophrenia, as defined by the American Psychiatric 
Association: positive symptoms, which refer to an excess or distortion of normal 
functions (e.g. hallucinations and delusions), and negative symptoms, which represent 
a diminution or loss of normal functions. A face-to-face interviewed of the scale will 
capture three components: positive scale (7 items), negative scale (7 items) and 
general psychopathology scale (16 items). 
ii) Clinical Global Impression Scale- Severity Scale (CGI-S)  
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The Clinical Global Impression rating scales are commonly used measures of 
symptom severity, treatment response and the efficacy of treatments in treatment 
studies of patients with mental disorders (Guy,1976). The Clinical Global Impression - 
Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity 
of the patient's illness at the time of assessment, relative to the clinician's past 
experience with patients who have the same diagnosis. Considering total clinical 
experience, a patient is assessed on severity of mental illness at the time of rating 
1,normal/not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, 
markedly ill; 6, severely ill; or 7, extremely ill. 
3.4.12.4.  Safety Assessment  
i) Abnormal Involuntary Movement Scale (AIMS) (Rush,2000) 
The Abnormal Involuntary Movement Scale (AIMS) is a rating scale  that was 
originally designed in Italian language in the 1980s (Burti et al.,1981), to measure 
involuntary movements known as tardive dyskinesia (TD). TD is a disorder that 
sometimes develops as a side effect of long-term treatment with neuroleptic 
(antipsychotic) medications. The AIMS test is used not only to detect tardive 
dyskinesia but also to follow the severity of a patient's TD over time. It is a valuable 
tool for clinicians who are monitoring the effects of long-term treatment with 
neuroleptic medications.  
ii) Barnes Akathasia Scale (BAS) (Barnes,1989)  
The Barnes Akathisia Scale (commonly known as BAS or BARS) is a rating scale that 
is administered by physicians to assess the severity of drug-induced akathisia. 
Akathisia is a syndrome of motor restlessness, principally seen in association with 
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antipsychotic medication. It is characterized by a subjective experience of mental 
unease and the urge to move, and manifests physically as particular patterns of restless 
movement. 
The Barnes Akathisia Scale is the most widely used rating scale for akathisia. This 
scale includes objective and subjective items such as the level of the patient's 
restlessness. It comprises items for rating the observable, restless movements which 
characterise the condition, the subjective awareness of restlessness, and any distress 
associated with the akathisia. In addition, there is an item for rating global severity. A 
standard examination procedure is recommended. The inter-rater reliability for the 
scale items (Cohen's kappa) ranged from 0.738 to 0.955. 
iii) Simpson Angus Scale (SAS) (Simpson and Angus,1970)  
Simpson-Angus Scale (SAS) is a 10-item rating scale that has been used widely for 
assessment of Neuroleptic Induce Parkinson in both clinical practice and research 
settings. It consists of one item measuring gait (hypokinesia), six items measuring 
rigidity and three items measuring glabella tap, tremor and salivation, respectively. 
Items are rated for severity on a 0-4 scale, with definitions given for each anchor 
point. SAS is a reliable and a valid instrument. It performs well and similarly to DSM-
IV in Neuroleptic Induce Parkinsonism case detection (Janno et al.,2005). 
iv)   Adverse events 
All adverse events, either observed or spontaneously reported were recorded. 
3.4.13. Study Drug - Intervention 
i) Ziprazidone 
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Ziprazidone is a psychotropic drug and supplied in 40mg, 60mg and 80mg capsules. 
Different doses of ziprasidone has different colour of capsule.  Ziprasidone was given 
twice daily as active treatment and was put in an opaque gelatine capsule in order to be 
identical to aripiprazole and placebo. 
ii) Aripiprazole 
Aripiprazole is a psychotropic drug. It is a light yellow colour, round, flat, bevelled 
edged, uncoated tablets that contain 10mg of aripiprazole. Aripiprazole was put in an 
opaque gelatine capsule in order to be identical to ziprasidone and placebo. Patients 
treated with aripiprazole received active treatment daily in the morning and matching 
with placebo compose only of vitamin B complex daily at night to simulate twice daily 
dosage as ziprasidone. Patients were advised to take each daily dose at 8:00 a.m or 
after breakfast and 8:00 p.m. 
iii) Placebo  
The placebo formulation for this study is vitamin B complex in a tablet form. In order 
for the placebo to appear identical to aripiprazole, the placebo was put in an opaque 
gelatine capsule that has same colour, shape and size for aripiprazole.  
3.4.14. Packaging of Study Drug 
Study drug (intervention) was supplied in bulk shipments by a pharmaceutical 
company whereas placebo (vitamin B complex) was obtained from a pharmacy. A 
study coordinator repackaged the bulk drug into packs containing of 28 gelatin 
capsules per pack (4 weekly study follow up).  
3.4.15. Concomitant Therapy  
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The concomitant medications such as antidepressant, benzodiazepine and benzhexol 
were allowed for this study. Commitment therapy that not permitted during the study 
was:  
i). Carbamazepine  
ii). Ketoconazole  
iii). Quinidine  
iv). Fluoxetine  
v). Paroxetine 
3.4.16. Receiving, Storage, Dispensing and Return 
i). Receipt of Drug Supplies 
An inventory was performed after accepting the drug shipment. The study coordinator 
counted and verified the shipment contained all the items mentioned in the supply. The 
principle investigator (PI) would notify to the pharmaceutical company of any 
damaged of the study drug.  
ii). Storage 
Stock study drug and drug packaged in patient kits was stored in a locked cabinet in 
the research centre with climate control maintaining the temperatures within a range of 
20°C to 25°C. Only the study coordinator and principle investigator have accessed to 
the study drug.  
iii). Dispensing of Study Drug 
The principle investigator or study coordinator would dispense the appropriate amount 
of study drug, according to the number of day of follow up to the research subject base 
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on the randomization list. Subject compliance monitoring was conducted by doing pill 
counts at every study visit for all patients. 
iv). Return of Study Drug 
At the completion of the study, the final reconciliation of drug shipped, drug 
consumed and drug remaining was done. After appropriate accounting the 
pharmaceutical company was informed, the unused study drug was returned to the 
pharmaceutical company.  
3.4.17. Study procedures       
3.4.17.1    Patients screening and recruitment  
i). All schizophrenia patients were approached during the screening of this study. 
Prior to the written consent, patients were briefed on detail this study. Patient was 
explained information regarding aripiprazole and ziprasidone, the rationale for 
why they were being studied, frequency of dosing, and length of treatment, 
potential benefits, side effects and risks, safeguards and emergency procedures. 
The collections of all laboratory specimens were described in detail, as the number 
and frequency of the research follow up.  They were asked to fast for at least 8 
hour for baseline laboratory blood evaluations. Only patients with at least one 
metabolic syndrome component were approached for clinical trial study. 
ii). Patients were assured that their participation was voluntary and that withdrawal 
from the study would not jeopardize current or future treatment. Randomization 
was explained to the patients, as they would know their treatment assignment at 
the end of the study, after the blind has broken.   
iii). A Mini International Neuropsychiatric Inventory (M.I.N.I.) was administered to 
obtain DSM-IV diagnoses of schizophrenia. All current medications taken by the 
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patient prior to screening was documented. A face-to-face interview was 
conducted to collect primary data by using a structured questionnaire. Some 
secondary data pertaining medication, dosage and history of relapse and 
hospitalisation were obtained from patient’s case note. The principal investigator 
(PI) confirmed and signed off on the inclusion and exclusion criteria on a case 
report form (CRF) prior to the patient formally recruited in the study.  
3.4.17.2   Randomization  
The treatment started after the screening visit and once the laboratory results have 
been reviewed by the investigator. Patient was assigned to study drug either 
aripiprazole or ziprasidone according to a randomization list in a ratio of 1:1. The 
randomization list in the block of 4, 6 and 8 was computer generated using 
Randomization.com programme by a statistician. The blinded randomisation list with 
randomization code for aripiprazole and ziprasidone, A and B was given to principle 
investigator. The statistician put the randomization code in an envelope for individual 
patient according to randomization list and kept in the Psychiatric Unit Research 
Center, PPUM. Envelop with the randomization code of the particular patient can only 
be assessed by principle investigator in the case of severe adverse event happen during 
the study.  
3.4.17.3   Treatment Regimen  
Patients were tapered from prior antipsychotic treatment and discontinued within 4 
weeks and at the same time, study drug such as aripiprazole and ziprasidone were 
titrated simultaneously to reach target doses within 4 weeks according to clinical 
effect, at the discretion of the study psychiatrists. Patients on aripiprazole were started 
with fixed dose 10mg/day which could be increased up to 30mg/day depending on the 
3   RCT Aripiprazole vs. Ziprasidone  
 
158 
 
clinical response for subsequent visits. Patients on ziprasidone were started fixed dose 
40mg twice daily which could be increased to 80mg twice daily later depending on the 
clinical response. Flexible dosing of study medications was then permitted, which 
means that the dose of aripiprazole and ziprasidone can be adjusted either increased or 
reduced based on clinical assessment. The total daily dosage of ziprasidone ranges at 
80mg, 100mg, 120mg, 140mg and 160mg and the total daily dosage of aripiprazole at 
10mg, 15mg, 20mg, 25mg and 30 mg. All patients were recommended to take 
medication with a meal. This was because the optimum absorption of ziprasidone 
required to be taken with meal. 
Patient could receive antidepressants, trihexyphenidyl to control of extrapyramidal 
symptoms (EPS) and lorazepam was permitted for control of agitation or insomnia. 
Trihexyphenidyl was permitted for EPS but only after assessment with the BARS, 
SAS and AIMS Rating Scales were performed. Lorazepam was permitted after 
administration, for a minimum of 4 hours had to elapse before completing efficacy 
evaluations. Treatment of antihypertensive, antidiabetic or antihyperlipidemia prior 
the study were allowed, provided the treatment was initiated ≥ 3 months prior to 
screening with no dosage changes 30 days before study recruitment. Schizophrenia 
patients were treated as per clinical practice, when diabetes mellitus, hypertension or 
hyperlipidemia was detected during study visit. The initiation of antidiabetic, 
antihyperlipidemia and antihypertensive was allowed after randomization when 
clinically indicated. Patients were also excluded if they had been treated with depot 
neuroleptics, unless the last injection had been at least one treatment cycle before 
entry.   
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3.4.17.4   Blinding of Study Drug 
For the conduct of this double blind study, both patients and the independent rater who 
was the non treating psychiatrist, were blinded to the study drug. After assignment to 
treatment groups, patients received a fixed dose of their assigned study drug for the 
first week of treatment. For the subsequent visits, the dosage of the medication was 
flexible as the psychiatrists’ clinical decision. The study medications were repackaged 
in opaque capsule and labeled as “1”, “2a”, “2b”, “3a” and “3b” strength (Appendix 
M) to maintain blinding from the rater.  
3.4.17.5   Baseline visit 
Patients would be assessed for baseline visit only when prior antipsychotic treatment 
completely discontinued. The patients were evaluated with Positive and Negative 
Symptoms Scale (PANSS), Clinical Global Impression - Severity Scale (CGI-S), 
Abnormal Involuntary Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and 
Simpson Angus Scale (SAS). A complete physical examination was done including 
vital signs, weight, height, waist circumference, blood pressure (BP) and baseline 
ECG (12-lead). BP was performed as a single, seated determination. Baseline blood 
tests were taken for fasting blood sugar(1 ml),fasting lipid profile (2.5ml) and Hba1c 
(1.5ml). A urine pregnancy test was conducted for female patients with history of 
amenorrhea or delayed in their menses. 
3.4.17.6   Follow-Up Evaluation  
A follow-up evaluation was scheduled on day week 4, week 8, week 12, week 16, 
week 20 and week 24 after the beginning of the study. If patients could not attend the 
scheduled visit, patients were given appointment on the subsequent day.  
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The patients were evaluated with Positive and Negative Symptoms Scale (PANSS), 
Clinical Global Impression - Severity Scale (CGI-S), Abnormal Involuntary 
Movement Scale (AIMS), Barnes Akathasia Scale (BAS), Simpson Angus Scale 
(SAS) and assessment of the side effects. Weight, waist circumference, blood pressure 
were also taken. Fasting blood tests were taken for blood sugar (1 ml) and lipid profile 
(2.5ml). HbA1c (1.5ml) was only taken during last study visit. A urine pregnancy test 
was conducted for female patients with history of amenorrhea or delayed in their 
menses. 
If patients experienced significant side effects from the study drug, the principal 
investigator (PI) would inform the study psychiatrist. The psychiatrist would decide to 
reduce the dose for study drug during the study, depending on the clinical interview. 
Upward titration following a dose reduction was allowed in order to maintain efficacy 
of treatment during the study. Dose titration was documented in the study chart along 
with the clinical rationale. The concomitant medications were reviewed. During the 
study visit, the study termination form was completed in case of discontinuation of 
patient from this study.  
3.4.17.7 Subject Compliance Monitoring 
The research coordinator conducted pill counts at the follow-up visit for all study 
patients. The unused study drug was collected from the previous follow up and 
documented. Proper drug dosing was reviewed with patients at each visit with clear 
instructions to take all study drugs. The new study drug would be dispensed for every 
study visit. 
3.4.17.8   Safety and Tolerability - Early Withdrawal of Patients 
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Any patients experiencing a serious adverse event felt to be related to study drug were 
withdrawn from the study. Patients were also withdrawn if they required 
hospitalization for psychiatric treatment, received other psychotropic medications, or 
if discontinuation from the study was deemed by the psychiatrist base on their best 
interest. Patients discontinued from the clinical trial were given appropriate treatment 
referrals to the outpatient psychiatric clinic. Patients were instructed to return all 
unused medications. For the early withdrawal, patients had all final assessments that 
originally were scheduled for the end of study visit.  
All patients randomized into the study were included in the final study analyses. 
Although patients were withdrawn from the study, they were still contactable unless 
they requested not to be contacted or could not be located for the 2-weeks follow-up 
assessment. Patients were informed at the consent session that treatment might be 
discontinued due to:  
i) Intolerable side effects 
ii) Development or exacerbation of psychiatric symptoms necessitating inpatient 
admission or a more aggressive therapeutic intervention needed than was 
provided by the protocol  
iii) Clinical deterioration for any reason or any clinical status that necessitates 
inpatient admission 
iv) Incarceration for more than 2 weeks 
v) Failure to attend 3 consecutive outpatient evaluation visits 
vi) Failure to provide 2 consecutives laboratory specimens 
Reasons why patients discontinued from the clinical trial were documented on the 
Study Termination Form, along with any referrals that were made. A final safety 
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evaluation was conducted as soon as possible on all randomized patients who have 
been discontinued from the study.  
3.4.18. Adverse Events  
i). Recording of Adverse Events 
During the research evaluation visit, the patient was asked on adverse events through 
specific questioning and by examination. Information on all adverse events was 
recorded immediately in the case report form (CRF). Each adverse event was followed 
up until resolution or stabilization has been achieved. 
In the case of the occurrence of serious adverse event (SAE), it was followed up to 
determine the final outcome. Any serious adverse event that occurred after the study 
period was recorded and reported immediately, if PI considered possibly related to the 
study drug.   
ii). Reporting of Serious Adverse Events To Ethic Committee (EC) by 
Principle Investigator 
A serious adverse event must be reported to the EC within 24 hours (one working day) 
of the event. The principle investigator would keep a copy of the SAE form in the file. 
Within the following 48 hours, the principle investigator would provide further 
information and progress on the serious adverse event to the EC.   
In the SAE form, the following information should be provided: 
(a) Study identifier 
(b) Subject number 
(c) A description of the event 
(d) Date of onset 
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(e) Current status 
(f) Whether study treatment was discontinued 
(g) The reason why the event was classified as serious 
(h) Principle investigator assessment of the association between the event and 
study drug 
iii). Unblinding Procedures 
In the event that patients were prematurely discontinued from the trial, it was 
necessary to avoid breaking the blind whenever possible, in order to protect the 
integrity of the study. If an emergency necessitates that the blind be broken, only the 
principle investigator (PI) has the authority to inform the actual study drug to the study 
psychiatrist.  
iv). Medical Monitoring 
The PI was responsible to oversee the safety of the study. This safety monitoring 
would include careful assessment and appropriate reporting of adverse events. Medical 
monitoring would include a regular assessment of the number and type of serious 
adverse events. 
v). Protection of Subjects 
Additional procedures would be conducted to protect the safety of the study patients. 
Potential patients would be screened for medical illnesses that would preclude the use 
of aripiprazole and ziprasidone. Patients selected for the study would be evaluated for 
AE while receiving study drug. Venipuncture was carried out with good aseptic 
technique by an experienced nurse or physician. Before randomized to study drug, a 
physical examination, ECG and a urine pregnancy test (if female of childbearing 
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capability) were performed. Patients were given a 24-hour emergency number to call 
if necessary. The PI would follow all patients who were discontinued due to any 
serious AEs until the AE resolved and become completely stable, unless a referral to 
another physician or specialist was clinically indicated or requested by the patient.  
3.4.19. Data Handling and Record Keeping 
i). Data Management 
The data were checked before ending each interview session and before compilation to 
ensure completeness. If missing data was found, the patient will be contacted through 
telephone. Raw data obtained were coded and entered into Statistical Package for 
Social Sciences (SPSS) Version 16.0. Statistical analysis was done on an intention-to-
treat basis. 
The data were summarized by running frequency distributions and simple descriptive 
statistics (means and standard deviations). Cleaning for double entry and outliers 
before analysis was done.   
ii). Confidentiality 
Information about study patients was kept confidential and managed according to the 
requirements of the EC.  
iii). Source Data and Case Report Form 
Source data was all information, original records of clinical findings, observations, or 
other activities in a clinical trial necessary for the evaluation of the trial. Source data 
were contained in source documents such as hospital records, clinic charts, laboratory 
results, pharmacy dispensing records, recorded data such as ECG from automated 
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instruments, x-rays, subject files, records kept at the pharmacy, at the laboratories, at 
medical record department and other related documents. 
The study case report form (CRF) was the primary data collection instrument for the 
study. All data requested on the CRF were recorded and all missing data were 
explained. “N/D” was written if a space on the CRF was left blank because the 
procedure was not done or the question was not asked. “N/A” was written if the item 
was not applicable to the individual case. All entries should be printed legibly in black 
ink. If any entry error has been made, to correct such an error, a single straight line 
was drawn through the incorrect entry and the correct data was entered above it. All 
such changes were initialed and dated.  
3.4.20. Ethical consideration 
Ethical clearance had been obtained earlier from UMMC’s and Ministry of Health 
(MOH) ethical committees (Appendix I). Before any interview, patients had been 
informed regarding the nature and purpose of study and ensuring the respondent on 
confidentiality of the information.  
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3.4.21. Sample Size Estimation 
 
Based on non-inferior of efficacy and safety between aripiprazole and ziprasidone, the 
minimum sample size required for this study was calculated by using the PS software.  
i). The power of the study was taken at 80% level.  
ii). The significance level of the statistic tests done was at 95% Confidence Interval 
level and  was set at 0.05. The Null hypothesis was rejected when p < 0.05. 
iii). p0 - The probability of the outcome for aripiprazole (reduction of prevalence of 
metabolic syndrome) was 0.45.    
iv). p1 - The probability of the outcome for ziprasidone (reduction of prevalence of 
metabolic syndrome) was 0.3.    
v). The ratio of intervention drug to comparison drug was 1: 1. 
Therefore the sample size obtained for this study as follow: 
Number of treatment arm  = 162 patients 
Number of control arm = 162 patients 
Total number of subjects = 324 patients 
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3.4.22. Statistical Analysis 
The analyses were done on an intent-to-treat (ITT) basis. Patients with both a baseline 
assessment and had at least one follow-up visit and assessment were included in 
efficacy analyses. Patients receiving at least one dose of study drug were included in 
safety analyses. 
The independent t-test was used to examine changes in means of continuous variables 
and rating scales such as PANSS ,CGI-S, BARS, SAS and AIMS. Skewed data was 
analysed using non parametric test. Categorical values were compared between groups 
using chi-square analysis. The discontinuation rate in treatment was analyzed using the 
log-rank test, and the respective survival distributions were estimated using the 
Kaplan-Meier Survival analysis. 
Bivariate analysis was also used to observe the reversing of metabolic syndrome and 
its components from baseline to 6-month visit, by using the last observation carried 
forward (LOCF) and on the ITT population. The outcome for metabolic syndrome and 
its components either resolved or not, were determined by the change form baseline to 
endpoint with at least one study visit (LOCF).   
In addition, the mean of Framingham risk score was also compared according to 
patients’ age group with the treatment groups (aripiprazole and ziprasidone) at 
baseline and 6-month visit. The multiple comparisons were analyzed using Two-Way 
Interaction in Three-Way Anova with Bonferroni correction and adjusting for sex.  
The measures of comparative efficacy and safety were determined by using two 
analytic approaches: mixed-effects model with repeated measures (MMRM) to 
analyze continuous data repeated measures such PANSS, CGI-S, BARS, SAS, AIMS, 
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the metabolic effects such as fasting glucose level, waist circumference, lipid levels 
and other paremeters (e.g weight, BMI, CHD risk score-Framingham). The MMRM 
provided estimates of missing data by using available data from all subjects. 
Generalised estimating equations (GEE) was used of analysing categorical data 
repeated measures such as prevalence of metabolic syndrome and its components, 
CVRF and CHD risk –Framingham and discontinuation rate. GEE assumed that 
missing data were missing ‘completely at random’ 
For MMRM, least squares (LS) means were used to estimate the treatment effects 
from an analysis of covariance model, with fixed effect terms for treatment 
(aripiprazole and ziprasidone), study visit (baseline, month 1, 2, 3, 4, 5, 6) and 
interaction of treatment and visit on the ITT population. The correlation of the 
repeated measures within each subject was modeled with an unstructured covariance 
matrix. The LS mean change of each study visit was the difference of LS means each 
study visit with baseline, after adjusting with pairwise comparisons and Bonferroni 
correction. The overall difference in LS means over a 24-week period was evaluated 
by having the p value associated with the overall drug effect in MMRM obtained using 
type III analysis.  
 
The adverse events between aripiprazole and ziprasidone were described as proportion 
on the ITT population. Sensitivity analyses were conducted by excluding from the 
analysis individuals who began antihyperlipidemic, antihypertensive and antidiabetic 
drug therapy after randomization as concomitant medication. The SPSS version 16.0 
statistical package was used throughout. An alpha level of significance p< 0.05 was set 
for all analyses. 
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3.5  Results  
3.5.1. RESULTS AT THE BASELINE OF RANDOMIZATION   
Demographics   
Out of 175 patients recruited for the study, 51.4% (90/175) was randomized to 
aripiprazole and 48.6% (85/175) to ziprasidone.  
At baseline, 30% of the patients randomized to aripiprazole have age 30-39 years old 
whereas 25.9% of the patients randomized to ziprasidone have age 40-49 years old.  
The mean age of the patient randomized to ziprasidone was younger than aripiprazole 
group although not statistically significant. (38.8 ± 11.8 vs. 40.5 ± 11.8 years old). The 
means BMI of the patients randomized to aripiprazole and ziprasidone were in the 
overweight group (BMI 25 to < 30). Majority of the patients randomized in both 
groups were male, single, has education level of secondary school and unemployed.  
There was no statistically significant for demographic characteristic among 
schizophrenic patients either randomized to aripiprazole or ziprasidone at baseline 
(Table 3.4). 
Lifestyle  
At baseline, the percentage of smokers and former smokers were high in the 
aripiprazole and ziprasidone group (47.1% vs. 49.4%). Among the current and former 
smokers, majority smoked less than 20 sticks cigarettes/day for both groups. Majority 
of the patients have sedentary lifestyle with hardly any physical activity for both 
aripiprazole and ziprasidone group (Table 3.5). 
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Table 3.4  Demographics characteristics at baseline of schizophrenia patient 
between aripiprazole and ziprasidone  
Characteristics Aripiprazole (n=90) Ziprasidone(n=85) P value 
    
Age(year)mean ± SD  40.5 ± 11.8 38.8.± 11.8 p>0.05* 
    
Age group (n =175 ),n (%)    
< 20
‡
 0(0) 3(3.5) p>0.05 
20 – 29 19(21.1) 20(23.5)  
30 – 39 27(30.0) 21(24.7)  
40 – 49 17(18.9) 22(25.9)  
50 – 59  20(22.2) 15(17.6)  
> 60 7(7.8) 4(4.8)  
    
BMI( kg/m
2
) mean ± SD 27.7 ± 5.2 28.1± 5.6 p>0.05*  
    
BMI
¶
(n =175 ),n(%)    
Underweight(<18.5) 2(2.2) 0(0) p>0.05 
Normal( 18.5 – 24.9)
 ‡
 28(31.1) 28(32.9)  
Overweight( 25 – < 30) 35(38.9) 32(37.6)  
Obese(≥ 30) 25(27.8) 25(29.5)  
    
Sex (n =175 ),n (%)    
Male
‡
 52(57.8) 55(64.7)  
Female  38(42.2) 30(35.3) p>0.05 
    
Race (n = 175 ),n (%)    
Malay
‡
 34(37.8) 31(36.5) p>0.05 
Chinese 35(38.9) 29(34.1)  
Indian 9(10.0) 12(14.1)  
others 12(13.3) 13(15.3)  
    
Marital status (n=173) ,n (%)   
Married
‡
 30(33.3) 17(20.5) p>0.05 
Single 51(56.7) 58(69.9)  
Divorced 5(5.6) 6(7.2)  
widowed 4(4.4) 2(2.4)  
    
Education level(n=164) ,n (%)   
No formal education
‡
 4(4.7) 2(2.6) p>0.05 
Primary  15(17.4) 17(21.8)  
Secondary  56(65.1) 55(70.5)  
Tertiary  11(12.8) 4(5.1)  
    
Occupation (n=172),n (%)    
Employed
‡ 
 29(32.6) 23(27.7) p>0.05 
Unemployed  55(61.8) 56(67.5)  
Housewife 5(5.6) 4(4.8)  
    
Care setting (n=175), n (%)    
General hospital
‡
 42(46.7) 42(49.4) p>0.05 
Institution  48(43.3) 43 (50.6)  
    
Chi square test, *t-test, ‡ Reference group  
BMI
¶ 
- Chi square test based on category normal (reference group), overweight and obese.   
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Medical and Psychiatric History  
At baseline, only four out of ten patients in the aripiprazole randomized group and one 
out of five patients in ziprasidone randomized group knew they developed 
hypertension after initiation of antipsychotics treatment.  
Only two out of 15 patients in the aripiprazole randomized group and three out of six 
patients in ziprasidone randomized group knew they developed diabetes mellitus after 
initiation of antipsychotics treatment. 
At baseline, patients randomized to aripiprazole have 31.3% family history of 
hypertension and patients randomized to ziprasidone have 42.3% family history of 
hypertension. Patients in ziprasidone randomized group have 32.9% family history of 
diabetes mellitus and 24.4% of aripiprazole randomized group has family history of 
diabetes mellitus. Patients in ariprazole randomized group have 17.8% family history 
of obese and 25.9% of ziprasidone randomized patients have family history of obese. 
The mean age of onset for schizophrenia in aripiprazole randomized group was 
slightly younger (25.7 ± 8.7 vs. 27.2 ± 8.6 years old) and the mean duration of illness 
in year was longer (12.5 ± 10.0 vs. 10.5 ± 8.9 year) compared to ziprasidone 
randomized group. About one third of both treatment groups had history of relapse of 
schizophrenia.     
However, there was no statistically significant for lifestyle, medical and psychiatric 
history among schizophrenia patients randomized to aripiprazole and ziprasidone at 
baseline (Table 3.5).  
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Table 3.5  Lifestyle, medical and psychiatric history between aripiprazole and 
ziprasidone 
Characteristics Aripiprazole (n=90) Ziprasidone(n=85) P value 
 n (%) n (%)  
Smoking n=85 n=79  
Never
‡
 45(52.9) 40(50.6) p>0.05 
Former smoker  < 20 sticks/day 17(20.0) 11(13.9)  
Former smoker  > 20 sticks/day 2(2.4) 1(1.3)  
Current smoker < 20 sticks/day 13(15.3) 18(22.8)  
Current smoker > 20 sticks/day 8(9.4) 9(11.4)  
    
Duration of quitting smoking n=4 n=6  
≥ 10 years
‡
 3(75.0) 5(83.3) p>0.05 
5 - 9 years 0(0) 1(16.7)  
1 – 4 years  1(25.0) 0(0)  
< 1 year 0(0) 0(0)  
    
Physical activity n=86 n=79  
Never
‡ 
 35(40.7) 38(48.1) p>0.05 
Rarely 24(27.9) 22(27.8)  
1 -3 times/month 3(3.5) 1(1.4)  
1-2 times /week 5(5.8) 8(10.1)  
3 -4 times /week 9(10.5) 5(6.3)  
≥ 5 times /week 10(11.6) 5(6.3)  
    
Medical history     
Hypertension after initiation of 
antipsychotics(n=161) 
10(11.9) 5(6.5) p>0.05 
Diabetes mellitus after initiation of 
antipsychotics(n=158) 
15(18.1) 6(8.0) p>0.05 
Gestational diabetes (female)(n=30)  1(5.9) 1(7.7) p>0.05 
    
Family history    
Hypertension(n=154) 26(31.3) 30(42.3) p>0.05 
Diabetes mellitus(n=155) 20(24.4) 24(32.9) p>0.05 
Parent obese(n=156) 7(8.5) 13(17.6) p>0.05 
Siblings obese(n=156)  9(11.0) 9(12.2) p>0.05 
    
Psychiatric history    
Age of onset(year) mean ± SD  26.3 (8.9) 27.2 (8.5) p>0.05* 
Duration of illness (year) mean ± SD 12.6 (9.3) 10.5 (9.2) p>0.05* 
History of relapse(n=175)  27(30.0) 27(31.8) p>0.05 
No of psychiatric hospitalization,  
mean ± SD 
1.2(2.6) 0.8(1.6) p>0.05* 
    
Chi square test, *t-test, ‡ Reference group 
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Characteristics of treatment with antipsychotics and other medication   
Comparing the antipsychotic used before the randomization of aripiprazole and 
ziprasidone, the usage of atypical antipsychotics monotherapy (60.0% vs. 56.5%) was 
more than typical antipsychotics monotherapy (17.8% vs. 17.6%) for both groups. As 
for the combination of antipsychotics, the combination of typical and atypical 
antipsychotics was commonly used before the randomization of aripiprazole and 
ziprasidone (Table 3.6). 
Perphenazine and chlorpromazine were the commonest typical antipsychotics used as 
monotherapy before randomization to aripiprazole and ziprasidone. Olanzapine has the 
highest proportion of monotherapy usage of atypical antipsychotics (42.6% vs. 43.7%) 
followed by risperidone (31.5% vs. 37.5%) and paliperidone (24.1% vs. 12.5%) prior 
to randomization to aripiprazole and ziprasidone.  
Prior to randomization, anticholinergic e.g trihexyphenydyl (benzhexol) was 
commonly used for both patients randomized to aripiprazole and ziprasidone. The 
usage of benzodiazepine prior randomized to ziprassidone and aripiprazole was 15.3% 
vs. 13.3%. (p< 0.05). Very few patients were on hyperglycaemic agent, 
antihypertensive and lipid-lowering medications prior randomized to aripiprazole and 
ziprasidone (Table 3.6). 
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Table 3.6  Characteristics of treatment with antipsychotic and other medication 
between aripiprazole and ziprasidone at baseline  
 
Characteristics Aripiprazole 
(n=90) 
Ziprasidone 
(n=85) 
P value 
Use antipsychotic before study n(%) n(%) 
 
Atypical antipsychotics (monotherapy)
‡
 54(60.0) 48(56.5) p>0.05 
Typical antipsychotics (monotherapy) 16(17.8) 15(17.6)  
Combination of Typical and Atypical 
Antipsychotics 
12(13.3) 11(12.9)  
Combination of Atypical Antipsychotics 4(4.4) 3(3.6)  
Combination of Typical  Antipsychotics 4(4.4) 8(9.4)  
    
Typical antipsychotics(monotherapy)     
Haloperidol
‡
  1(6.2) 2(13.3) p>0.05 
Perphenazine 5(31.3) 3(20.0)  
Sulpiride 3(18.8) 4(26.7)  
Chlorpromazine 4(25.0) 3(20.0)  
Trifluoperazine 2(12.5) 1(6.7)  
Flupenthixol decanoate 0(0) 2(13.3)  
Fluphenazine decanoate 1(6.2) 0(0)  
    
Atypical antipsychotics(monotherapy)      
Olanzapine
‡
 23(42.6) 21(43.7) p>0.05 
Risperidone 17(31.5) 18(37.5)  
Quetiapine 1(1.8) 2(4.2)  
Amisulpride 0(0) 1(2.1)  
Paliperidone 13(24.1) 6(12.5)  
    
Concomitant medication     
Anticholinergic 32(35.6) 30(35.3) p>0.05 
Benzodiazepine 12(13.3) 13(15.3) p<0.05 
antidepressants 10(11.1) 6(7.1) p>0.05 
    
Other medication    
Antidiabetic medication 5(5.6) 7(8.2) p>0.05 
Blood pressure lowering 2(2.2) 7(8.2) p>0.05 
Lipid-lowering medication  9(10.0) 5(5.9) p>0.05 
    
Chi square test, ‡ Reference group, NA- not applicable 
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Table 3.6  Characteristics of treatment with antipsychotic and other medication 
between aripiprazole and ziprasidone at baseline (con’t) 
 
Characteristics Aripiprazole 
(n=90) 
Ziprasidone 
(n=85) 
P value 
    
    
Antipsychotic Mean Daily Dose, mg(SD)   
    
Typical antipsychotics    
Haloperidol 15.6(9.3) 11(8.6) p>0.05 
Perphenazine 8(3.3) 15(10.0) p>0.05 
Sulpiride 470(282.0) 475(452.8) p>0.05 
Chlorpromazine 230(168.7) 210(157.0) p>0.05 
Trifluoperazine 10(0.0) 15(5.0) p>0.05 
Flupenthixol decanoate - 35.7(19.7) NA 
Fluphenazine decanoate 50(14.1) - NA 
    
Atypical antipsychotics      
Olanzapine 13(4.9) 14.6(7.7) p>0.05 
Oral risperidone 3(1.8) 3.3(1.6) p>0.05 
IM risperidone 25(0.0) 43.8(8.8) p>0.05 
Quetiapine 372(240.7) 550(353.6) p>0.05 
Amisulpride - 800 NA 
Paliperidone 6.9(2.2) 9(6.9) p>0.05 
    
Duration of antipsychotics treatment in year, mean(SD)    
    
Typical antipsychotics    
Haloperidol 15.3(6.3) 7.4(5.6) p>0.05 
Perphenazine 2.9(2.3) 4.8(1.4) p>0.05 
Sulpiride 6.6(6.1) 9.3(9.8) p>0.05 
Chlorpromazine 5.5(2.7) 9.7(8.6) p>0.05 
Trifluoperazine 10.7(5.4) 11.4(2.4) p>0.05 
Flupenthixol decanoate - 7.8(8.9) NA 
Fluphenazine decanoate 3.5(1.8) - NA 
    
Atypical antipsychotics      
Olanzapine 4.5(4.0) 3.1(0.9) p>0.05 
risperidone 5.6(3.9) 3.3(2.3) p>0.05 
Quetiapine 3.0(1.2) 2.7(1.0) p>0.05 
Amisulpride - 2.2(1.1) NA 
Paliperidone 4.6(0.4) 5.7(0.3) p>0.05 
    
Chi square test, ‡ Reference group, NA- not applicable 
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Table 3.7  Mean and Median of Clinical Rating Scale Scores between aripiprazole or 
ziprasidone treatment at baseline 
Rating Scale Aripiprazole (n=90) Ziprasidone(n=85) P value 
    
PANSS score     
Total    
Mean (±SD)   56.4 ± 17.0 59.4.± 21.8  
Median (Interquartile range) 53.5(46.0-65.3) 56.0(43.5-71.5) p>0.05* 
    
Positive    
Mean (±SD)   13.5 ± 4.7 14.7 ± 6.3  
Median (Interquartile range) 12.5(10.0-16.0) 13.0(10.0-17.0) p>0.05* 
    
Negative     
Mean (±SD)   14.9 ± 5.8 16.1 ± 7.2  
Median (Interquartile range) 14.0(10.0-18.3) 15(10.0-21.0) p>0.05* 
    
CGI-S score    
Mean (±SD)   3.1 ± 0.8 3.3 ± 1.0 p>0.05 
Median (Interquartile range) 3.0(3.0-3.0) 3.0(3.0-4.0)  
    
BARS     
Mean (±SD)   0.7 ± 2.2 0.4 ± 1.4  
Median (Interquartile range) 0(0.0-0.0) 0(0.0-0.0) p>0.05* 
    
SAS    
Mean (±SD)   1.1 ± 2.4 1.2 ± 2.6  
Median (Interquartile range) 0(0-1.0) 0(0-1.0) p>0.05* 
    
AIMS    
Mean (±SD)   0.8 ± 2.8 0.8 ± 2.2  
Median (Interquartile range) 0(0.0-0.0) 0(0.0-0.0) p>0.05* 
    
t-test ,* Mann-Whitney U test 
PANSS -Positive and Negative Syndrome Scale, CGI-S : Clinical Global Impression-
Severity Scale, SAS- Simpson-Angus Rating Scale, BARS-Barnes Akathisia Rating Scale, 
AIMS- Abnormal Involuntary Movement Scale 
 
Rating Scales 
At baseline, there was no statistically significant difference in the mean and median of 
all the rating scales (PANSS, CGI-S, BARS, SAS and AIMS) between patients 
randomized to aripiprazole and ziprasidone (Table 3.7).  
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Prevalence of metabolic syndrome and its criteria 
The definition of metabolic syndrome was based on two different definitions, namely 
Modified National Cholesterol Education Program Adult Treatment Panel (NCEP 
ATP III) with Asians values for waist circumference and modified International 
Diabetes Federation (IDF) with South Asians values for waist circumference. 
At baseline, the prevalence of metabolic syndrome was higher in aripiprazole 
randomized group compare to ziprasidone randomized group either using NCEP ATP 
III (60.0% vs. 51.8%) or IDF criteria (57.8% vs. 51.8%). The overall prevalence of 
metabolic syndrome was 56% (95% CI: 48.6 - 63.2) with NCEP ATP III and 54.9% 
(95% CI: 47.5 – 62.1) with IDF criteria. There was no statistically significant in the 
proportion of metabolic syndrome status among those randomized to aripiprazole and 
ziprasidone (Table 3.8).  
For the prevalence of metabolic syndrome components at baseline in those 
randomized to aripiprazole and ziprasidone, the prevalence of abnormal waist 
circumference was the highest (83.3% vs. 88.2%) followed by abnormal HDL (54.4% 
vs. 48.2%).  
The mean waist circumference for male was higher than female in those randomized 
to aripiprazole (97.6 ± 13.7cm vs. 93.8 ± 9.1cm) and ziprasidone (97.7± 11.2cm vs. 
94.6 ± 12.6 cm). The median of HDL cholesterol for female in patients randomized to 
aripiprazole and ziprasidone at baseline fulfilled the metabolic syndrome criteria (45.4 
mg/dl, Interquartile range: 36.6 - 56.0 mg/dl vs. 44.1 mg/dl, Interquartile range: 36.8 - 
53.6 mg/dl). 
There was statistically significant difference in the proportion and median of FBS 
between those randomized to aripiprazole and ziprasidone. The median of FBS for 
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aripiprazole baseline group was higher compared to ziprasidone group (95.4 
mg/dL,interquartile range 86.4-113.4 mg/dl vs. 90.0 mg/dL, interquartile range 84.6-
100.8 mg/dl). There was statistically significant difference also for median of Hba1c 
between both randomized to aripiprazole and ziprasidone (Table 3.8). 
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Table 3.8     Prevalence of Metabolic Syndrome(MetS) and its components 
according aripiprazole and ziprasidone at Baseline  
 Aripiprazole(n=90) Ziprasidone(n=85) Overall (n=175) p 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI  
                                                                                                                                                                                                       
MetS Prevalence        
NCEP ATP III* 53(58.9) 48.6-68.5 44(51.8) 41.8-62.7 97(55.4) 48.0-62.6 p>0.05 
IDF** 52(57.8) 47.5-67.5 44(51.8) 41.8-62.7 96(54.9) 47.5-62.1 p>0.05 
        
Metabolic syndrome components       
Waist circumference (Male ≥90 
cm , female ≥80 cm) 
76(84.4) 75.6-90.5 74(87.1) 78.3-92.6 150(85.7) 79.8-90.1 p>0.05 
 
       
HDL (Male< 40 mg/dL ,female < 
50mg/dL) 
49(54.4) 44.2-64.3 45(52.9) 42.4-63.2 94(53.7) 46.3-60.9 p>0.05 
 
       
Triglyceride (≥150mg/dL) 45(50.0) 39.9-60.1 32(37.6) 28.1-48.3 77(44.0) 36.9-51.4 p>0.05 
 
       
BP( ≥130/85 mmHg) 37(41.1) 31.5-51.4 42(49.4) 39.0-59.8 79(45.1) 38.0-52.5 p>0.05 
 
       
Fasting glucose(≥100 mg/dL) 38(42.2) 32.5-52.5 22(25.9) 17.8-36.1 60(34.3) 27.7-41.6 p<0.05 
        
Laboratory test parameters  95% CI  95% CI  95% CI  
Fasting blood glucose(mg/dL)        
Mean(SD) 109.9(40.9) 101.3-118.5 95.8(24.7) 90.5-101.2 103.1(34.7) 97.9-108.3  
Median (Interquartile range)  95.4 (86.4-113.4) 90.0 (84.6-100.8) 91.8 (86.4-106.2) p<0.05** 
HbA1c (%)        
Mean(SD) 6.5(1.8) 6.1-6.8 5.9(0.9) 5.7-6.1 6.2(1.4) 5.9-6.4  
Median (Interquartile range)  5.8 (5.5-6.6) 5.7 (5.4-6.0) 5.8 (5.5-6.2) p<0.05** 
Total Cholesterol (mg/dL)         
mean(SD) 214.2(50.0) 203.7-224.7 206.4(36.8) 198.5-214.3 210.4(44.1) 203.8-217.0 p>0.05* 
LDL Cholesterol (mg/dL)        
Mean(SD) 137.6(44.2) 128.3-147.0 131.5(33.4) 124.2-138.8 134.7(39.3) 128.7-140.6  
Median (Interquartile range)  129.2 (108.9-157.7) 129.9 (114.8-152.8) 129.7 (111.2-155.1) p>0.05** 
HDL Cholesterol(mg/dL)        
Male, Mean(SD) 41.3(8.7) 38.9-43.7 43.1(14.8) 39.2-47.1 42.3(12.2) 39.9-44.6  
Median (Interquartile range) 39.8 (34.9-48.2) 41.4 (35.6-46.0) 40.6 (35.2-46.8) p>0.05** 
Female, Mean(SD) 47.8(13.0) 43.5-52.1 46.2(11.8) 41.8-50.6 47.1(12.4) 44.1-50.1  
Median (Interquartile range) 45.4 (36.6-56.0) 44.1 (36.8-53.6) 45.1 (36.8-53.9) p>0.05** 
Triglycerides (mg/dL)        
Mean(SD) 176.6(140.0) 147.3-205.9 161.1(126.1) 133.9-188.3 169.1 (133.3) 149.2-189.0  
Median (Interquartile range)  150.1 (112.5-204.8) 131.1 (101.9-191.3) 138.2 (108.9-194.0) p>0.05** 
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Table 3.8     Prevalence of Metabolic Syndrome(MetS) and its components 
according aripiprazole and ziprasidone at Baseline(Cont’) 
 
 
       
 Aripiprazole(n=90) Ziprasidone(n=85) Overall (n=175)       p 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI  
Other parameters Mean(SD) 95% CI Mean(SD) 95% CI Mean(SD) 95% CI  
Waist circumference (cm)        
Male 97.6(13.7) 93.8-101.4 97.7(11.2) 94.7-100.7 97.7(12.4) 95.3-100.1 p>0.05* 
Female 93.8(9.1) 90.8-96.8 94.6(12.6) 89.9-99.3 94.2(10.7) 91.6-96.8  
Median (Interquartile range) 93.0 (87.4-100.3) 92.5 (84.6-104.5) 92.5 (85.3-101.0) p>0.05** 
Systolic BP(mm Hg) 125.0(16.7) 121.5-128.5 123.6(15.1) 120.3-126.9 124.3(16.0) 122.6-126.1 p>0.05* 
Diastolic BP(mm Hg) 80.8(12.4) 78.2-83.4 80.9(11.4) 78.4-83.4 80.9(11.9) 79.6-82.8 p>0.05* 
        
NCEP ATP-III* and IDF** have Asian values for waist circumference  
Chi square test, *t-test ,** Mann-Whitney U test 
 
 
 
Prevalence of CVRFs and CHD risk (Framingham)  
Among the cardiovascular risk factors (CVRFs) according to Framingham criteria, 
there was statistically significant difference for the proportion of diabetes mellitus 
between patients randomized to aripiprazole and ziprasidone at baseline. The 
prevalence of diabetes mellitus in aripiprazole randomized group was much higher 
than ziprasidone randomized group at baseline (22.2%, 95% CI: 14.9%-31.9% vs. 
9.4%, 95% CI: 4.9%-17.5%). For other risk factors, the prevalence of HDL cholesterol 
was the highest (66.7%, 95% CI: 56.4%-75.6% vs. 74.1%, 95% CI: 63.9%-82.2%) 
followed by total cholesterol (56.7%, 95% CI: 46.4%-66.4% vs. 61.2%, 95% CI: 
50.6%-70.8%) for both randomized groups of aripiprazole and ziprasidone at baseline, 
however there was no statistically significant for the above findings (Table 3.9). 
There was no statistically significant difference in the median of Framingham risk 
score between patients randomized to aripiprazole and ziprasidone at baseline. In the 
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ziprasidone group, the means of Framingham risk score was 4.5 ± 5.7, which means 
about 5 of 100 people with this level of risk would have a heart attack in the next 10 
years. In the aripiprazole group, the means of Framingham risk score was 3.6 ± 4.3, 
which means that about 4 of 100 people with this level of risk would have a heart 
attack in the next 10 years. 
The prevalence of patients with high and very high risk of CHD in 10 years 
(Framingham) was much higher at baseline in those randomized to ziprasidone 
compared to aripiprazole randomized group. (18.8%, 95% CI: 11.9%-28.4% vs. 8.9%, 
95% CI: 4.6%-16.6%)  However there was no statistically significant difference 
between patients with high and very high risk of CHD in 10 years at baseline between 
patients randomized to aripiprazole and ziprasidone. 
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Table 3.9  Prevalence of CVRFs and CHD risk (Framingham) according to aripiprazole 
and ziprasidone at Baseline  
 Aripiprazole (n=90) Ziprasidone(n=85) Overall (n=175) p 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI  
Age≥40(male) or≥45(female) years 42(46.7) 36.7-56.9 36(42.4) 32.4-53.0 78(44.6) 37.4-52.0 p>0.05 
Smoker  21(23.3) 15.8-33.1 27(31.8) 22.8-42.3 48(27.4) 21.4-34.5 p>0.05 
Diabetes (known diagnosis or glucose 
≥126 mg/dL)  
20(22.2) 14.9-31.9 8(9.4) 4.9-17.5 28(16.0) 11.3-22.2 p<0.05 
        
Total cholesterol ≥ 200 mg/dL 51(56.7) 46.4-66.4 52(61.2) 50.6-70.8 103(58.9) 51.5-65.9 p>0.05 
HDL cholesterol (male< 45mg/ dL or 
female< 50mg/dL) 
60(66.7) 56.4-75.6 63(74.1) 63.9-82.2 123(70.3) 63.1-76.6 p>0.05 
        
SBP ≥140 or ≥ 130 mmHg (Diabetes, 
prior cardiovascular or kidney disease) 
20(22.2) 14.9-31.9 15(17.6) 11.0-27.1 35(20.0) 14.8-26.5 p>0.05 
        
DBP ≥90 or ≥ 80 mmHg (Diabetes, 
prior cardiovascular or kidney disease) 
21(23.3) 15.8-33.1 22(25.9) 17.8-36.1 43(24.6) 18.8-31.5 p>0.05 
        
        
Risk of CHD in 10 years(Framingham)        
Mean(SD) 3.6(4.3) 2.7-4.5 4.5(5.7) 3.3-5.8 4.1(5.0) 3.3-4.8  
Median (Interquartile range) 2.0 (0.5-5.0) 2.0 (0.5-7.0) 2.0 (0.5-6.0) p>0.05* 
Patients (%)with very high/high(≥10%) n(%) 95% CI n(%) 95% CI n(%) 95% CI  
risk of CHD in 10 years(Framingham) 
8(8.9) 4.6-16.6 16(18.8) 11.9-28.4 24(13.7) 9.4-19.6 p>0.05 
        
Chi square test, * Mann-Whitney U test 
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Figure 3.5 Risk of CHD (Framingham) at baseline according to aripiprazole 
and ziprasidone  
MANCOVA adjusted for sex , corrected by Bonferroni formula for multiple comparisons *p<0.007 
Model:Intercept , sex, age group, randomization, age group*randomization 
CHD - coronary heart disease 
 
 
 
The means of CHD risk score (Framingham) was increased in trend from age group < 
30 years old to ≥ 60 years old for aripiprazole and ziprasidone group at baseline. Later, 
a Multivariate General Linear Model (MANCOVA) was performed adjusted for sex 
and using Bonferroni correction p<0.007 for multiple comparisons of means age 
group. There was significant differences in comparing the effect of all age groups and 
randomization at baseline (aripiprazole vs. ziprasidone) with the means CHD risk 
score (Framingham) except for age groups 50-54 years old and ≥ 60 years old (Figure 
3.5). 
* 
 
* 
* * * 
* 
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Figure 3.6  Flow Chart of Screening, Randomization, Follow-up and Assessments of 
Study Participants 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility 
(n= 527) 
 
Aripiprazole 
Allocated to intervention 
(n=90) 
 
 
 
Ziprasidone 
Allocated to intervention 
(n= 85) 
 
 
    
Allocation 
Excluded (n= 352) 
Not meeting inclusion criteria=57 
- Bipolar disorder=42, clozapine=6, 
aripiprazole =7, no medication=2 
No fasting blood investigation=87 
Absence of metabolic 
abnormalities=57 
Antipsychotics treatment < 1 year=52  
Refused to participate= 99 
   
Other reasons (n=     ) 
 
 
Enrollment 
Lost to follow-up  (n=9) 
Discontinued intervention(n= 
26) 
-Withdraw consent =16 
-Lack of efficacy = 6 
-Adverse event=2 
- Non compliance=2     
Lost to follow-up  (n=4) 
Discontinued 
intervention(n=36) 
-Withdraw consent =20 
-Lack of efficacy = 3 
-Adverse event=9 
- Non compliance=2  
- Relapse =2    
Per protocol Analysis (n=55) 
   ITT Analysis (n=90) 
 
Per protocol Analysis (n=45) 
  ITT Analysis (n=85) 
 
Follow-up 
Analysis 
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RESULTS AT THE STUDY VISITS 
Prevalence of Metabolic Syndrome 
The prevalence of metabolic syndrome was significantly reduced from baseline to 6 
months study visit for both aripiprazole and ziprasidone group either using NCEP ATP 
III and IDF definitions. The prevalence of metabolic syndrome was slightly lower with 
IDF definition compared to NCEP ATP III definition. At 6 months, the prevalence of 
metabolic syndrome dropped by 30.0% for aripiprazole and 36.5% for ziprasidone by 
using to NCEP ATP III definition. Whereas by using IDF definition, the prevalence of 
metabolic syndrome dropped by 27.8% for aripiprazole and 36.5% for ziprasidone 
(Table 3.10).  
Both aripiprazole and ziprasidone significantly cause reduction in prevalence of 
metabolic syndrome at 6 month, and there was statistically significant difference in the 
prevalence of metabolic syndrome at 6 months between aripiprazole and ziprasidone. 
When GEE was performed, there was statistically significant for the time effect for 
prevalence of metabolic syndrome, indicating reduction in prevalence of metabolic 
syndrome over time. However there was no statistically significant difference for 
intervention x time interaction effect comparing the reduction of prevalence of 
metabolic syndrome between aripiprazole and ziprasidone (Table 3.11).       
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Table 3.10 Prevalence of metabolic syndrome with NCEP ATP III and IDF definition by study visit   
 Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   
NCEP ATP III*                 
 Aripiprazole (N=90) 58.9  (53) 40.0 (36) 32.2 (29) 33.3 (30) 33.3 (30) 25.6 (23) 30.0 (27) 
Ziprasidone  (N=85)  51.8 (44) 41.2 (35) 31.8 (27)    27.1 (23) 24.7 (21) 23.5 (20) 15.3 (13) 
    
 
 
 
 
 
 
 
 
 
 
 
IDF**                
 Aripiprazole (N=90)  57.8  (52) 37.8 (34) 31.1 (28) 33.3 (30) 33.3 (30) 25.6 (23) 30.0 (27)  
Ziprasidone  (N=85) 51.8 (44) 35.3 (30) 30.6 (26) 25.9 (22) 24.7 (21) 22.4 (19) 15.3 (13)  
               
             Chi square test, ¶ p<0.05 , NCEP ATP-III* and IDF** have Asians values for waist circumference 
    
                   
                                  Table 3.11   Generalized estimating equation (GEE) for NCEP ATP III and IDF among schizophrenia patients  
 NCEP ATP III*   IDF** 
Source Wald  
Chi-Square  Sig. 
Wald  
Chi-Square Sig. 
Intercept 0.799 0.371 1.731 0.188 
Time 15.407 0.017 13.387 0.037 
Intervention 0.535 0.464 0.890 0.345 
Intervention * Time 13.599 0.034 8.923 0.178 
                              
                             Dependent Variable: NCEP ATP III and IDF, Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6),  
                             Intervention (aripiprazole and ziprasidone), Intervention * Time 
¶ 
¶ 
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Metabolic syndrome and its components resolved or developed after 6 
months of treatment  
The overall prevalence of metabolic syndrome and its components reduced at 6 
months visit as compared to baseline for both NCEP ATP III and IDF definitions. At 6 
months, the prevalence of waist circumference dropped by 45.1%, 26.3% dropped for 
the prevalence of triglycerides and 23.4% dropped for the prevalence of HDL 
cholesterol. For both definitions, the overall cases of metabolic syndrome resolved 
were 16% vs. 15.4%, whereas only 5.1% vs. 4.6% new cases of metabolic syndrome 
developed. For metabolic syndrome components, the highest overall prevalence of 
cases resolved was triglycerides followed by waist circumference (16.0% vs. 15.4%). 
However, the highest overall prevalence of cases developed was blood pressure 
followed by HDL cholesterol (13.1% vs. 8.6%) after 6 months of treatment. 
Nevertheless, the overall cases resolved for metabolic syndrome components were 
more than new cases developed except for blood pressure (Table 3.12).        
Metabolic syndrome resolved or developed after 6 months of treatment 
between aripiprazole and ziprasidone 
The cases of metabolic syndrome resolved for both aripiprazole and ziprasidone were 
14.4% vs. 17.6% using NCEP ATP III definition and 13.3% vs.17.6% when using IDF 
definition. The cases resolved for metabolic syndrome in aripiprazole and ziprasidone 
group were much higher as compared to new cases of metabolic syndrome developed 
in both groups (NCEP ATP III: 6.7% vs. 3.5%, IDF: 5.6% vs.3.5%) (Table 3.13).   
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Table 3.12 Prevalence of metabolic syndrome at baseline and 6 months after 
randomization, metabolic syndrome and its components resolved or 
developed after 6 months of randomization 
Criterion 
Baseline 
prevalence 
 n (%)(N=175) 
6-months 
prevalence 
      n (%)(N=175)                     
Cases resolved 
(N=175)                            
n(%) 
Cases developed 
           (N=175) 
          n (%)                    
NCEP ATP III* 97(55.4) 40(22.9) 29(16.6) 9(5.1) 
IDF** 96(54.9) 40(22.9) 29(16.6)) 9(5.1) 
Waist circumference 150(85.7) 70(40.0) 25(14.3) 2(1.1) 
Blood pressure 79(45.1) 40(22.9) 18(10.3)      23(13.1) 
HDL 94(53.7) 50(28.6) 23(13.1)        16(9.1) 
Triglycerides 77(44.0) 30(17.1) 27(15.4)          9(5.1) 
Blood glucose 60(34.3) 25(14.3) 16(9.1) 5(2.9) 
    NCEP ATP-III* and IDF** have Asian values for waist circumference  
 
Table 3.13   Prevalence of metabolic syndrome (MetS) at baseline and 6 
months after randomization, metabolic syndrome (MetS) resolved or 
developed 6 months after randomization  
 
Aripiprazole(N= 90) 
%    (n) 
Ziprasidone(N=85) 
%    (n) 
p value 
Baseline prevalence MetS  58.9(53) 51.8(44) p> 0.05 
6-month prevalence MetS  30.0(27) 15.3(13) p< 0.05 
Cases resolved MetS 14.4(13) 18.8(16) p> 0.05 
Cases developed MetS 5.6(5) 4.7(4) p> 0.05 
Baseline prevalence IDF  57.8(52) 51.8(44) p> 0.05 
6-month prevalence IDF  30.0(27) 15.3(13) p< 0.05 
Cases resolved IDF 14.4(13) 18.8(16) p> 0.05 
Cases developed IDF 5.6(5) 4.7(4) p> 0.05 
Chi square test 
Mets based on definition NCEP ATP-III , IDF - International Diabetes Federation  
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Prevalence of metabolic syndrome components by study visit between 
aripiprazole and ziprasidone 
From baseline to 6 months study visit, there was reduction in the prevalence of all 
metabolic syndrome components for both aripiprazole and ziprasidone group. The 
highest reduction in prevalence was waist circumference, dropped by 40.0% in 
aripiprazole and 51.8% in ziprasidone group. The lowest reduction in prevalence was 
blood pressure in both groups (15.5% vs. 15.9%) (Table 3.14).           
There was statistically significant difference in the prevalence of triglycerides at 
baseline between aripiprazole and ziprasidone (50.0% vs. 37.6%). There was also 
statistically significant difference in the prevalence of fasting blood glucose at baseline 
(42.2% vs. 25.9%) and 6 months (20.0% vs. 8.2%) between aripiprazole and 
ziprasidone (Table 3.14). When GEE was performed for metabolic syndrome 
components, there was statistically significant for intervention x time interaction effect 
comparing the reduction of prevalence of fasting blood glucose between aripiprazole 
and ziprasidone.  There was also statistically significant in the time effect for waist 
circumference, indicating reduction in prevalence of waist circumference over time. 
However there was no statistically significant difference for intervention x time 
interaction effect for waist circumference (Table 3.15). 
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Table 3.14 Prevalence of metabolic syndrome components by study visit between 
aripiprazole and ziprasidone   
Variable  Aripiprazole(N=90) 
%    (n) 
Ziprasidone(N=85) 
%    (n) 
p value 
Waist circumference    
Baseline prevalence  84.4(76) 87.1(74) NS 
1-month prevalence  58.9(53) 60.0(51) NS 
2-month prevalence  53.3(48) 54.1(46) NS 
3-month prevalence  48.9(44) 48.2(41) NS 
4-month prevalence  46.7(42) 42.4(36) NS 
5-month prevalence  45.6(41) 38.8(33) NS 
6-month prevalence  44.4(40) 35.3(30) NS 
    
HDL cholesterol    
Baseline prevalence  54.4(49) 52.9(45) NS 
1-month prevalence  43.3(39) 48.2(41) NS 
2-month prevalence  36.7(33) 37.6(32) NS 
3-month prevalence  34.4(31) 34.1(29) NS 
4-month prevalence  31.1(28) 25.9(22) NS 
5-month prevalence  31.1(28) 25.9(22) NS 
6-month prevalence  33.3(30) 23.5(20) NS 
    
Blood pressure    
Baseline prevalence  41.1(37) 32.9(28) NS 
1-month prevalence  35.6(32) 35.3(30) NS 
2-month prevalence  18.9(17) 27.1(23) NS 
3-month prevalence  22.2(20) 30.6(26) NS 
4-month prevalence  26.7(24) 23.5(20) NS 
5-month prevalence  26.7(24) 18.8(16) NS 
6-month prevalence  25.6(23) 20.0(17) NS 
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Table 3.14 Prevalence of metabolic syndrome components by study visit between 
aripiprazole and ziprasidone (cont’)  
Variable  Aripiprazole(N=90) 
%    (n) 
Ziprasidone(N=85) 
%    (n) 
p value 
Triglycerides    
Baseline prevalence  50.0(45) 37.6(32) p< 0.05 
1-month prevalence  28.9(26) 27.1(23) NS 
2-month prevalence  26.7(24) 25.9(22) NS 
3-month prevalence  25.6(23) 17.6(15) NS 
4-month prevalence  27.8(25) 16.5(14) NS 
5-month prevalence  22.2(20) 10.6(9) NS 
6-month prevalence  21.1(19) 12.9(11) NS 
    
Fasting Blood Glucose   
Baseline prevalence  42.2(38) 25.9(22) p< 0.05 
1-month prevalence  26.7(24) 23.5(20) NS 
2-month prevalence  23.3(21) 23.5(20) NS 
3-month prevalence  22.2(20) 16.5(14) NS 
4-month prevalence  23.3(21) 18.8(16) NS 
5-month prevalence  17.8(16) 18.8(16) NS 
6-month prevalence  20.0(18) 8.2(7) p< 0.05 
    
Chi square test, NS – not significant  
Metabolic syndrome components based on NCEP ATP-III definition  
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Table 3.15  Generalized estimating equation (GEE) for  metabolic syndrome 
components among the schizophrenia patients  
 Fasting glucose Triglycerides  HDL  
Source Wald  
Chi-Square  Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig.   
Intercept 23.618 0.001 19.482 0.001 0.264 0.607   
Time 9.504 0.147 12.210 0.057 8.478 0.205   
Intervention 0.824 0.364 2.223 0.136 0.016 0.899   
Intervention * Time 19.588 0.003 8.389 0.211 6.452 0.374   
     
 Systolic Diastolic  Waist  
Source Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig.   
Intercept 182.744 0.001 162.061 0.001 41.751 0.001   
Time 9.892 0.129 4.527 0.606 19.530 0.003   
Intervention 0.029 0.865 1.902 0.168 0.019 0.889   
Intervention * Time 12.068 0.060 6.529 0.367 3.336 0.766   
Dependent Variable: Fasting glucose, Triglycerides, HDL, Blood pressure, Waist circumference   
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention (aripiprazole and 
ziprasidone), Intervention * Time 
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Metabolic syndrome components resolved or developed after 6 months 
treatment of aripiprazole and ziprasidone 
The highest prevalence of metabolic syndrome component resolved 6 months after 
treatment of aripiprazole was triglycerides followed by waist circumference (17.8% 
vs. 15.6%). In ziprasidone group, the highest prevalence of metabolic syndrome 
components resolved 6 months after treatment were waist circumference and 
triglycerides (12.9% respectively). The lowest prevalence of metabolic syndrome 
component resolved 6 months after treatment of aripiprazole and ziprasidone was 
fasting blood glucose (1.1% vs. 4.7%, respectively).  
The highest prevalence of metabolic syndrome component developed 6 months after 
treatment of aripiprazole and ziprasidone was blood pressure (14.4% vs. 11.8%, 
respectively). The lowest prevalence of metabolic syndrome component developed 6 
months after treatment of aripiprazole and ziprasidone was waist circumference (1.1% 
vs. 1.2%, respectively) (Table 3.16).  
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Table 3.16 Prevalence of metabolic syndrome components at baseline and 6 
months after randomization, metabolic syndrome components resolved or 
developed 6 months after randomization  
Variable  
Aripiprazole(N=90) 
%    (n) 
Ziprasidone(N=85) 
%    (n) 
p value 
Waist circumference    
Baseline prevalence  84.4(76) 87.1(74) NS 
6-month prevalence  44.4(40) 35.3(30) NS 
Cases resolved  15.6(14) 12.9(11) NS 
Cases developed  1.1(1) 1.2(1) NS 
    
HDL cholesterol    
Baseline prevalence  54.4(49) 52.9(45) NS 
6-month prevalence  33.3(30) 23.5(20) NS 
Cases resolved  14.4(13) 11.8(10) NS 
Cases developed  10.0(9) 8.2(7) NS 
    
Blood pressure    
Baseline prevalence  41.1(37) 32.9(28) NS 
6-month prevalence  25.6(23) 20.0(17) NS 
Cases resolved  13.3(12) 7.1(6) NS 
Cases developed  14.4(13) 11.8(10) NS 
    
Triglycerides    
Baseline prevalence  50.0(45) 37.6(32) NS 
6-month prevalence  21.1(19) 12.9(11) NS 
Cases resolved  17.8(16) 12.9(11) NS 
Cases developed  4.4(4) 5.9(5) NS 
    
Glucose    
Baseline prevalence  42.2(38) 25.9(22) p< 0.05 
6-month prevalence  20.0(18) 8.2(7) p< 0.05 
Cases resolved  8.9(8) 9.4(8) NS 
Cases developed  1.1(1) 4.7(4) NS 
    
Chi square test 
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MMRM least squares mean change over 6 months in rating scales 
between aripiprazole and ziprasidone    
Table 3.17 showed the mixed model estimated mean change in rating scale scores over 
time by treatment group. There was marked reduction of LS mean change of all rating 
scales for every monthly study visits after treatment of aripiprazole and ziprasidone. 
The ziprasidone group improved more than the aripiprazole group for PANSS total 
and positive score but not statiscally significant. Significant pairwise differences were 
found in aripiprazole and ziprasidone groups for PANSS total, positive and negative 
score. There were also significant pairwise differences for both aripiprazole and 
ziprasidone groups for SAS.  
When MMRM was performed for the rating scales, there was statistically significant 
in the time effect for PANSS total and Positive subscales, CGI-S, BARS and SAS 
indicating reduction in LS mean change over time. However there was no statistically 
significant difference for intervention x time interaction effect for all rating scales 
(Table 3.18). 
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Table 3.17 MMRM least squares mean change of rating scale by study visit between aripiprazole and ziprasidone  
 Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 Mean (±SD)   LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE 
PANSS , Total score                
Aripiprazole  56.4 ±17.0 -4.4 1.1¶ -5.6 1.2¶ -5.1 1.3¶ -7.5 1.3¶ -8.7 1.3¶ -10.5 1.3¶ 
Ziprasidone  59.4 ±21.8 -4.0 1.1¶ -4.9 1.2¶ -7.4 1.2¶ -8.5 1.3¶ -9.4 1.3¶ -11.3 1.3¶ 
               
PANSS, Positive score               
Aripiprazole  13.5 ±4.7 -1.1 0.3¶ -1.5 0.3¶ -1.1 0.3¶ -1.8 0.4¶ -2.3 0.4¶ -2.5 0.4¶ 
Ziprasidone  14.7 ±6.3 -1.8 0.4¶ -1.9 0.4¶ -2.7 0.4¶ -2.7 0.4¶ -2.9 0.4¶ -3.7 0.4¶ 
               
PANSS, Negative score               
Aripiprazole  14.9 ±5.8 -1.1 0.3¶ -1.4 0.4¶ -1.4 0.4¶ -2.0 0.4¶ -2.8 0.4¶ -2.9 0.4¶ 
Ziprasidone  16.1 ±7.2 -0.9 0.4 -1.2 0.4¶ -2.0 0.4¶ -2.4 0.4¶ -2.7 0.4¶ -3.0 0.4¶ 
               
CGI-S score                
Aripiprazole  3.1 ±0.8 -0.2 0.1 -0.2 0.1 -0.2 0.1 -0.3 0.1¶ -0.4 0.1¶ -0.4 0.1¶ 
Ziprasidone  3.3 ±1.0 -0.1 0.1 -0.2 0.1¶ -0.3 0.1¶ -0.4 0.1¶ -0.4 0.1¶ -0.5 0.1¶ 
               
BARS                
Aripiprazole  0.7 ±2.2 -0.3 0.1 -0.4 0.1 -0.3 0.1 -0.5 0.1 -0.5 0.1 -0.5 0.1 
Ziprasidone  0.4 ±1.4 -0.1 0.1 -0.2 0.1 -0.3 0.1 -0.2 0.1 -0.3 0.1 -0.3 0.1 
               
SAS                
Aripiprazole  1.1 ±2.4 -0.7 0.1¶ -0.7 0.1¶ -0.7 0.1¶ -0.8 0.1¶ -0.8 0.1¶ -0.9 0.1¶ 
Ziprasidone  1.2 ±2.6 -0.5 0.2 -0.8 0.2¶ -0.98 0.2¶ -1.1 0.2¶ -1.1 0.2¶ -1.1 0.3¶ 
               
AIMS                
Aripiprazole  0.8 ±2.8 -0.1 0.2 -0.4 0.2 -0.6 0.2 -0.6 0.2 -0.7 0.2 -0.7 0.2¶ 
Ziprasidone  0.8 ±2.2 -0.5 0.2 -0.5 0.2¶ -0.6 0.2¶ -0.6 0.2¶ -0.5 0.2 -0.4 0.2 
               
PANSS -Positive and Negative Syndrome Scale, CGI-S : Clinical Global Impression-Severity Scale, SAS- Simpson-Angus Rating Scale, BARS-Barnes Akathisia Rating Scale, AIMS- 
Abnormal Involuntary Movement Scale, ¶LS – Least square mean change for multiple comparison with Bonferonni correction p< 0.008, MMRM- mixed models for repeated measures, SE- 
standard error
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Table 3.18 Mixed Model Repeated Measures (MMRM) for rating scale between 
aripiprazole and ziprasidone 
 
PANSS PANSS 
-positive  score  
PANSS 
-negative  score 
CGI-S 
Source F Sig. F Sig. F Sig. F Sig. 
         
Intercept 1739 0.001 1298 0.001 5170 0.001 8118 0.001 
Time 29.948 0.001 27.094 0.001 1.750 0.111 2.420 0.028 
Intervention 1.042 0.309 0.481 0.489 31.994 0.001 45.192 0.001 
Intervention * Time 0.605 0.727 1.746 0.108 0.413 0.870 0.764 0.599 
         
 BARS SAS AIMS   
Source F Sig. F Sig. F Sig. 
 
        
Intercept 8.818 0.003 90.484 0.001 59.634 0.001  
Time 3.793 0.001 3.978 0.001 1.813 0.098  
Intervention 0.488 0.486 4.948 0.026 0.534 0.465  
Intervention * Time 0.690 0.658 0.266 0.952 0.831 0.547  
Dependent Variable: PANSS, PANSS positive score, PANSS negative score, CGI-S, 
BARS, SAS and AIMS 
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention (aripiprazole 
and ziprasidone), Intervention * Time 
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MMRM least squares mean change of metabolic syndrome components 
over 6 months between aripiprazole and ziprasidone 
Table 3.19 showed the LS mean change and statistical significant of individual 
treatment, with no comparison between aripiprazole and ziprasidone.  There was 
marked reduction of least square mean change of total cholesterol, LDL, weight, BMI 
and waist circumference from study visit 1 to 6 months after treatment of aripiprazole. 
The reduction of least square mean change of TG was only noted after 6 months 
treatment of aripiprazole. There was marked reduction of least square mean change of 
total cholesterol, weight, BMI and waist circumference from study visit 1 to 6 months 
after treatment of ziprasidone. The reduction of least square mean change of TG was 
only noted after 5 months treatment of ziprasidone. The reduction of the LS mean 
change of total cholesterol for aripiprazole and ziprasidone has significant clinical 
implication for reduction of cardiovascular risk, as both groups had mean baseline 
total cholesterol ≥ 200 mg/dL (Table 3.19).   
For MMRM analysis of metabolic syndrome components, there were statistically 
significant in the time effect for LS mean change of total cholesterol, LDL, 
triglycerides, weight, and waist circumference. However there was no statistically 
significant difference for intervention x time interaction effect for these parameters 
(Table 3.20).        
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Table 3.19 MMRM least squares mean change of metabolic syndrome components and other parameters by study visit in schizophrenia 
patients  
 Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 Mean (±SD)    LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE 
 Total Cholesterol (mg/dL)              
Aripiprazole  214.2 ±50.0 -17.4 3.9¶ -15.8 4.1¶ -22.9 4.2¶ -23.6 4.2¶ -29.4 4.3¶ -27.3 4.3¶ 
Ziprasidone  206.4 ±36.8 -9.7 3.1¶ -9.7 3.2¶ -12.6 3.3¶ -10.3 3.4¶ -19.0 3.4¶ -13.2 3.5¶ 
               
LDL(mg/dL)                
Aripiprazole  137.6 ±44.2 -15.8 3.7¶ -14.2 3.9¶ -20.5 4.1¶ -23.9 4.2¶ -25.5 4.2¶ -22.9 4.2¶ 
Ziprasidone  131.5 ±33.4 -5.5 3.1 -6.5 3.2¶ -9.1 3.3 -7.3 3.4 -11.1 3.4¶ -10.4 3.5¶ 
               
HDL(mg/dL)                 
Aripiprazole  44.0 ±11.2 0.1 1.2 0.6 1.3 -0.2 1.3 1.4 1.3 0.4 1.3 1.0 1.3 
Ziprasidone  44.2 ±13.8 -1.0 1.2 -0.9 1.2 -0.2 1.3 0.3 1.3 -0.1 1.3 1.1 1.4 
               
Triglyceride(mg/dL)                 
Aripiprazole  176.6 ±140.0 -20.4 8.9 -20.2 9.4 -16.9 9.7 -16.7 9.8 -22.6 9.9 -35.7 9.9¶ 
Ziprasidone  161.1 ±126.1 -18.7 6.7 -12.2 6.9¶ -15.4 7.2 -16.5 7.3 -28.2 7.5¶ -21.4 7.6¶ 
               
FBS (mg/dL)               
Aripiprazole  109.9 ±40.9 -2.7 2.9 -1.5 3.2 -3.8 3.3 -0.8 3.3 -6.1 3.3 -8.3 3.3 
Ziprasidone  95.8 ±24.7 2.7 2.3 2.2 2.3 1.3 2.4 0.8 2.5 1.3 2.5 2.5 2.6 
               
Systolic(mm/Hg)                
Aripiprazole  125.0 ±16.7 0.8 1.8 -1.9 1.9 -0.7 1.9 0.1 1.9 1.3 2.0 -0.2 2.7 
Ziprasidone  123.6 ±15.1 4.5 1.9 4.1 2.0 2.9 2.1 1.3 2.1 0.97 2.2 0.8 2.2 
               
Diastolic (mm/Hg)               
Aripiprazole  80.8 ±12.4 1.2 1.2 -0.7 1.3 -0.9 1.4 -1.2 1.4 -1.5 1.4 -3.1 1.4 
Ziprasidone  80.9 ±11.4 1.3 1.3 0.6 1.3 0.7 1.4 2.5 1.4 0.7 1.4 0.3 1.4 
               
Waist(cm)               
Aripiprazole  96.0 ±12.1 -1.7 0.6¶ -1.9 0.6¶ -2.3 0.7¶ -2.4 0.7¶ -2.9 0.7¶ -3.4 0.7¶ 
Ziprasidone  96.6 ±11.7 -1.4 0.5¶ -2.2 0.5¶ -2.9 0.5¶ -3.4 0.5¶ -4.2 0.5¶ -3.7 0.5¶ 
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 Table 3.19 MMRM least squares mean change of metabolic syndrome components and other parameters by study visit in schizophrenia 
patients(con’t) 
 
Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 
Mean (±SD)    LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE 
Weight(kg)               
Aripiprazole  73.5 ±16.8 -1.2 0.3¶ -1.5 0.3¶ -1.6 0.4¶ -1.6 0.4¶ -1.5 0.4¶ -1.8 0.4¶ 
Ziprasidone  75.0 ±15.1 -1.9 0.9 -3.0 0.9¶ -2.3 0.96 -2.9 0.98¶ -3.4 0.99¶ -3.4 1.0¶ 
               
BMI               
Aripiprazole  27.7 ±5.2 -0.5 0.1¶ -0.6 0.1¶ -0.6 0.1¶ -0.6 0.1¶ -0.6 0.1¶ -0.7 0.1¶ 
Ziprasidone  28.1 ±5.6 -0.6 0.3 -1.1 0.3¶ -0.8 0.3 -1.1 0.3¶ -1.2 0.3¶ -1.2 0.3¶ 
               
Framingham               
Aripiprazole  6.7 ±5.2 -0.9 0.8 -0.3 0.8 -0.5 0.8 -0.4 0.8 -0.3 0.9 -0.9 0.8 
Ziprasidone  6.6 ±6.7 -1.1 1.2 -1.2 1.2 -0.9 1.3 -1.5 1.4 -0.1 1.2 -0.2 1.2 
               
               
 FBS- Fasting blood sugar, BMI - body mass index; HDL- high-density lipoprotein cholesterol; LDL- low density lipoprotein cholesterol 
¶LS – Least square mean change for multiple comparison with Bonferonni correction p< 0.008, MMRM- mixed models for repeated measures, SE- standard error
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Table 3.20  Mixed Model Repeated Measures (MMRM) for metabolic 
syndrome components and other parameters among schizophrenia patients  
 
Total 
Cholesterol 
LDL  HDL TG 
Source F Sig. F Sig. F Sig. F Sig. 
Intercept 5527 0.001 2915 0.001 3810 0.001 298.2 0.001 
Time 15.931 0.001 10.831 0.001 0.643 0.696 4.410 0.001 
Intervention 0.039 0.845 0.845 0.359 0.078 0.781 0.531 0.467 
Intervention * Time 1.512 0.171 2.074 0.054 0.231 0.966 0.462 0.836 
     
 
FBS Systolic Diastolic Weight  
Source F Sig. F Sig. F Sig. F Sig. 
Intercept 1753 0.001 42650 0.001 12710 0.001 3043 0.001 
Time 0.676 0.669 0.341 0.915 1.323 0.244 6.467 0.001 
Intervention 3.687 0.056 0.630 0.428 0.322 0.571 1.120 0.291 
Intervention * Time 1.348 0.234 0.644 0.695 1.037 0.400 0.853 0.529 
     
 
BMI  Waist Framingham  
Source F Sig. F Sig. F Sig.   
Intercept 3862 0.001 1160 0.001 979.39 0.001   
Time 7.671 0.001 17.091 0.001 3.875 0.049   
Intervention 1.063 0.304 0.387 0.535 0.512 0.799   
Intervention * Time 1.009 0.418 0.806 0.565 0.365 0.900   
 
Dependent Variable: Total Cholesterol, LDL, HDL, TG, FBS, Systolic, 
Diastolic, weight, BMI, Waist and Framingham  
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention 
(aripiprazole and ziprasidone), Intervention * Time
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MMRM least squares mean change of total cholesterol and LDL over 6 
months between aripiprazole and ziprasidone 
There was marked reduction of least square mean change of total cholesterol and LDL for 
study visit 1 to 6 months after treatment of aripiprazole and ziprasidone. There were 
statistically significant differences of LS mean change for multiple comparisons with 
Bonferonni correction p< 0.008 for study visit 1 to 6 months in total cholesterol in both 
groups. For aripiprazole group, there was statistically significant difference of LS mean 
change for every study visit in LDL cholesterol. For ziprasidone group, there was 
statistically significant different of LS mean change at study visit month 2, 5 and 6 in 
LDL cholesterol (Table 3.19).   
For MMRM analysis of total cholesterol and LDL, there was statistically significant in 
the time effect for both lipid profile parameters, indicating reduction in LS mean change 
over time. However there was no statistically significant difference for intervention x 
time interaction effect for cholesterol and LDL cholesterol (Table 3.20).        
MMRM least squares mean change of CHD risk score (Framingham) and other 
parameters over 6 months between aripiprazole and ziprasidone 
There was marked reduction in least square mean change of weight, BMI and CHD risk 
score (Framingham) after treatment of aripiprazole and ziprasidone. There were 
significant differences in LS mean change of weight and BMI from study visit 1 to 6 
months for aripiprazole. Whereas in ziprasidone group, the significant differences in LS 
mean change of weight and BMI were for study visit month 2, 4, 5 and 6 (Table 3.19).  
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For the overall modelling analysis (MMRM), there were statistically significant in the 
time effect for weight, BMI and CHD risk score (Framingham) but not for intervention x 
time interaction effect for these variables (Table 3.20).  
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TABLE 3.21 Prevalence of CVRFs and CHD risk (Framingham) between aripiprazole(N=90) and ziprasidone(N=85) by study visit   
CVRFs Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   
Diabetes Mellitus                 
Aripiprazole  22.2  (20) 16.7 (15) 15.6 (14) 14.4 (13) 12.2 (11) 11.1 (10) 8.9 (8) 
Ziprasidone  9.4 (8) 10.6 (9) 17.8  (10) 10.6 (9) 9.4 (8) 8.2 (7) 8.2 (7) 
               
Total Cholesterol                
Aripiprazole  56.7  (51) 37.8 (34) 33.3 (30) 26.7 (24) 23.3 (21) 20.0 (18) 20.0 (18) 
Ziprasidone  61.2 (52) 28.2 (24) 31.8 (27) 28.2 (24) 21.2 (18) 17.6 (15) 20.0 (17) 
               
HDL                
Aripiprazole  66.7  (60) 55.6 (50) 53.3 (48) 44.4 (40) 38.9 (35) 37.8 (34) 40.0 (36) 
Ziprasidone  74.1 (63) 54.1 (46) 42.4  (36) 40.0 (34) 38.8 (33) 37.6 (32) 35.3 (30) 
               
Systolic               
Aripiprazole  22.2  (20) 22.2  (20) 13.3 (12) 12.2 (11) 10.0 (9) 14.4 (13) 16.7 (15) 
Ziprasidone  17.6 (15) 23.5 (20) 23.5 (20) 15.3 (13) 11.8 (10) 12.9 (11) 9.4 (8) 
               
Diastolic                
Aripiprazole  23.3 (21) 21.1 (19) 17.8 (16) 12.2 (11) 8.9 (8) 11.1 (10) 11.1 (10) 
Ziprasidone  25.9 (22) 18.8 (16) 17.6 (15) 20.0 (17) 18.8 (16) 11.8 (10) 11.8 (10) 
               
Patients (%)with very high/high risk (≥10%) of CHD in 10 years (Framingham)        
Aripiprazole  25.5 (23) 21.1 (19) 13.3 (12) 13.3 (12) 13.3 (12) 16.5 (14) 10.0 (9) 
Ziprasidone  21.2 (18) 21.2 (18) 20.0 (17) 14.1 (12) 16.5 (14) 10.6 (9) 11.8 (10) 
               
               
Chi square test,¶ p < 0.05. CVRFs- Cardiovascular risk factors, CHD- coronary heart disease 
¶ 
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Table 3.22  Generalized estimating equation (GEE) for  CVRFs and CHD risk 
(Framingham) between aripiprazole and ziprasidone  
 Diabetes Mellitus Total Cholesterol  HDL 
Source Wald  
Chi-Square  Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig. 
Intercept 1739 0.001 1298 0.001 5170 0.001 
Time 29.948 0.001 27.094 0.001 1.750 0.111 
Intervention 1.042 0.309 0.481 0.489 31.994 0.001 
Intervention * Time 0.605 0.727 1.746 0.108 0.413 0.870 
    
 Systolic Diastolic Framingham 
Source Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig. 
Intercept 8118 0.001 8.818 0.003 44.881 0.001 
Time 2.420 0.028 3.793 0.001 9.484 0.148 
Intervention 45.192 0.001 0.488 0.486 0.142 0.707 
Intervention * Time 0.764 0.599 0.690 0.658 9.746 0.136 
Dependent Variable: Diabetes Mellitus, Total Cholesterol, HDL, Systolic, Diastolic, CHD  
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention (aripiprazole and ziprasidone), 
Intervention * Time 
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Prevalence of CVRFs and CHD risk (Framingham) by study visit between 
aripiprazole and ziprasidone 
For prevalence of all CVRFs showed reduction by study visit after treatment of 
aripiprazole and ziprasidone. For CVRFs of diabetes mellitus, the reduction of 
prevalence was 13.3% and the dropped was greater after treatment of aripiprazole. 
There was statistically significant difference in the prevalence of CVRFs diabetes 
mellitus between aripiprazole and ziprasidone at baseline (22.2% vs. 9.4%). For other 
CVRFs, the dropped of prevalence was observed greater in ziprasidone group. The 
highest dropped of prevalence were total cholesterol followed by HDL cholesterol in 
ziprasidone group (41.2% vs. 38.8%).  
For patients with high risk and very high risk in CHD (Framingham), the dropped in 
prevalence were more in aripiprazole than ziprasidone group. The reduction in 
prevalence of patients with high risk and very high risk in CHD (Framingham) were 
15.5% in aripiprazole and 9.4% in ziprasidone group (Table 3.21).  
When GEE was performed for CVRFs, there were statistically significant in the time 
effect for diabetes mellitus, total cholesterol and diastolic blood pressure, indicating 
reduction in the above prevalence of over time. There were statistically significant in 
the intervention effect for HDL cholesterol, indicate significant reduction in the 
prevalence of HDL cholesterol between aripiprazole and ziprasidone. Although 
systolic blood pressure has statistically significant in time and intervention effect, the 
overall intervention x time interaction effect did not show statistically significant in 
the reduction of all prevalence between aripiprazole and ziprasidone (Table 3.22). 
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The discontinuation rate by study visit between aripiprazole and 
ziprasidone  
The discontinuation rate of ziprasidone was higher than aripiprazole for all study 
visits, however there was no statiscally significant of log rank test in survival analysis 
(Figure 3.7). The discontinuation rates of ziprasidone compared to aripiprazole at 
study visit 6 months were 47.1% (40/85) vs. 38.9% (35/90) (Table 3.23). 
 
 
 
 
Figure 3.7  Survival Analysis of Months to Discontinuation According to 
Aripiprazole and Ziprasidone  
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 Table 3.23  The discontinuation rate between aripiprazole(N=90) and ziprasidone(N=85) by study visit  
 Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   % (n)   
NCEP ATP III*                
Aripiprazole  100.0  (90) 16.7 (15) 27.8 (25) 34.4 (31) 36.7 (33) 38.9 (35) 38.9 (35) 
Ziprasidone  100.0 (85) 23.5 (20) 29.4 (25) 37.6 (32) 41.2 (35) 44.7 (38) 47.1 (40) 
               
               
                Chi square test , p>0.05          
 
 
 Table 3.24   Generalized estimating equation (GEE) of discontinuation rate between aripiprazole and ziprasidone 
 
 
 Discontinuation rate   
Source Wald  
Chi-Square  Sig. 
Intercept 115.534 0.001 
Time 132.592 0.001 
Intervention 0.606 0.436 
Intervention * Time 5.797 0.446 
Dependent Variable: Discontinuation rate   
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6),  
Intervention (aripiprazole and ziprasidone), Intervention * Time 
 
 
 
3   RCT Aripiprazole vs. Ziprasidone  
 
209 
 
The mean score of CHD risk (Framingham) between age groups and 
treatment   
When Multivariate General Linear Model (MANCOVA) was performed adjusted for 
sex for multiple comparisons of means CHD risk score (Framingham) by age group, 
there was no statistically significant (Bonferroni correction p<0.008) for intervention x 
age group interaction effect with the means of CHD risk score (Framingham) (Figure 
3.7).  
 
 
Figure 3.8  Risk of CHD (Framingham) at 6 months  according to aripiprazole 
and ziprasidone  
MANCOVA adjusted for sex , corrected by Bonferroni formula for multiple comparisons p < 0.008 
Model:Intercept , sex, age group, intervention, age group*intervention 
CHD - Coronary Heart Disease 
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The adverse events between aripiprazole and ziprasidone  
The common adverse events reported for aripiprazole and ziprasidone group were 
extrapyramidal syndrome (EPS) (20.0% vs. 18.8%) and insomnia (25.6% vs. 24.7%). 
Patients in the ziprasidone group reported to have higher incidence of somnolence as 
compared to aripiprazole group (18.8% vs. 2.2%). For serious adverse event, there 
were two cases of relapse in the ziprasidone group (Table 3.25).  
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Table 3.25 Incidence of treatment-emergent adverse events between aripiprazole 
and ziprasidone  
Body system Aripiprazole (N=90 ) Ziprasidone  (N=85 ) 
 %    (n)                %    (n) 
Body as a whole   
Asthenia 3.3(3) 7.1(6) 
Pain 4.4(4) 5.9(5) 
   
Digestive   
Constipation 1.1(1) - 
Diarrhoea 1.1(1) - 
Dyspepsia - 3.5(3) 
Nausea 2.2(2) 1.2(1) 
Vomiting - 1.2(1) 
   
Skin & musculoskeletal   
Arthralgia 2.2(2) 1.2(1) 
Itchiness 1.1(1) 1.2(1) 
Cellulites - 1.2(1) 
   
Nervous system   
Agitation 2.2(2) 7.1(6) 
Akathisia 2.2(2) 4.7(4) 
Dizziness 5.6(5) 5.9(5) 
Headache 2.2(2) 7.1(6) 
Extrapyramidal Syndrome 20.0(18) 18.8(16) 
Insomnia 25.6(23) 24.7(21) 
Somnolence 2.2(2) 18.8(16) 
   
Cardiovascular   
Palpitation - 2.4(2) 
   
Respiratory   
Upper respiratory tract 
infection 
- 1.2(1) 
   
Urogenital   
Incontinence - 1.2(1) 
   
Others   
Fall - 1.2(1) 
Tinnitus - 1.2(1) 
Conjunctivitis - 1.2(1) 
   
Relapse   2.4(2) 
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RESULTS FOR SENSITIVITY ANALYSIS 
 
Table 3.26   Sentitivity Analysis: Prevalence of metabolic syndrome (MetS) at 
baseline and 6 months after randomization, metabolic syndrome (MetS) resolved 
or developed 6 months after randomization  
 
Aripiprazole(N= 63) 
%    (n) 
Ziprasidone(N=73) 
%    (n) 
p value 
Baseline prevalence MetS  49.2(31) 49.3(36) p> 0.05 
6-month prevalence MetS  19.0(12) 15.1(11) p> 0.05 
Cases resolved MetS 15.9(10) 15.1(11) p> 0.05 
Cases developed MetS 6.3(4) 5.5(4) p> 0.05 
Baseline prevalence IDF  47.6(30) 49.3(36) p> 0.05 
6-month prevalence IDF  19.0(12) 15.1(11) p> 0.05 
Cases resolved IDF 15.9(10) 15.1(11) p> 0.05 
Cases developed IDF 6.3(4) 5.5(4) p> 0.05 
Chi square test 
Mets based on definition NCEP ATP-III , IDF - International Diabetes Federation  
 
Metabolic syndrome resolved or developed after 6 months of treatment 
between aripiprazole and ziprasidone 
For sentivitivy analysis, thirty-nine schizophrenia patients were excluded when treated 
with antihyperlipidemic, antihypertensive and antidiabetic after randomization as 
concomitant medication. The cases of metabolic syndrome resolved for both 
aripiprazole and ziprasidone were 15.9% vs. 15.1% respectively using NCEP ATP III 
definition and IDF definition. The cases resolved for metabolic syndrome in 
aripiprazole and ziprasidone group were much higher as compared to new cases of 
metabolic syndrome developed in both groups (NCEP ATP III & IDF: 6.3% vs. 5.5%) 
(Table 3.26).   
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Table 3.27  Sensitivity Analysis: Prevalence of metabolic syndrome components by 
study visit between aripiprazole and ziprasidone   
Variable  Aripiprazole(N=63) 
%    (n) 
Ziprasidone(N=73) 
%    (n) 
p value 
Waist circumference    
Baseline prevalence  81.0(51) 86.3(63) NS 
1-month prevalence  52.4(33) 57.5(42) NS 
2-month prevalence  47.6(30) 50.7(46) NS 
3-month prevalence  41.3(26) 43.8(32) NS 
4-month prevalence  36.5(23) 38.4(28) NS 
5-month prevalence  36.5(23) 35.6(26) NS 
6-month prevalence  34.9(22) 32.9(24) NS 
    
HDL cholesterol    
Baseline prevalence  50.8(32) 54.8(40) NS 
1-month prevalence  38.1(24) 43.8(32) NS 
2-month prevalence  30.2(19) 38.4(28) NS 
3-month prevalence  25.4(16) 32.9(24) NS 
4-month prevalence  22.2(14) 26.0(19) NS 
5-month prevalence  20.6(13) 24.7(18) NS 
6-month prevalence  23.8(15) 20.5(15) NS 
    
Blood pressure    
Baseline prevalence  38.1(24) 30.1(22) NS 
1-month prevalence  30.0(17) 32.9(24) NS 
2-month prevalence  12.7(8) 24.7(18) NS 
3-month prevalence  12.7(8) 26.0(19) p<0.05 
4-month prevalence  17.5(11) 19.2(14) NS 
5-month prevalence  20.6(13) 15.1(11) NS 
6-month prevalence  17.5(11) 19.2(14) NS 
 
 
 
 
3   RCT Aripiprazole vs. Ziprasidone  
 
214 
 
Table 3.27 Sensitivity Analysis: Prevalence of metabolic syndrome components by 
study visit between aripiprazole and ziprasidone (cont’)  
Variable  Aripiprazole(N=63) 
%    (n) 
Ziprasidone(N=73) 
%    (n) 
p value 
Triglycerides    
Baseline prevalence  47.6(30) 38.4(28) NS 
1-month prevalence  17.5(11) 23.3(17) NS 
2-month prevalence  22.2(14) 24.7(18) NS 
3-month prevalence  17.5(11) 16.4(12) NS 
4-month prevalence  15.9(10) 16.4(12) NS 
5-month prevalence  14.3(9) 8.2(6) NS 
6-month prevalence  17.5(11) 9.6(7) NS 
    
Fasting Blood Glucose   
Baseline prevalence  33.3(21) 24.7(18) NS 
1-month prevalence  15.9(10) 20.5(15) NS 
2-month prevalence  12.7(8) 20.5(15) NS 
3-month prevalence  12.7(8) 13.7(10) NS 
4-month prevalence  15.9(10) 16.4(12) NS 
5-month prevalence  11.1(7) 16.4(12) NS 
6-month prevalence  12.7(8) 8.2(6) NS 
    
Chi square test, NS – not significant  
Metabolic syndrome components based on NCEP ATP-III definition  
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Table 3.28   Sensitivity Analysis : Generalized estimating equation (GEE) for  
metabolic syndrome components among the schizophrenia patients  
 Fasting glucose Triglycerides  HDL  
Source Wald  
Chi-Square  Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig.   
Intercept 27.158 0.001 23.920 0.001 0.170 0.680   
Time 8.861 0.182 19.908 0.003 7.138 0.308   
Intervention 0.116 0.733 0.171 0.679 0.924 0.336   
Intervention * Time 17.298 0.008 9.999 0.125 3.750 0.711   
     
 Systolic Diastolic  Waist  
Source Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig. 
Wald  
Chi-Square Sig.   
Intercept 22.205 0.001 34.870 0.001 24.476 0.001   
Time 5.043 0.538 2.562 0.862 18.802 0.005   
Intervention 1.160 0.281 5.071 0.024 0.556 0.456   
Intervention * Time 13.728 0.033 6.958 0.325 1.982 0.921   
Dependent Variable: Fasting glucose, Triglycerides, HDL, Blood pressure, Waist 
circumference   
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention (aripiprazole 
and ziprasidone), Intervention * Time 
 
 
Prevalence of metabolic syndrome components by study visit between 
aripiprazole and ziprasidone 
From baseline to 6 months study visit, there was reduction in the prevalence of all 
metabolic syndrome components for both aripiprazole and ziprasidone group. The 
highest reduction in prevalence was waist circumference, dropped by 46.1% in 
aripiprazole and 53.4% in ziprasidone group. The lowest reduction in prevalence was 
blood pressure in both groups (20.6% for aripiprazole vs. 10.9% for ziprasidone) 
(Table 3.27).           
When GEE was performed for metabolic syndrome components, there was statistically 
significant for intervention x time interaction effect comparing the reduction of 
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prevalence of fasting blood glucose and systolic blood pressure between aripiprazole 
and ziprasidone. There was statistically significant in the time effect for waist 
circumference and triglyceride, indicating reduction in prevalence of waist 
circumference and triglyceride over time. There was also statistically significant in the 
treatment effect for diastolic blood pressure. However there was no statistically 
significant difference for intervention x time interaction effect for waist circumference, 
triglyceride, systolic and diastolic blood pressure (Table 3.28). 
 Metabolic syndrome components resolved or developed after 6 months 
treatment of aripiprazole and ziprasidone 
The highest prevalence of metabolic syndrome component resolved 6 months after 
treatment of in aripiprazole group was waist circumference (18.9%). In ziprasidone 
group, the highest prevalence of metabolic syndrome component resolved 6 months 
after treatment was triglycerides (15.1%). As the lowest prevalence of metabolic 
syndrome component resolved 6 months after treatment of was fasting blood glucose 
for aripiprazole and blood pressure for ziprasidone (6.3% vs. 4.1% respectively).  
The highest prevalence of metabolic syndrome component developed 6 months after 
treatment of aripiprazole and ziprasidone was blood pressure (11.1% vs. 12.3%). As 
the lowest prevalence of metabolic syndrome component developed 6 months after 
treatment ziprasidone was waist circumference (1.4%). No patient has impaired fasting 
blood glucose after 6 months treatment of aripiprazole (Table 3.29).  
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Table 3.29  Sensitivity Analysis: Prevalence of metabolic syndrome components at 
baseline and 6 months after randomization, metabolic syndrome components 
resolved or developed 6 months after randomization  
Variable  
Aripiprazole(N=63) 
%    (n) 
Ziprasidone(N=73) 
%    (n) 
p value 
Waist circumference    
Baseline prevalence  81.0(51) 86.3(63) NS 
6-month prevalence  34.9(22) 32.9(24) NS 
Cases resolved  19.0(12) 12.3(9) NS 
Cases developed  1.6(1) 1.4(1) NS 
    
HDL cholesterol    
Baseline prevalence  50.8(32) 54.8(40) NS 
6-month prevalence  23.8(15) 20.5(15) NS 
Cases resolved  15.9(10) 12.3(9) NS 
Cases developed  9.5(6) 8.2(6) NS 
    
Blood pressure    
Baseline prevalence  38.1(24) 30.1(22) NS 
6-month prevalence  17.5(11) 19.2(14) NS 
Cases resolved  14.3(9) 4.1(3) p< 0.05 
Cases developed  11.1(7) 12.3(9) NS 
    
Triglycerides    
Baseline prevalence  47.6(30) 38.4(28) NS 
6-month prevalence  17.5(11) 9.6(7) NS 
Cases resolved            15.9(10)           15.1(11) NS 
Cases developed            4.8(3)           5.5(4) NS 
    
Glucose    
Baseline prevalence  33.3(21) 24.7(18) NS 
6-month prevalence  12.7(8) 8.2(6) NS 
Cases resolved  6.3(4) 6.8(5) NS 
Cases developed  0.0(0) 4.1(3) NS 
    
Chi square test 
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MMRM least squares mean change of metabolic syndrome components 
over 6 months between aripiprazole and ziprasidone 
Table 3.30 showed the LS mean change and statistical significant of individual 
treatment, with no comparison between aripiprazole and ziprasidone.  There was 
marked reduction of least square mean change of total cholesterol, LDL, FBS, weight, 
BMI and waist circumference from study visit 1 to 6 months after treatment of 
aripiprazole. The reduction of least square mean change of TG and diastolic blood 
pressure were only noted after 6 months treatment of aripiprazole. There was marked 
reduction of least square mean change of total cholesterol, weight, BMI and waist 
circumference from study visit 1 to 6 months after treatment of ziprasidone. The 
reduction of least square mean change of TG and LDL were only noted after 5 months 
treatment of ziprasidone.  
The reduction of the LS mean change of total cholesterol for aripiprazole and 
ziprasidone has significant clinical implication for reduction of cardiovascular risk, as 
both groups had mean baseline total cholesterol ≥ 200 mg/dL. The reduction of the LS 
mean change of FBS for aripiprazole has significant clinical implication for 
prevalence reduction of impaired FBS and normalised the fasting blood sugar level, as 
aripiprazole group had mean baseline FBS ≥ 100 mg/dL (Table 3.30).   
The MMRM analysis was used to compare the treatment differences and the 
interaction between time and treatment. For MMRM analysis of metabolic syndrome 
components, there were statistically significant differences for intervention x time 
interaction effect for FBS and systolic blood pressure. These indicating differences in 
LS mean change of FBS and systolic blood pressure observed in both groups were the 
interaction effect of time and treatment (Table 3.31). This can be explained as there 
was increased of LS mean change of FBS and systolic blood pressure from study visit 
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1 to 6 months after treatment of ziprasidone and there was reduction of LS mean 
change of FBS and systolic blood pressure from study visit 1 to 6 months after 
treatment of aripiprazole (Table 3.30). Although there were raised of FBS and systolic 
blood pressure from study visit 1 to 6 months after treatment of ziprasidone,   there 
was no significant clinical implication as the FBS and systolic blood pressure in range 
of the normal value.   
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Table 3.30 Sensitivity Analysis:  MMRM least squares mean change of metabolic syndrome components and other parameters by study visit 
in schizophrenia patients  
 Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 Mean (±SD)    LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE 
 Total Cholesterol (mg/dL)              
Aripiprazole  211.2 ±42.9 -16.1 3.8¶ -16.4 4.1¶ -23.8 4.3¶ -24.2 4.4¶ -23.1 4.4¶ -20.1 4.4¶ 
Ziprasidone  205.5 ±33.0 -7.3 3.3¶ -7.2 3.4¶ -9.0 3.6¶ -16.1 3.7¶ -8.3 3.6¶ -10.0 3.8¶ 
               
LDL(mg/dL)                
Aripiprazole  136.0 ±36.2 -14.3 3.7¶ -14.9 3.9¶ -21.3 4.1¶ -18.9 4.3¶ -19.6 4.3¶ -15.4 4.3¶ 
Ziprasidone  132.5 ±32.8 -3.8 3.4 -5.0 3.6 -7.4 3.7 -6.3 3.8 -8.4 4.0¶ -8.7 4.0¶ 
               
HDL(mg/dL)                 
Aripiprazole  45.6 ±12.0 -0.8 1.2 -0.1 1.3 -0.6 1.4 -0.7 1.4 0.4 1.4 1.6 1.4 
Ziprasidone  44.0 ±13.9 -0.4 1.4 -1.3 1.4 -0.2 1.5 0.2 1.5 0.04 1.6 1.2 1.6 
               
Triglyceride(mg/dL)                 
Aripiprazole  153.9 ±71.3 -13.2 9.2 -10.4 9.8 -17.6 10.4 -21.0 10.6¶ -12.7 10.7 -31.9 10.7¶ 
Ziprasidone  156.2 ±117.9 -19.7 6.2¶ -7.4 6.4 -10.1 6.8 -13.2 6.9 -24.0 7.1¶ -14.5 7.1¶ 
               
FBS (mg/dL)               
Aripiprazole  101.7 ±33.1 -6.6 2.7¶ -7.4 2.8¶ -10.2 3.0¶ -7.3 3.0¶ -8.3 3.1¶ -8.4 3.1¶ 
Ziprasidone  94.4 ±19.4 4.0 2.3 4.0 2.3 2.6 2.5 1.9 2.5 3.7 2.6 5.7 2.6¶ 
               
Systolic(mm/Hg)                
Aripiprazole  126.1 ±16.6 -2.1 2.0 -5.7 2.1¶ -3.3 2.2 -2.7 2.2 -0.7 2.3 -1.6 2.3 
Ziprasidone  122.7 ±16.4 5.0 2.1¶ 4.4 2.2¶ 2.6 2.3 0.4 2.4 -0.2 2.4 1.7 2.4 
               
Diastolic (mm/Hg)               
Aripiprazole  80.7 ±12.7 -0.8 1.4 -2.6 1.5 -2.7 1.5 -1.8 1.6 -2.8 1.6 -4.2 1.6¶ 
Ziprasidone  79.4 ±10.9 1.8 1.6 1.3 1.4 1.2 1.5 2.7 1.5 1.7 1.5 2.0 1.6 
               
Waist(cm)               
Aripiprazole  92.8 ±9.3 -2.2 0.6¶ -3.0 0.6¶ -3.8 0.6¶ -4.2 0.6¶ -4.2 0.6¶ -4.9 0.6¶ 
Ziprasidone  96.8 ±11.1 -1.0 0.5¶ -1.7 0.5¶ -2.5 0.6¶ -3.0 0.6¶ -4.0 0.6¶ -3.5 0.6¶ 
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 Table 3.30 Sensitivity Analysis: MMRM least squares mean change of metabolic syndrome components and other parameters by study visit in 
schizophrenia patients(con’t) 
 
Baseline 1 month 2 months 3 months 4 months 5 months 6 months 
 
Mean (±SD)    LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE  LS Mean 
Change 
SE 
Weight(kg)               
Aripiprazole  69.6 ±13.5 -1.6 0.3¶ -1.9 0.4¶ -1.9 0.4¶ -2.2 0.4¶ -2.1 0.4¶ -2.2 0.4¶ 
Ziprasidone  77.4 ±21.4 -2.4 1.1¶ -3.3 1.1¶ -2.4 1.2¶ -3.0 1.2¶ -3.4 1.2¶ -3.3 1.2¶ 
               
BMI               
Aripiprazole  26.6 ±4.5 -0.6 0.1¶ -0.7 0.1¶ -0.7 0.1¶ -0.8 0.2¶ -0.8 0.2¶ -0.8 0.2¶ 
Ziprasidone  29.1 ±7.4 -0.8 0.4¶ -1.1 0.4¶ -0.8 0.4¶ -1.1 0.4¶ -1.2 0.4¶ -1.2 0.4¶ 
               
               
 FBS- Fasting blood sugar, BMI - body mass index; HDL- high-density lipoprotein cholesterol; LDL- low density lipoprotein cholesterol 
¶LS – Least square mean change for multiple comparison with Bonferonni correction p< 0.008, MMRM- mixed models for repeated measures, SE- standard error
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Table 3.31  Sensitivity Analysis: Mixed Model Repeated Measures (MMRM) for 
metabolic syndrome components and other parameters among schizophrenia 
patients  
 
Total 
Cholesterol 
LDL  HDL TG 
Source F Sig. F Sig. F Sig. F Sig. 
Intercept 5021 0.001 2615 0.001 3056 0.001 313.1 0.001 
Time 10.78   0.001 6.437 0.001 0.770 0.594 3.100 0.005 
Intervention 0.438 0.509 1.437 0.233 1.120 0.292 0.045 0.832 
Intervention * Time 1.669 0.127 1.512 0.172 0.208 0.974 1.056 0.388 
     
 
FBS Systolic Diastolic Weight  
Source F Sig. F Sig. F Sig. F Sig. 
Intercept 2510 0.001 9104 0.001 9363 0.001 2608 0.001 
Time 0.791 0.577 0.512 0.800 0.619 0.715 4.725 0.001 
Intervention 0.534 0.466 0.098 0.755 2.059 0.154 6.372 0.013 
Intervention * Time 3.273 0.004 2.622 0.016 1.623 0.139 0.278 0.947 
     
 
BMI  Waist   
Source F Sig. F Sig.     
Intercept 2936 0.001 9974 0.001     
Time 5.665 0.001 24.650 0.001     
Intervention 5.234 0.024 7.158 0.008     
Intervention * Time 0.280 0.946 0.967 0.447     
 
Dependent Variable: Total Cholesterol, LDL, HDL, TG, FBS, Systolic, Diastolic, 
weight, BMI, Waist and Framingham  
Model: Intercept, Time (Baseline, month 1, 2, 3, 4, 5 and 6), Intervention (aripiprazole and 
ziprasidone), Intervention * Time
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3.6   Discussion 
 
This was among the first double-blind, randomized study to evaluate the comparative 
efficacy and safety, between aripiprazole and ziprasidone in outpatients setting with 
schizophrenia disorder. Zimbroff at al.(2007) has conducted similar study however the 
study population include schizoaffective disorder in hospitalized patients.  
Efficacy of Aripiprazole and Ziprasidone in Reversing Metabolic 
Syndrome  
Following the initiation of treatment, our data showed that the prevalence of metabolic 
syndrome was significantly reduced from baseline to end of the study at 6 months in 
both aripiprazole and ziprasidone groups, regardless of the metabolic syndrome 
definition used. There was improvement in the prevalence of metabolic syndrome 
from baseline to 6-month after switching to aripiprazole or ziprasidone; NCEP ATP III 
definition (aripiprazole 58.9% vs. 30.0%, ziprasidone 51.8% vs. 15.3%), IDF 
definition (aripiprazole 57.8% vs. 30.0%, ziprasidone 51.8% vs. 15.3%). There was no 
statistically significant difference in the prevalence of metabolic syndrome between 
aripiprazole and ziprasidone from baseline to 6-month study visit. Overall, there were 
more cases of metabolic syndrome resolved than developed in both groups using 
NCEP ATP III; resolved cases (aripiprazole 14.4% vs. ziprasidone 18.8%, p>0.05), 
incidence cases (aripiprazole 5.6% vs. ziprasidone 4.7%, p>0.05). Both drugs 
demonstrate similar efficacy in reversing the metabolic syndrome as an effect from 
previous antipsychotics treatment.   
 
This was the first nationwide survey, where we compare the prevalence of metabolic 
syndrome in a prospective 6-month study among Malaysian adults with schizophrenia 
based on NCEP ATP III criteria-modified for Asian waist circumference and modified 
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IDF definition. NCEP ATP III for Western populations and IDF had higher waist 
circumference cut-off values that might lead to an underestimation of Asian patients 
with metabolic syndrome. In our study, the prevalence of metabolic syndrome with 
modified IDF criteria was lower as compared to NCEP ATP III criteria-modified for 
Asian waist circumference. This was because modified IDF criteria include central 
obesity as a requisite feature causing underestimates the number of people with 
metabolic syndrome. NCEP ATP III criteria-modified for Asian waist circumference 
has the advantage of identifying more people with metabolic syndrome who might 
subsequently benefit from intervention targeted to reduce their risk of developing 
diabetes and cardiovascular disease. 
Efficacy of Aripiprazole and Ziprasidone in Reversing Metabolic 
Syndrome Components and Parameters 
From baseline to 6 months study visit, there was reduction in the prevalence of all 
metabolic syndrome components for both aripiprazole and ziprasidone group. The 
highest reduction in prevalence was waist circumference and the lowest reduction in 
prevalence was blood pressure for both groups. There was statistically significant 
difference in modelling analysis of prevalence rate for FBS between aripiprazole and 
ziprasidone from baseline to the endpoint 6-month. This could be due to patients who 
were randomized to aripiprazole showed much more reduction in FBS level as 
compared to ziprasidone.  
The highest prevalence of metabolic syndrome component resolved after 6 months 
treatment of aripiprazole was triglycerides followed by waist circumference and in 
ziprasidone group, the highest prevalence of metabolic syndrome components resolved 
were waist circumference and triglycerides. For both groups, the highest incidence of 
metabolic syndrome component after 6 months treatment was blood pressure.  
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There were not many publications for randomised controlled trial in comparison of 
aripiprazole and ziprasidone for the metabolic effects among schizophrenia patients 
(Zimbroff et al.,2007). Our study showed statistically significant improvement in total 
cholesterol, waist circumference, body weight and BMI, occurred over 6 months 
following a switch to aripiprazole or ziprasidone from previous treatment with other 
antipsychotic drugs. However there was no significant difference between those who 
were randomised to aripiprazole or ziprasidone. These findings suggested that both 
drugs were equally effective in improving metabolic parameters in schizophrenia 
patients. 
Many non randomized studies have shown switching to aripiprazole or ziprasidone in 
schizophrenia patients who required long-term antipsychotic treatment, managed to 
alleviate antipsychotic-induced obesity, hyperglycemia or dyslipidemia (Alptekin et 
al.,2009; Kim et al.,2009; Schorr et al.,2008; Takeuchi et al.,2010).  
The results reported in this study provided further support to other randomized 
efficacy trials in the improvement of metabolic effects following a switch to 
aripiprazole or ziprasidone. In primary analyses, our study reported the mean weight 
loss of -1.2 to -1.8 kg, mean reduction of -0.5 to -0.7 for BMI and mean reduction of -
1.7 to -3.4 cm for waist circumference over 6-month duration following initiation of 
aripiprazole. For the ziprasidone group our study reported significant mean weight loss 
of -1.9 to -3.4 kg, mean reduction of -0.6 to -1.2 for BMI and mean reduction of -1.4 
to -4.2 cm for waist circumference over 6-month duration following initiation of 
ziprasidone. 
A recent meta-analysis of nine published efficacy studies with various follow-up 
intervals following aripiprazole initiation reported a pooled mean weight loss of -2.55 
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± 1.5 kg (Barak and Aizenberg,2011). Other randomized studies found mean weight 
loss of 1.26kg + 1.37kg in aripiprazole group (Pigott et al.,2003; McQuade et al.,2004; 
Kerwin et al.,2007). Weight loss was also noted in other randomized studies, with 
mean weight loss -0.29 to -3.6 kg in the ziprasidone group (Arato et al.,2002; Simpson 
et al.,2005; Stroup et al.,2006; Sacchetti et al.,2009; Potkin et al.,2011).    
We found that switching to aripiprazole was associated with significant improvement 
in total cholesterol and LDL in patients who previously on antipsychotics. In primary 
analyses, our study reported the mean reduction of -15.8 to -29.4 mg/dL for total 
cholesterol, mean reduction of -14.2 to -25.5 mg/dL for LDL, over 6-month duration 
following initiation of aripiprazole. The mean HDL of 0.4 to 1.4 mg/dL only improved 
after 4 months and the significant reduction of TG -35.7 mg/dL was noted after 6 
months following switching to aripiprazole. Six other randomized studies found 
improvement of lipid measures with mean reduction of -0.3 to -17.0 mg/dL for total 
cholesterol, mean reduction of -3.86 to -17.0 mg/dL for LDL, mean improvement of 
1.43 to 5.4 mg/dL for HDL  and mean reduction of -0.1 to -37.2 mg/dL for TG in 
aripiprazole group (Pigott et al.,2003; McQuade et al.,2004; Chan et al.,2007; Kane et 
al.,2009; Fleischhacker et al.,2009; Macfadden et al.,2010). 
Switching to ziprasidone was associated with significant improvement in total 
cholesterol in patients who previously on antipsychotics. In primary analyses, our 
study reported the mean reduction of -9.7 to -19.0 mg/dL for total cholesterol over 6-
month duration following initiation of ziprasidone. The mean HDL of 0.3 to 1.1 
mg/dL only improved after 4 months and the significant reduction of TG -21.4 to -28.2 
mg/dL, mean reduction of -10.4 to -11.1 mg/dL for LDL, were noted after 5 months 
following switching to ziprasidone. 
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Several other randomized studies found improvement of lipid measures with mean 
reduction of -7.8 to -12.8 mg/dL for total cholesterol, mean reduction of -6.0 to -10.4 
mg/dL for LDL, mean improvement of 0.8 to 8.0 mg/dL for HDL  and mean reduction 
of -3.5 to -32.1 mg/dL for TG in ziprasidone group (Breier et al.,2005; Lieberman et 
al.,2005; Meyer et al.,2008; Sacchetti et al.,2009). 
In primary analyses of our study, switching to aripiprazole was associated with 
improvement in FBS -0.8 to -8.3 mg/dL. Mean FBS reduction of -1.3 mg/dL over 52 
weeks was reported in a randomized trial by Chrzanowski et al (2006). Switching to 
ziprasidone was associated with slight increased of FBS 0.8 to 2.7 mg/dL. Increased of 
mean FBS range from 2.9 to 4.8 mg/dL was also reported by other randomized trial 
(Grootens et al.,2011; Potkin et al.,2011; Cutler et al.,2008; Lieberman et al.,2005). 
Sensitivity Analyses for Aripiprazole and Ziprasidone 
Aripiprazole and ziprasidone demonstrated similar efficacy in reversing the metabolic 
syndrome as an effect from previous antipsychotics treatment, and the proportion 
resolved cases was higher than incidence cases. The findings of sensitivity analyses 
were consistent with the results of the primary analyses.  
There was statistically significant difference in modelling analysis of mean change 
FBS and systolic blood pressure between aripiprazole and ziprasidone from baseline to 
the endpoint 6-month. Therefore, there were independent effects of treatments on FBS 
and systolic blood pressure response over time. This could be due to increased of 
mean change of FBS and systolic blood pressure from study visit 1 to 6 months after 
treatment of ziprasidone and there was reduction of mean change of FBS and systolic 
blood pressure from study visit 1 to 6 months after treatment of aripiprazole. For 
metabolic syndrome components, aripiprazole has better effect in improving FBS and 
systolic blood pressure than ziprasidone.   
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Efficacy of Aripiprazole and Ziprasidone in Improving Coronary Heart 
Disease Risk  
From baseline to 6 months study visit, there was reduction in the prevalence of all 
CVRFs for both aripiprazole and ziprasidone group. However, there was no 
statistically significant difference observed for all CVRFs for both groups. 
There was significant reduction on CHD risk score (Framingham) for both 
aripiprazole and ziprasidone. Both drugs demonstrated similar efficacy in reducing 
CHD risk among schizophrenia patients. 
Efficacy of Aripiprazole and Ziprasidone in Improving Psychotic 
Symptoms among Schizophrenia Patients with Metabolic Syndrome  
Aripiprazole and ziprasidone demonstrated similar efficacy in the positive and 
negative symptoms of schizophrenia indicating that patients who were switched to 
aripiprazole or ziprasidone did not experience worsening of their psychotic symptoms. 
In fact both drugs produced statistically significant improvements which were 
sustained throughout the whole duration of 6-month study (PANSS total, PANSS 
positive, PANSS negative and CGI-S scores). The efficacy data of this study were 
similar to that of previous studies (Grootens et al.,2011; Potkin et al.,2011; Macfadden 
et al.,2010; Kane et al.,2009). 
Safety of Aripiprazole and Ziprasidone in the Treatment of Schizophrenia 
Patients with Metabolic Syndrome  
For the safety assessment of aripiprazole and ziprasidone, both drugs were not 
associated with worsening of EPS symptoms. There was statistically significant 
reduction of SAS, BARS and AIMS score throughout 6-month study. In this study, 
discontinuation rate was used as a proxy measure for clinical effectiveness. Although 
ziprasidone group showed a higher discontinuation rate than aripiprazole group from 
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baseline to 6-month study visit, the difference in the discontinuation rates was not 
statistically significant.  
The adverse events reported in our study patients were the common side effects 
associated with antipsychotic therapy, including extrapyramidal syndrome and 
insomnia, with similar prevalence across aripiprazole and ziprasidone groups. 
However, the incidence of somnolence was higher in the ziprasidone group than in the 
aripiprazole group (18.8% vs 2.2%). This was not unexpected, as a small 12-week 
study reported that when switching patients to ziprasidone, sedation was the most 
common adverse event associated with the switch (Kim et al.,2010). Somnolence 
caused by ziprasidone might be a result of histamine H1 receptor antagonism. All the 
adverse events reported were mild to moderate in severity. The adverse events were 
resolved before the trial end. There were only two serious adverse events (SAE) 
during the study. Both events were hospitalization due to relapse of psychotic 
symptoms.       
Strengths    
Our study has several methodological strengths:  
i). This was the first randomized efficacious study with head to head comparisons 
between aripiprazole and ziprasidone in the treatment of schizophrenia patients 
with metabolic syndrome for 6-month duration. Among atypical antipsychotics, 
aripiprazole and ziprasidone were associated with a lower metabolic risk (ADA-
APA-AACE,2004; Newcomer,2005). Both medications were used in this study to 
reverse the metabolic effects from previous antipsychotics treatment without 
compromising the efficacy of controlling the psychotic symptoms.  
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ii). The study population was schizophrenia patients with at least one year duration of 
antipsychotic treatment. The minimal one year duration of antipsychotic exposure 
would be sufficient for the development of metabolic abnormalities. During 
screening, patients who were on mood stabilizer were excluded from this study. 
This is because mood stabilizer can be associated with weight gain, therefore could 
confound the results.       
iii). Beside primary analysis, we conducted a series of sensitivity analyses in order to 
assess the robustness of our findings in the face of concomitant medication use. 
Schizophrenia patients were treated as per clinical practice, when diabetes 
mellitus, hypertension or hyperlipidemia was detected during study visit. The 
initiation of antidiabetic, antihyperlipidemia and antihypertensive was allowed 
after randomization when clinically indicated. It was unethical for not treating such 
conditions during the trial. Any of these concomitant treatments could have 
obscured the effects of aripiprazole or ziprasidone on metabolic and 
anthropometric measures. For sensitivity analyses, patients with these medications 
were excluded from the analysis.   
Limitations 
The primary limitations of this study include a relatively small sample size and the 
omission of behavioural measures of reinforcing effects of aripiprazole and 
ziprasidone. 
i). Adequacy of Sample Size  
Although the required sample size was 162 per arm and maintained 80% power of the 
study, we only managed to get aripiprazole n=90 and ziprasidone n=85. A 
fundamental issue in non-inferiority analysis was defining the non-inferiority margin. 
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A larger sample size may have been necessary to maintain 80% power for the 
demonstration of non-inferiority for the endpoints in this study. 
Although with the relatively small sample size, there were statistical significance 
differences in the reduction of psychotics symptoms and some metabolic syndrome 
components in both groups, either in primary analyses (cohen’s d, effect size r : 
PANSS total = 0.81,0.38 and PANSS positive = 0.72,0.34) and sensitivity analyses 
(cohen’s d, effect size r : FBS = 0.02,0.01 and systolic blood pressure = - 0.06, -0.03).  
We were not able to enroll a larger number of samples due to financial limitations. We 
were only given a small amount of study grants (RM136,000) by University of 
Malaya. In order to get more samples, we need to open up more study sites, hire more 
investigators and study coordinators, and have enough funds to buy the study 
medications. 
Another factor that limits bigger sample recruitment was time factor. We have to 
complete the whole project within two years as required by the research grant 
provider.    
ii). Instruments of the study 
All the scales have been used widely in this country however until now, there was no 
paper being published regarding the validation of the scales in the local population.  
iii). Conduct of Study 
We did not examine the effects of psychosocial treatments aimed at improving 
lifestyle factors known to impact body weight and metabolic profile, nor were we able 
to account for such factors in our data analyses. 
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3.7 Conclusions 
Switching to aripiprazole or ziprazidone was effective in reversing the metabolic 
syndrome and its components among schizophrenia patients who had metabolic 
syndrome. Aripiprazole and ziprasidone were efficacious and safe in the treatment of 
schizophrenia patients with metabolic syndrome.  
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Chapter FOUR:  Overall Conclusions and Recommendations  
4.1   Overall Conclusions 
Atypical antipsychotics were reported to be associated with increased risk of impaired 
glucose level and hyperglycaemia, and subsequently increase the risk of the metabolic 
syndrome (Newcomer et al.,2002). Nevertheless, it has been shown that psychiatric 
disorders, including schizophrenia, were associated with an elevated risk of 
developing diabetes regardless of antipsychotic use (Henderson,2002). Patients with 
schizophrenia were at greater risk for metabolic dysfunctions than other individuals 
due to a number of reasons, including inactive lifestyle, poor dietary choices, and side 
effects of antipsychotic medications (Cohn,2009).  
While the metabolic syndrome itself poses serious health complications, it also places 
individuals at an increased risk for other serious medical conditions, such as 
cardiovascular mortality. Individuals with the metabolic syndrome were three times as 
likely to have a myocardial infarction or stroke compared with people without the 
syndrome. While the pathophysiology of the metabolic syndrome was extremely 
complex and remained to be fully elucidated, currently both insulin resistance and 
central obesity were considered to be the significant underlying causes of this 
syndrome (Anderson et al.,2001; Nesto,2003).  
We conducted a study to determine the prevalence of metabolic syndrome and 
prevalence of coronary heart disease risk among schizophrenia patients receiving 
antipsychotics in Malaysia. The study was conducted at four mental institutions, two 
army hospitals and two general hospitals namely Hospital Bahagia Ulu Kinta, Perak, 
Hospital Permai Johor Bahru, Johor, Hospital Sentosa Kuching, Sarawak, Hospital 
Mesra Kota Kinabalu, Sabah, Hospital Terendak Melaka, Navy Hospital Lumut, 
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Perak, University Malaya Medical Centre (UMMC), Kuala Lumpur and Hospital Sg. 
Petani, Kedah. Study population were schizophrenia patients aged between 18 and 65 
years old, who met the DSM-IV TR criteria for schizophrenia. Patients should receive 
antipsychotic treatment for at least 1 year and were not on mood stabilizer or depot 
neuroleptics. Metabolic syndrome was defined by using the NCEP ATP III criteria-
modified for Asian waist circumference. The cardiovascular heart disease risk was 
assessed by using Framingham function (10-year all coronary heart disease event). A 
structured questionnaire to assess: (i) sociodemographic and lifestyle background (ii) 
medical, psychiatry and family history (iii) physical examination and blood 
investigation for metabolic syndrome profile. 
A total of 270 patients were screened for metabolic syndrome. The prevalence of 
metabolic syndrome was 46.7%. The mean BMI value was 29.4 ± 5.1 kg/m
2
 for 
patients with metabolic syndrome and 25.0 ± 5.6 kg/m
2 
for patient, without metabolic 
syndrome (p<0.05). The usage of commonest monotherapy atypical antipsychotics 
was olanzapine (42.2%) and chlorpromazine for typical antipsychotics (33.3%) in the 
metabolic syndrome group. The prevalence of diabetes mellitus after initiation of 
antipsychotics was 15.2%. There was statistically significant for all metabolic 
syndrome components between metabolic syndrome and non-metabolic syndrome 
groups i.e. Waist circumference (OR=34.8, 95% CI: 12.2, 99.4), HDL Cholesterol 
(OR=5.4, 95% CI: 3.2, 9.2), Triglycerides (OR= 8.6, 95% CI: 4.9, 15.2), BP (OR=5.5, 
95% CI: 3.2, 9.3), FBS (OR= 11.4, 95% CI: 5.5, 23.6). Coronary heart disease 10-year 
risk was significantly higher in the metabolic syndrome patients. The prevalence of 
patients with high/very high cardiovascular event risk (Framingham ≥ 10%) was 
31.5% in the metabolic syndrome patients vs. 11.0% in the non-metabolic syndrome 
patients (OR = 3.7, 95% CI: 1.9, 7.1, p<0.0001).  
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The prevalence of metabolic syndrome in schizophrenia patients receiving 
antipsychotic in Malaysia was very high. It was associated with increased 
cardiovascular risk. Our data adds to the mounting evidence that schizophrenia 
patients are at increased risk for developing metabolic syndrome. The high prevalence 
of the syndrome underscores an urgent need to formulate a comprehensive 
intervention measures to combat these problems. 
4.1.1.  Safety and Efficacy of Aripiprazole Vs Ziprazidone in 
Schizophrenic Patients with Metabolic Syndrome 
Not all antipsychotic agents carry the same adverse metabolic risk. Of the atypical 
antipsychotics, aripiprazole and ziprasidone were associated with a lower metabolic 
risk (ADA-APA-AACE,2004; Newcomer,2005). Both ziprasidone and aripiprazole 
were known to be the second generation atypical antipsychotics that were least likely 
to cause dyslipidaemia, and in fact might improve the lipid profile of patients switched 
from another antipsychotic drug to one of these agents (Spurling et al.,2007; 
Greenberg and Citrome,2007). 
Therefore, switching patients with schizophrenia who require long-term treatment with 
antipsychotic drugs to either aripiprazole or ziprasidone appeared as a rational choice 
to lessen the metabolic effects (e.g. obesity, hyperglycaemia, dyslipidaemia) induced 
by the antipsychotics.  
We conducted a study to determine the improvement and reversibility of metabolic 
syndrome, its components and lipid profiles after switching to aripiprazole or 
ziprasidone. We also determine the safety and efficacy of aripiprazole and ziprasidone 
in the treatment of schizophrenia patients with metabolic syndrome.  
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We conducted a double blind randomized controlled trial at four mental institutions 
and four general hospitals. Study population were patients aged between 18 and 65 
years old, with a current Diagnostic and Statistical Manual of Mental Disorders-IV 
Text Revision (DSM-IV TR) diagnosis of schizophrenia. Eligible patients were 
randomised either to aripiprazole or ziprasidone. The dose of aripiprazole and 
ziprasidone, can be either increased or reduced based on clinical assessment. The total 
daily dosage of ziprasidone ranges from 80mg - 160mg.The total daily dosage of 
aripiprazole ranges from 10mg - 30 mg.  Metabolic syndrome was defined by using 
the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
III) criteria-modified for Asian waist circumference. For baseline and follow-up 
evaluation, the outcome measures included body mass index (BMI), waist 
circumference, blood pressure (BP), fasting blood sugar (FBS), lipid profile, adverse 
effects monitoring and clinical rating scale such as Positive and Negative Symptoms 
Scale (PANSS), Clinical Global Impression Scale (CGI), Abnormal Involuntary 
Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and Simpson Angus Scale 
(SAS). Intention-to-treat was used for the data analysis.   Generalized Estimating 
Equation (GEE) and Mixed-Effects Model Repeated-Measures (MMRM) analysis was 
utilized to examine changes in outcome measures over time with the treatment of 
aripiprazole and ziprasidone. 
175 patients were recruited for the study. 51.4% (90/175) of patients was randomized 
to aripiprazole and 48.6% (85/175) to ziprasidone. There was improvement in the 
prevalence of metabolic syndrome from baseline to 6-month after switching to 
aripiprazole or ziprasidone; (aripiprazole 58.9% vs. 30.0%, ziprasizone 51.8% vs. 
15.3%, p<0.05), 14.4% of patients had resolved metabolic syndrome after switching to 
aripiprazole and 18.8% of patients had resolved metabolic syndrome after switching to 
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ziprasidone. There was improvement in the prevalence of all metabolic syndrome 
component from baseline to 6-month after switching to aripiprazole or ziprasidone; 
waist circumference (aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), 
HDL cholesterol (aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), 
triglycerides (aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), BP 
(aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%) ,FBS (aripiprazole 
42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). There was statistically 
significant improvement in PANSS, CGI, BARS and SAS after switching to 
aripiprazole or ziprasidone. The commonest side effects reported were EPS and 
insomnia for both treatment groups.    
Switching to aripiprazole or ziprazidone was effective in reversing the metabolic 
syndrome and its components among schizophrenia patients who had metabolic 
syndrome. Our study showed that aripiprazole was not inferior to ziprasidone in 
improving metabolic syndrome and metabolic syndrome components. The results 
reported here provide further support for the improvement in metabolic effects 
following a switch to aripiprazole or ziprasidone. An appropriately powered study 
with larger sample size is warranted to further confirm our results and address several 
issues that the current study design is not able to account for. 
4.2   Recommendations  
4.2.1. We feel that identification and treatment of metabolic syndrome in this 
population is of utmost importance. It is unethical not to screen and treat 
metabolic syndrome in this population, and cause unnecessary suffering, 
knowing very well the rate of morbidity and mortality in them is high. Failure 
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to identify metabolic syndrome here means an opportunity for treatment is lost 
in a population that is otherwise difficult to reach in the community. 
4.2.2. Identification and treatment of metabolic syndrome must be address as a 
central role and should be part of overall management of schizophrenia. 
Treatment should not only focus on the efficacy of antipsychotic treatment but 
also must address the potential side effect profile such as metabolic syndrome.  
4.2.3. Since the prevalence of metabolic syndrome was very high among 
schizophrenia patients receiving antipsychotics in Malaysia, the screening 
should be mandatory for all patients. The screening should not be limited to 
atypical antipsychotics or certain antipsychotics but should be employed to all 
types of antipsychotics. 
4.2.4. We would like to recommend developing a practice guideline in Malaysia 
where all schizophrenia patients should have their waist circumference, blood 
pressure and BMI being routinely measured every time they come for follow 
up. Blood screening for fasting blood and lipids must be scheduled regularly 
for all patients. Currently this is not done regularly in many hospitals and 
clinics in Malaysia.    
4.2.5. Among schizophrenia patients who developed metabolic syndrome, they can 
be safety switched to aripiprazole or ziprazidone as an alternative treatment. 
4.2.6. Aripiprazole and ziprazidone were both efficacious treatment for schizophrenia 
patients who developed metabolic syndrome. 
4.2.7. Aripiprazole and ziprazidone could be used to reverse the metabolic syndrome 
among schizophrenia patients who developed metabolic syndrome while they 
were on other antipsychotics. 
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4.2.8. We would like to recommend incorporating aripiprazole or ziprazidone as one 
of the antipsychotics of choice for the treatment of schizophrenia who had 
metabolic syndrome or who have high risk to develop metabolic syndrome. At 
the moment the Malaysian Clinical Practice guideline does not have such 
recommendations. 
4.2.9. We would like to suggest conducting further study with a larger sample size 
and a longer duration of follow up to confirm the efficacy and safety of 
aripiprazole or ziprazidone in the treatment on schizophrenia patients with 
metabolic syndrome. 
4.2.10.   We would like to recommend conducting a study which combined 
aripiprazole or ziprazidone with one of the behavioural treatment method 
(wellness program, psychoeducation, diet and exercise) to confirm if it will 
yield a better outcome). 
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Appendix A - Operational Definitions 
 
 
Age: 
Age of the schizophrenia patient in years at last birthday. 
Race: 
Ethnicity recorded in the medical case record. 
Marital status: 
Legal marital status either single or married, widowed or divorce as mentioned 
by patient during interview.   
Education level: 
Type of education institution last attended by the patient. 
Occupation: 
Patient’s current occupation 
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Appendix B - Mini International Neuropsychiatric Interview (M.I.N.I.) 
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Appendix C - Positive and Negative Symptoms Scale(PANSS) 
 
 
Positive and Negative Symptoms Scale 
Initials: 
Date: 
Visit: 
 
Positive Symptoms 
P1 Delusions  1 2 3 4 5 6 7 
 
P2 Conceptual disorganisation  1 2 3 4 5 6 7 
 
P3 Hallucinatory behaviour  1 2 3 4 5 6 7 
 
P4 Excitement  1 2 3 4 5 6 7 
 
P5 Grandiosity  1 2 3 4 5 6 7 
 
P6 Suspiciousness/persecution  1 2 3 4 5 6 7 
 
P7 Hostility  1 2 3 4 5 6 7 
 
 
 
Negative Symptoms 
N1  Blunted affect  1 2 3 4 5 6 7 
 
N2  Emotional withdrawal  1 2 3 4 5 6 7 
 
N3  Poor rapport  1 2 3 4 5 6 7 
 
N4 Passive/apathetic social 
withdrawal  
 
1 2 3 4 5 6 7 
 
N5  Difficulty in abstract 
thinking  
 
1 2 3 4 5 6 7 
 
N6  Lack of spontaneity & 
flow of conversation  
 
1 2 3 4 5 6 7 
 
N7  Stereotyped thinking  1 2 3 4 5 6 7 
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General Psychopathology 
G1 Somatic concern  1 2 3 4 5 6 7 
 
G2  Anxiety  1 2 3 4 5 6 7 
 
G3  Guilt feelings  1 2 3 4 5 6 7 
 
G4  Tension  1 2 3 4 5 6 7 
 
G5  Mannerisms & 
posturing  
1 2 3 4 5 6 7 
 
G6  Depression  1 2 3 4 5 6 7 
 
G7  Motor retardation  1 2 3 4 5 6 7 
 
G8 Uncooperativeness  1 2 3 4 5 6 7 
 
G9  Unusual thought 
content  
1 2 3 4 5 6 7 
 
G10  Disorientation  1 2 3 4 5 6 7 
 
G11 Poor attention  1 2 3 4 5 6 7 
 
G12 Lack of judgement & 
insight  
 
1 2 3 4 5 6 7 
 
G13 Disturbance of 
volition  
1 2 3 4 5 6 7 
 
G14  Poor impulse control  1 2 3 4 5 6 7 
 
G15  Preoccupation  1 2 3 4 5 6 7 
 
G16  Active social 
avoidance  
1 2 3 4 5 6 7 
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Appendix D - Clinical Global Impressions Scale (CGI-S) 
 
 
Clinical Global Impressions Scale 
Initials: 
Date: 
Visit: 
 
 
SEVERITY OF ILLNESS 
 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
 
Normal, not at all ill       �1 
 
Borderline mentally ill      �2 
 
Mildly ill        �3 
 
Moderately ill       �4 
 
Markedly ill        �5 
 
Severely ill        �6 
 
Among the most extremely ill patients    �7 
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Appendix E - Abnormal Involuntary Movement Scale (AIMS) 
 
 
Abnormal Involuntary Movement Scales 
 
Initials: 
 
Date: 
 
Visit: 
 
 
 
Instructions: Complete examination procedure before making ratings. 
Rate highest severity observed. 
 
Code:   1 None 
2 Minimal, may be extreme normal 
3 Mild 
4 Moderate 
5 Severe 
 
 
Facial and Oral Movements: 
 
1.  Muscles of facial Expression (e.g., movement of forehead, eyebrows, 
periorbital area, cheeks; include frowning, blinking, smiling, grimacing) 
1  2 3 4  5 
 
2.  Lips and Perioral Area (e.g., puckering, pouting, smacking) 
1  2  3  4   5 
 
3.  Jaws (e.g. biting, clenching, chewing, mouth opening, lateral movement) 
1  2  3  4  5 
 
4.  Tongue (Rate only increase in movement both in and out of mouth, NOT 
inability to sustain movement.) 
1  2  3  4  5 
 
Extremity Movements: 
 
5. Upper (arms, wrists, hands, fingers). Include choreic movements (i.e., rapid, 
objectively purposeless, irregular, spontaneous), athetoid movements (i.e., 
slow, irregular, complex, serpentine). Do NOT include tremor (i.e., repetitive, 
regular, rhythmic). 
1  2  3  4  5 
6.  Lower (legs, knees, ankles, toes). (E.g., lateral knee movement, foot taping, 
heel dropping, foot squirming, inversion and eversion of foot.) 
 
1  2  3  4  5 
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Trunk Movements: 
 
7.  Neck, shoulders, hips ( e.g., rocking, twisting, squirming, pelvic gyrations) 
1  2  3  4  5 
 
Global judgments 
 
8. Severity of abnormal movements: 
 
1. None, normal 
2. Minimal 
3. Mild 
4. Moderate 
5. Severe 
 
9. Incapacitation due to abnormal movements: 
 
1. None, normal 
2. Minimal 
3. Mild 
4. Moderate 
5. Severe 
 
 
10. Patient’s awareness of abnormal movements (Rate only patient’s report) 
 
1. No awareness 
2. Aware, no distress 
3. Aware, mild distress 
4. Aware, moderate distress 
5. Aware, severe distress 
 
Dental Status: 
 
11. Current problems with teeth and/or dentures 
 
1. No 
2. Yes 
 
12. Does patient usually wear dentures? 
 
1. No 
2. Yes 
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Appendix F - Barnes Akathasia Scale (BARS) 
 
Barnes Akathisia Rating Scale (BARS) 
 
Initials: 
 
Date: 
 
Visit: 
 
Instructions: Patient should be observed while they are seated, and then standing 
while engaged in neutral conversation (for a minimum of two minutes in each 
position). Symptoms observed in other situations, for example while engaged in 
activity on the ward, may also be rated. Subsequently, the subjective phenomena 
should be elicited by direct questioning. 
 
Objective 
 
0  Normal, occasional fidgety movements of the limbs 
1 Presence of characteristic restless movements: shuffling or tramping 
movements of the legs/feet, or swinging of one leg while sitting, and/or 
rocking from foot to foot or “walking on the spot” when standing, but 
movements present for less than half the time observed 
2  Observed phenomena, as described in (1) above, which are present for at 
least half the observation period 
3  Patient is constantly engaged in characteristic restless movements, and/or 
has the inability to remain seated or standing without walking or pacing, 
during the time observed 
 
Subjective 
Awareness of restlessness 
0  Absence of inner restlessness 
1  Non-specific sense of inner restlessness 
2  The patient is aware of an inability to keep the legs still, or a desire to 
move the legs, and/or complains of inner restlessness aggravated 
specifically by being required to stand still 
3  Awareness of intense compulsion to move most of the time and/or reports 
strong desire to walk or pace most of the time 
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Distress related to restlessness: 
0  No distress 
1 Mild 
2  Moderate 
3  Severe 
 
Global Clinical Assessment of Akathisia: 
 
0  Absent. No evidence of awareness of restlessness. Observation of 
characteristic movements of akathisia in the absence of a subjective report 
of inner restlessness or compulsive desire to move the legs should be 
classified as pseudoakathisia 
 
1  Questionable. Non-specific inner tension and fidgety movements 
 
2  Mild akathisia. Awareness of restlessness in the legs and/or inner 
restlessness worse when required to stand still. Fidgety movements 
present, but characteristic restless movements of akathisia not necessarily 
observed. Condition causes little or no distress. 
 
3  Moderate akathisia. Awareness of restlessness as described for mild 
akathisia above, combined with characteristic restless movements such as 
rocking from foot to foot when standing. Patient finds the condition 
distressing 
 
4  Marked akathisia. Subjective experience of restlessness includes a 
compulsive desire to walk or pace. However, the patient is able to remain 
seated for at least five minutes. The condition is obviously distressing. 
 
5  Severe akathisia. The patient reports a strong compulsion to pace up and 
down most of the time. Unable to sit or lie down for more than a few 
minutes. Constant restlessness which is associated with intense distress 
and insomnia. 
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Appendix G - Simpson Angus Scale (SAS) 
 
 
SIMPSON-ANGUS EXTRAPYRAMIDAL SIDE EFFECTS SCALE 
 
Initials: 
Date: 
Visit: 
 
The exam should be conducted in a room where the subject can walk a 
sufficient distance to allow him/her to get into a natural rhythm (e.g. 15 
paces). Each side of the body should be examined. If one side shows more 
pronounced pathology than the other, this score should be noted and this 
taken. Cogwheel rigidity may be palpated when the examination is 
carried out for items 3, 4, 5, and 6. It is not rated separately and is merely 
another way to detect rigidity. It would indicate that a minimum score of 
1 would be mandatory. 
 
1.  Gait: The patient is examined as he walks into the examining room, his 
gait, the swing of his arms, his general posture; all form the basis for 
an overall score for this item. This is rated as follows: 
 
0 Normal 
1 Diminution in swing while the patient is walking 
2 Marked diminution in swing with obvious rigidity in the arm 
3 Stiff gait with arms held rigidly before the abdomen 
4 Stooped shuffling gait with propulsion and retropulsion 
 
2.  Arm Dropping: The patient and the examiner both raise their arms to 
shoulder height and let them fall to their sides. In a normal subject, a 
stout slap is heard as the arms hit the sides. In the patient with extreme 
Parkinson’s syndrome, the arms fall very slowly: 
 
0 Normal, free fall with loud slap and rebound 
1 Fall slowed slightly with less audible contact and little rebound 
2 Fall slowed, no rebound 
3 Marked slowing, no slap at all 
4 Arms fall as though against resistance; as though through glue 
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3.  Shoulder Shaking: The subject’s arms are bent at a right angle at the 
elbow and are taken one at a  time by the examiner who grasps one 
hand and also clasps the other around the patient’s elbow. The 
subject’s upper arm is pushed to and fro and the humerus is externally 
rotated. The degree of resistance from normal to extreme rigidity is 
scored as follows: 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost a frozen shoulder 
 
4. Elbow Rigidity: The elbow joints are separately bent  at right angles 
and passively extended and flexed, with the subject’s biceps observed 
and simultaneously palpated. The resistance to this procedure is rated. 
(The presence of cogwheel rigidity is noted separately.) 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost a frozen elbow 
 
5. Wrist Rigidity or Fixation of Position: The wrist is held in one hand 
and the fingers held by the examiner’s other hand, with the wrist 
moved to extension, flexion and ulnar and radial deviation: 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost frozen 
 
6. Leg Pendulousness: The patient sits on a table with his legs hanging 
down and swinging free. The ankle is grasped by the examiner and 
raised until the knee is partially extended. It is then allowed to fall. The 
resistance to falling and the lack of swinging form the basis for the 
score on this item: 
 
0 The legs swing freely 
1 Slight diminution in the swing of the legs 
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2 Moderate resistance to swing 
3 Marked resistance and damping of swing 
4 Complete absence of swing 
 
7.  Head Dropping: The patient lies on a well-padded examining table 
and his head is raised by the examiner’s hand. The hand is then 
withdrawn and the head allowed to drop. In the normal subject the 
head will fall upon the table. The movement is delayed in 
extrapyramidal system disorder, and in extreme parkinsonism it is 
absent. The neck muscles are rigid and the head does not reach the 
examining table.  
 
0 The head falls completely with a good thump as it hits the table 
1 Slight slowing in fall, mainly noted by lack of slap as head meets the table 
2 Moderate slowing in the fall quite noticeable to the eye 
3 Head falls stiffly and slowly 
4 Head does not reach the examining table 
 
8.  Glabella Tap: Subject is told to open eyes wide and not to blink. The 
glabella region is tapped at a steady, rapid speed. The number of times 
patient blinks in succession is noted: 
 
0 0-5 blinks 
1 6-10 blinks 
2 11-15 blinks 
3 16-20 blinks 
4 21 and more blinks 
 
9. Tremor: Patient is observed walking into examining room and is then 
reexamined for this item: 
 
0 Normal 
1 Mild finger tremor, obvious to sight and touch 
2 Tremor of hand or arm occurring spasmodically 
3 Persistent tremor of one or more limbs 
4 Whole body tremor 
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10.  Salivation: Patient is observed while talking and then asked to open 
his mouth and elevate his tongue. The following ratings are given: 
 
0 Normal 
1 Excess salivation to the extent that pooling takes place if the mouth is 
open and the tongue raised 
2 When excess salivation is present and might occasionally result in 
difficulty speaking 
3 Speaking with difficulty because of excess salivation 
4 Frank drooling 
 
 
 
 
 
 
 
 
 
   
 
 
Appendix H - Questionnaire 
 
280 
 
Appendix H - Questionnaire 
 
Appendix H - Questionnaire 
 
281 
 
Appendix H - Questionnaire 
 
282 
 
 
 
 
Appendix H - Questionnaire 
 
283 
 
Appendix H - Questionnaire 
 
284 
 
 
 
 
Appendix I – Ethics Approval 
 
285 
 
 
Appendix I - Approval Letter from Ethical Committee/ 
Government Authorities   
 
 
Appendix I – Ethics Approval 
 
286 
 
 
Appendix J – Research Grant 
 
287 
 
Appendix J - Research Grant 
 
Appendix J – Research Grant 
 
288 
 
 
Appendix J – Research Grant 
 
289 
 
 
   
 
 
Appendix K – Oral and Poster Presentation    
 
290 
 
Appendix K - Oral and Poster Presentation 
 
 
 
 
 
Appendix K – Oral and Poster Presentation    
 
291 
 
 
Appendix K – Oral and Poster Presentation    
 
292 
 
Appendix K – Oral and Poster Presentation    
 
293 
 
 
Appendix K – Oral and Poster Presentation    
 
294 
 
Appendix L – Publication    
 
295 
 
Appendix L - Publication 
 
The following papers have been published from this thesis: 
 
Journals 
 
1. Mas Ayu Said, Ahmad Hatim Sulaiman, Mohd Hussain Habil, Srijit Das, 
Abdul Kadir Abu Bakar, Rosliwati Md. Yusoff, Loo Tsui Huei, 
Shamshunnisah Abu Bakar. Metabolic syndrome and cardiovascular risk 
among schizophrenia patients receiving antipsychotics in Malaysia. 
Singapore Medical Journal, 2012.53(12):801-807   
2. Mas Ayu Said, Ahmad Hatim Sulaiman, Mohd Hussain Habil, Wan 
Zafidah, Haslina Mohd Yusof, Badiah Yahya, Ramli Mohd Ali, Ananjit 
Singh, Sapini Yaccob, Mohd Shah, Badli Mahmud, Awang Bulgiba, 
Noran Naqiah Hairi. Metabolic syndrome and monotherapy antipsychotic 
treatment among schizophrenia patients in Malaysia. Preventive 
Medicine,2013.Doi:10.1016/j.ypmed.2013.01.005. [Epub ahead of print]   
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